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ABSTRACT 
This doctoral work describes catalytic asymmetric reactions between alkenes and 
aldehydes, enabled by the development of chiral Brønsted acids. Valuable and 
functionalized enantiomerically enriched cyclic compounds were efficiently furnished 
from inexpensive and commercially available reagents with high degrees of atom 
economy. 
In the first part of this thesis, the first highly enantioselective organocatalytic 
intramolecular carbonyl−ene cyclization of olefinic aldehydes is presented. In the second 
part, asymmetric cyclizations via oxocarbenium ions are described. One is a general 
asymmetric catalytic Prins cyclization of aldehydes with homoallylic alcohols, in which 
the oxocarbenium ion is attacked intramolecularly by a pendent alkene. The other one is 
an asymmetric oxa-Pictet−Spengler reaction between aldehydes and homobenzyl 
alcohols, in which the oxocarbenium ion is trapped by an intramolecular arene. The first 
general asymmetric [4+2]-cycloaddition of simple and unactivated dienes with aldehydes 
is developed in the last part of this thesis. This methodology is extremely robust and 
scalable. Valuable enantiomerically enriched dihydropyran compounds could be readily 
obtained from inexpensive and abundant dienes and aldehydes.  
New types of confined Brønsted acids were rationally designed and synthesized, 
including imino-imidodiphosphates (iIDPs), nitrated imidodiphosphates (nIDPs), and 
imidodiphosphorimidates (IDPis). Beyond the application of these catalysts in various 
asymmetric reactions between simple alkenes and aldehydes, mechanistic investigations 
are also disclosed in this doctoral work. 
  
ABSTRACT 
 
IV 
 
Diese Doktorarbeit beschreibt hochenantioselektive Reaktionen zwischen einfachen 
Alkenen und Aldehyden, welche durch chirale Brønsted-Säuren als Katalysatoren 
ermöglicht wurden. Wertvolle, hochfunktionalisierte und enantiomerenangereicherte 
zyklische sowie heterozyklische Verbindungen wurden effizient und hochgradig 
atomökonomisch, ausgehend von kommerziell erhältlichen und günstigen 
Startmaterialien, hergestellt. 
Im ersten Teil der Arbeit wird eine hochenantioselektive und organokatalytische 
intramolekulare Carbonyl–En-Zyklisierung von olefinischen Aldehyden vorgestellt. Im 
zweiten Teil werden zwei verschiedene asymmetrische Zyklisierungsreaktionen über 
Oxocarbenium-Ionen beschrieben. Eine dieser Reaktionen stellt die katalytische Prins-
Zyklisierung von gängigen Aldehyden und homoallylischen Alkoholen dar, in welcher 
das Oxocarbeniumion intramolekular mit einem nukleophilen Alkenrest reagiert. Die 
andere Transformation beschreibt eine asymmetrische Oxa-Pictet–Spengler-Reaktion von 
Aldehyden mit homobenzylischen Alkoholen, wobei das Oxocarbeniumion mit dem 
aromatischen Ringsystem reagiert. Im letzten Teil der Arbeit wird die erste generelle 
asymmetrische [4+2]-Cycloaddition zwischen einfachen und nichtaktivierten Dienen und 
Aldehyden entwickelt. Diese Methode ist extrem robust und skalierbar. Wertvolle 
enantiomerenangereicherte Dihydropyran-Verbindungen konnten ausgehend von 
kommerziell erwerbbaren Dienen und Aldehyden hergestellt werden.  
Neue Klassen sterisch anspruchsvoller Brønsted-Säuren wurden konzipiert und 
synthetisiert. Hierbei standen Imino-Imidophosphate (IDPs), nitrierte Imidodiphosphate 
(nIDP) und Imidodiphorsphoimidate (IDPi) im Fokus. Neben der Anwendung dieser 
Katalysatoren in verschiedenen asymmetrischen Reaktionen, werden die erarbeiteten 
mechanistischen Studien am Ende dieser Doktorarbeit beschrieben und erläutert. 
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1 INTRODUCTION 
Chirality is a geometric property of three-dimensional objects,1,2 and it was recognized 
by the chemists Le Bel and van’t Hoff in the 1870s.3,4 Later, Mislow provided a 
definition of chirality: “An object is chiral if and only if it is not superposable on its 
mirror image; otherwise it is achiral.”5 
The inherent chirality in nature creates a unique world. The 20 life-sustaining 
proteinogenic α-amino acids found in eukaryotes are exclusively in levo-forms. The 
three-dimensional receptors in a living body, such as proteins built from chiral α-amino 
acids, are able to differentiate between enantiomers. For example, the levo-asparagine is 
tasteless, while the dextro-form is sweet. Chirality becomes more important in 
pharmacological research due to a three-dimensional specific recognition between a drug 
and its action target.6,7 According to the U.S. Food & Drug Administration in 2006, 75% 
of small-molecule drugs were single enantiomers.8 Therefore, the synthesis of 
enantiopure drugs is highly demanded in modern pharmaceutical research. 
Enantiopure compounds can be prepared via three main approaches: 1. resolution of 
racemates, which is not economical with a maximum yield of 50%;9 2. chiral pool 
synthesis, in which a stoichiometric enantiopure starting material is required;10 3. 
asymmetric synthesis, in which the stereogenic centers are created from achiral starting 
materials.11 Among all, asymmetric catalysis provides an optimal access to enantiopure 
products using catalytic amounts of chiral catalysts for enantioselective induction.  
Complementary to enzymatic catalysis and chiral transition metal catalysis, 
organocatalysis has emerged as the third pillar of asymmetric catalysis, which was 
triggered by the discovery of aminocatalysis in 2000.12,13 Different from the catalysts 
generated from chiral organic ligands and metal species in transition metal catalysis, the 
low-molecular-weight organic molecules themselves function as catalysts for chemical 
transformations in organocatalysis.14 In fact, many challenging asymmetric 
transformations, which could not be solved by either enzymatic catalysis or transition 
metal catalysis, have been realized using organocatalysis. Continuingly excellent work 
coming from the Denmark, Jacobsen, Yamamoto, MacMillan, List, and other groups, has 
demonstrated that the creation of robust catalyst motifs is the key to successful 
asymmetric catalysis.  
1 INTRODUCTION 
 
2 
 
“One challenge that is likely to be addressed includes the Brønsted acid-catalyzed activation 
of new substrate classes such as unactivated carbonyl compounds or simple olefins, which 
will presumably require the design of even stronger chiral acids.”
14                                                                                 
Benjamin List, 2010 
Despite tremendous progress and glorious moments in asymmetric synthesis, the lack of 
broad substrate scopes, especially unactivated and/or small substrates, is a common 
problem in this field. This doctoral work focuses on general catalytic asymmetric 
reactions between simple, unactivated alkenes and aldehydes, many of which are 
inexpensive and abundant chemical feedstocks.    
In the following chapters, an overview of organocatalysis, especially Brønsted acid 
catalysis, is given. This is succeeded by the development of the carbonyl−ene cyclization 
and the hetero-Diels−Alder reaction. Subsequently, my own work on chiral Brønsted 
acid-catalyzed asymmetric reactions between alkenes and aldehydes is presented.   
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2 BACKGROUND 
2.1 Asymmetric Organocatalysis 
2.1.1 Introduction 
As the demand for enantiopure compounds in pharmaceuticals, fragrances, flavors, and 
materials increases, the development of asymmetric catalysis has correspondingly 
escalated in modern synthetic chemistry research. Chiral catalysts accelerate a chemical 
reaction by lowering the energy barrier and provide chiral environments for 
stereoselective inductions, affording enantiomerically enriched products. Utilizing and/or 
inspired by catalytic processes with extraordinary activity and selectivity in nature, 
enzyme catalysis and chiral metal catalysis have been regarded as two main 
methodologies in asymmetric synthesis. In recognition of the importance and the 
achievement of this field, the 2001 Nobel Prize in Chemistry has been awarded to 
Knowles and Noyori for their work on transition metal-catalyzed enantioselective 
hydrogenations15 and to Sharpless for his work on transition metal-catalyzed asymmetric 
oxidations16. 
“New synthetic methods are most likely to be encountered in the fields of biological and 
organometallic chemistry.”
17 
                                                                                                Dieter Seebach, 1990 
Complementary to transition metal catalysis and enzyme catalysis, simple organic 
molecules have rapidly emerged as powerful catalysts at the beginning of the 21st century. 
There are several advantages in organocatalysis. For example, most organocatalysts are 
quite practical without the requirement of a glove box or ultra-dried solvents. In fact, as 
early as in 1860, von Liebig demonstrated that a small organic molecular acetaldehyde 
could catalyze the hydrolysis of cyanogen.18  
  
Scheme 2.1 Acetaldehyde-catalyszed hydrolysis of cyanogen.  
After one century, in 1960 Precejus reported an alkaloid-catalyzed enantioselective 
addition of methanol to ketenes with moderate enantioselectivity. This is the first 
significantly enantioselective organocatalytic reaction.19  
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Scheme 2.2 Organocatalytic asymmetric esterification of ketene. 
Subsequently, two different groups simultaneously discovered the Hajos-Parrish-Eder-
Sauer-Wiechert reaction in the early 1970s.20,21 In this reaction, a proline-catalyzed 
intramolecular aldol reaction occurred, and  important progesterone intermediates were 
furnished following dehydration. This discovery demonstrated the potential of 
organocatalysis in asymmetric synthesis.  
  
Scheme 2.3 Hajos-Parrish-Eder-Sauer-Wiechert reaction. 
Nevertheless, it was not until the beginning of the 21st century, that the design and 
development of enamine catalysis by List and coworkers triggered a gold rush in 
organocatalysis. Inspired by the active core of the enzyme aldolase, the authors reported 
a (S)-proline-catalyzed aldol reaction of acetone with aldehydes.12 Excellent 
enatioselectivity and yield were achieved. To elucidate the reaction mechanism, a 
computational study was conducted.22 The condensation of the chiral (S)-proline with the 
ketone forms a more nucleophic enamine species. Meanwhile, the hydrogen bond was 
formed between the acid group in the catalyst and the aldehyde, lowering the LUMO of 
the aldehyde. Therefore, the Proline-catalyzed aldol reaction of the ketone with 
aldehydes was accelerated via both a HOMO raising as well as a LUMO lowering 
process.  
  
Scheme 2.4 (S)-proline-catalyzed aldol reaction. 
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Subsequently, another breakthrough in organocatalysis was made by the MacMillan 
group.13 They demonstrated the first highly enantioselective organocatalytic Diels–Alder 
reaction of enals with dienes, which was catalyzed by a chiral imidazolidinone through 
iminium catalysis. The authors proposed that the LUMO of the dienophile was lowered 
due to the formation of iminium species, resulting from the condensation between the 
secondary amine catalyst and an enal. 
  
Scheme 2.5 Imidazolidinone-catalyzed Diels–Alder reaction. 
Triggered by the developed enamine catalysis and iminium catalysis, organocatalysis 
quickly emerged as a powerful tool in synthetic chemistry. The success of this rapid 
growth of organocatalysis highly relies on a deep understanding of the reaction 
mechanism and the creation of different activation modes. Several activation modes in 
organocatalysis have been established according to the interactions between catalysts and 
substrates. These activation modes are generally classified into two categories: covalent 
catalysis (Scheme 2.6a) and non-covalent catalysis (Scheme 2.6b).23 Covalent catalysis 
includes enamine catalysis, iminium catalysis, SOMO catalysis, nucleophilic catalysis, 
and carbene catalysis, while non-covalent catalysis includes hydrogen bonding catalysis, 
asymmetric counteranion-directed catalysis (ACDC), and phase transfer catalysis.24,25 
 
Scheme 2.6 (a) Covalent catalysis. (b) Non-covalent catalysis.  
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On the other hand, catalysts could be generally categorized into four distinct types on the 
basis of their interactions with substrates: Brønsted acid, Lewis acid, Brønsted base, and 
Lewis base. Accordingly, the List group introduced the following systematical 
classification of reaction modes based on the organocatalysts: Brønsted acid catalysis, 
Lewis acid catalysis, Brønsted base catalysis, and Lewis base catalysis (Scheme 2.7).26 In 
Lewis acid and Lewis base catalysis, catalysts activate the substrates by acceptting or 
donating electrons, while Brønsted acid and base catalysis are initiated by a protonation 
or deprotonation of the substrates.  
  
Scheme 2.7 Classification of reaction modes based on catalysts. S, substrate; P, product; 
A, Acid; and B, Base. 
However, many popular organocatalysts, for example proline, chiral phosphoric acids, 
and some chiral thiourea catalysts, are bifunctional and possess both acidic and basic 
sites. The nucleophiles in the reactions are activated by the basic sites, while the 
electronphiles are activated by the acidic sites (Scheme 2.8). 
 
Scheme 2.8 Bifunctional organocatalysts.  
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2.1.2 Asymmetric Brønsted Acid Catalysis 
Lewis acid catalysis plays a crucial role in chemical synthesis and has been extensively 
investigated. For example, several coordination modes have already been established to 
activate a carbonyl group in Lewis acid catalysis (Scheme 2.9): 1. electrostatic 
interaction between a metal and a carbonyl; 2. coordination between a metal and the lone 
pair of a carbonyl, in which the metal is in the nodal plane of the carbonyl group; 3. 
coordination between a metal and the lone pair of a carbonyl, in which the metal is bent 
out of the nodal plane of the carbonyl group; 4. η2 coordination of the metal to a carbonyl; 
5. bidentate coordination between a carbonyl and two metals.27  
 
Scheme 2.9 Activation modes of carbonyl in Lewis acid catalysis. 
Compared to diverse metal species in Lewis acid catalysis, the active site in Brønsted 
acid catalysis is a single acidic proton. Two distinct activation modes have been 
established on the basis of the interaction between Brønsted catalysts and eletrophiles: 
general Brønsted acid catalysis and specific Brønsted acid catalysis (Scheme 2.10).28  
 
Scheme 2.10 Activation modes in Brønsted acid catalysis. 
Weak chiral Brønsted acids, such as chiral thioureas,29 squaramides,30 TADDOLs31 and 
BINOLs,32 are classified as general Brønsted acid catalysts. Hydrogen bonds are formed 
between electrophiles and the weak Brønsted acids, leading to the lowering of the 
LUMOs of the electrophiles. These hydrogen bonding catalysts have been widely used in 
asymmetric transformations, such as the Strecker reactions, Michael additions, hetero-
Diels–Alder reactions, and many others.  
2 BACKGROUND 
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Scheme 2.11 Selected catalysts in general Brønsted acid catalysis.  
Strong achiral Brønsted acids have been used to catalyze chemical reactions.33 
Frequently-used ones include CF3SO3H, HNTf2, HCl, HBF4, and benzenesulfonic acids, 
which have been utilized to catalyze a variety of transformations such as allylation 
reactions, Aldol reactions, Mannich reactions, Michael additions, Diels–Alder reactions, 
and hydrations or hydroaminations of alkenes.  
In contrast, asymmetric Brønsted acid catalysis is still in its infancy. It was not until 2004 
that the Akiyama group reported a chiral BINOL‐derived phosphoric acid-catalyzed 
highly enantioselective Mannich reaction between aromatic imines and silyl ketene 
acetals (Scheme 2.12).  34 
 
Scheme 2.12 Chiral Brønsted acid-catalyzed Mannich reaction.  
Independently, the Terada group reported a proposed phosphoric acid-catalyzed 
asymmetric Mannich reaction between N-Boc protected aromatic imines and diketones in 
the same year (Scheme 2.13).35 However, it was revealed six years later that the real 
catalyst was not the phosphoric acid, but in this case rather the corresponding calcium 
salt.36 These two reports are regarded as milestones in  chiral Brønsted acid catalysis and 
initiated the rapid development of stronger chrial Brønsted acids. 
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Scheme 2.13 Proposed Phosphoric acid-catalyzed Mannich reaction. 
Chiral phosphoric acids have emerged as powerful catalysts since their discovery.33,37 We 
ascribe the success of these chiral BINOL‐derived phosphoric acids in asymmetric 
catalysis to their following features: 1. bifunctionality; 2. tunablility; 3. rigid and chiral 
backbone. The bifunctional property of chiral Brønsted acids plays a crucial role in the 
cooperative activations of both nucleophiles and electrophiles in the reactions. The 
modulation of the 3,3'-substituents leads to a class of diverse phosphoric acids since the 
substituents at the 3,3'-positions of phosphoric acids are highly related to the steric 
hindrance and the acidity of the catalysts. The List group introduced a bulky 2,4,6‐
iPr3C6H2 group to this position and obtained one of the most popular chiral phosphoric 
acids, TRIP,38 which has been successfully applied to asymmetric‐counteranion directed 
catalysis (ACDC) and other asymmetric reactions.39,40 
 
Scheme 2.14 Features of chiral phosphoric acids. 
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The rigid BINOL core can also be modulated and several strategies have been 
successfully implemented (Scheme 2.15). The Antilla group reported a VAPOL-derived 
phosphoric acid-catalyzed imine amidation.41 The Gong group introduced a H8-BINOL‐
derived phosphoric acid, which showed its privilege in a highly enantioselective Biginelli 
reaction.42 Du and coworkers developed a doubly axial chiral phosphoric acid and 
applied this new catalyst to an asymmetric reduction of quinolines.43 Two groups 
independently introduced SPINOL backbones to the phosphoric acid catalysis in 2010. 
Lin, Wang, and coworkers reported a highly enantioselective Friedel‐Crafts reaction 
between indoles and imines, which was catalyzed by a 1-naphtyl‐substituted SPINOL-
derived phosphoric acid.44 Simultaneously, the List group developed a bulky SPINOL-
derived phosphoric acid: STRIP, which was used for an enantioselective kinetic 
resolution of alcohols via transacetalization.45 SPINOL‐derived phosphoric acids proved 
superior over the corresponding BINOL counterparts in some transformations, however 
the lack of practical approaches to synthesize SPINOL hindered the development of this 
novel catalyst motif. Gratifyingly, Tan and coworker recently reported an efficient and 
catalytic approach to synthesize enantiomerically enriched SPINOL derivatives.46 
Yamada, Takasu, and coworkers reported another novel catalyst, nitrated-TRIP, which 
had been utilized to catalyze a kinetic resolution of secondary alcohols. High 
stereoselectivities were generally achieved at ambient temperatures.47 
 
Scheme 2.15 Selected diverse backbones of chiral phosphoric acid catalysts. 
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Different chiral bis-phosphoric acids have been developed. In 2008 Gong and coworkers 
reported an organocatalytic asymmetric three-component 1,3-dipolar addition reaction of 
aldehydes, amino esters, with dipolarophiles, which was enabled by an ether-linked 
BINOL-derived bisphosphoric acid.48 Momiyama, Terada and coworkers designed 
another chiral and axial bis-phosphoric acid and applied this new catalyst motif to an 
highly enantioselective Diels–Alder reaction between α,β-unsaturated aldehydes and 
amidodienes.49 
 
Scheme 2.16 Selected chiral bis-phosphoric acid catalysts. 
However, the initial progress of chiral phosphoric acids has mainly relied on using 
reactive and basic electrophiles, such as imines. The development of highly acidic chiral 
Brønsted acids (Scheme 2.17 and 2.18) enables chemists to tackle more challenging 
reactions, facilitating the diversity of asymmetric synthesis. 
In 2006, the Terada group developed a novel chiral phosphordiamidic acid, which was 
applied to an asymmetric Mannich reaction between N‐acyl imines and 1,3‐dicarbonyl 
compounds (Scheme 2.17).50 Simultaneously, the Yamamoto group developed a highly 
acidic chiral N-triflyl phosphoramide, which was used in an asymmetric Diels−Alder 
reaction of α,β-unsaturated ketone with silyloxydiene with excellent stereoselectivity.51 
Recently, List and Kaib developed an extremely acidic chiral phosphoramidimidate, 
which was applied to the synthesis of α-tocopherol.52 A dramatic improvement of 
conversion was obtained, compared to other previously reported stronger chiral Brønsted 
acids. 
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Scheme 2.17 Selected phosphoric acid derivatives. 
In 2007, Hashimoto and Maruoka developed a new chiral BINOL‐derived dicarboxylic 
acid and applied this catalyst to a highly enantioselective Mannich reaction of 
arylaldehyde N‐Boc imines with diazo compounds.53 One year later, the List group 
reported another even stronger chiral BINOL-derived disulfonic acid-catalyzed three-
component Hosomi–Sakurai reaction, although the enantioselectivity was not achieved.54a 
However, Ishihara and coworkers reported a higly enantioselective Mannich reaction, which 
was catalyzed by the corresponding  pyridium-disulfonates. 54b The List group also developed 
other highly acidic chiral disulfonimides which have been used as precatalysts for Lewis acids 
in several highly enantioselective transformations, such as Mukaiyama-Aldol reactions, 
Mukaiyama-Mannich reactions, and the cyanosilylation of aldehydes.55-57 Recently, List and 
coworkers introduced a chiral nitrated-disulfonimide, which was applied to an 
enantioselective Torgov cyclization. This methodology was further utilized in the 
shortest enantioselective synthesis of (+)-estrone.58 
 
Scheme 2.18 Selected stronger BINOL-derived chiral Brønsted acids. 
Due to their relatively open active site, scarce progress has been made in the asymmetric 
reactions of small substrates in phosphoric acid catalysis. To address this issue, the List 
group developed a chiral imidodiphosphate (IDP) with 2,4,6-Et3C6H2 substitutents, which 
possesses an extremely confined chiral microenvironment (Scheme 2.19). This Brønsted 
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acidic catalyst was successfully used for asymmetric reactions of small substrates 
(Scheme 2.20 and 2.21).59,60 
R = 2,4,6-(Et)3C6H2, List et al. 2012
O
P
O
O
O
P
H
N
O
R R
R R
O
 
Scheme 2.19 Chiral confined Brønsted acids. 
List and Čorić utilized this IDP to catalyze the spiroacetalization of hydroxyenol ethers 
and various enantiomerically enriched spiroacetals, including some natural products that 
were obtained with excellent stereoselectivities (Scheme 2.20).59   
 
Scheme 2.20 IDP-catalyzed spiroacetalization. 
This confined Brønsted acid imidodiphosphate (IDP) with 2,4,6-Et3C6H2 substitutents 
was also applied to an asymmetric oxidation of sulfides by the same group. A variety of 
chiral sulfoxides were furnished with excellent yields and enantioselectivities (Scheme 
2.21).60   
R = 2,4,6(Et)3-C6H2
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Scheme 2.21 IDP-catalyzed sulfoxidation. 
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Subsequently, this type of confined imidodiphosphate has been successfully utilized in 
other asymmetric reactions. Zheng, Zhang, and coworkers reported a 1-naphathyl 
substituted imidodiphosphate-catalyzed asymmetric three-component Mannich reaction. 
Syn-ß-amino ketones were obtained with generally high enantioselectivities (Scheme 
2.22).61   
 
Scheme 2.22 IDP-catalyzed Mannich reaction. 
The modulation of imidodiphosphaten has been implemented, even though the efforts 
have mainly been put in modifying the BINOL backbones. Jiang, Zhang and coworkers 
developed a novel hybrid imidodiphosphate which was derived from two BINOL 
frameworks with different 3,3′-substituents. This new chiral acid was applied to an 
asymmetric Friedel−Crafts reaction and functionalized pyrrolylsubstituted 
triarylmethanes were obtained with good yields and high enantioselectivities (Scheme 
2.23).62   
 
Scheme 2.23 IDP-catalyzed Friedel–Crafts reaction. 
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The same group reported H8-BINOL-derived chiral imidodiphosphate-catalyzed highly 
chemo-, regio- and enantioselective aza-Friedel–Crafts reactions between pyrroles and 
enamides or imines to afford enantiopure bioactive aryl-(2-pyrrolyl)methanamine 
products with high yields and enantioselectivities (Scheme 2.24).63  
 
Scheme 2.24 H8-IDP-catalyzed aza-Friedel-Craft reaction. 
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2.2 Asymmetric Reactions between Aldehydes and Olefins 
Despite tremendous progress in asymmetric synthesis, broad substrate scopes, especially 
unactivated and/or small substrates have remained challenging. This doctoral work aims 
at general asymmetric reactions between unactivated carbonyl compounds and simple 
olefins, such as the carbonyl−ene reaction and the hetero-Diels–Alder reaction of simple 
dienes with aldehydes.                                            
2.2.1 Asymmetric Carbonyl−Ene Cyclization 
The ene reaction is a chemical transformation between an olefin containing an allylic 
C−H (ene) and a multiple bond (enophile), discovered by Prof. Alder in 1943.64 A 
concerted pathway is always envisioned, and a new C–C σ bond is formed along with a 
migration of a π bond and 1,5-hydrogen shift (Scheme 2.25).  
 
Scheme 2.25 The ene reaction. 
The corresponding intramolecular carbonyl–ene reaction is one of the most efficient and 
atom economical approaches to form C–C bonds and to construct functionalized cyclic 
compounds.65–67 As shown in Scheme 2.26, the intramolecular ene reaction is generally 
categorized into six distinct types depending on the connectivity between the alkene and 
the electrophile, on the basis of the work by Mikami, Oppolzer, and Snider. 65  
Scheme 2.26 Classification of intramolecular ene reaction. 
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Intramolecular carbonyl–ene reactions, in which carbonyl groups act as the enophiles, 
normally require temperatures higher than 140 °C.68 Several strategies have been 
implemented to accelerate the carbonyl–ene cyclization: 1. introduction of Lewis acid 
catalysts, which significantly lower the LUMO of the carbonyl; 2. application of 
electron-biased substrates, such as an electron-deficient carbonyl and/or an electron-rich 
alkene69,70; 3. use of steric acceleration.    
BINOL-derived chiral Lewis acids with different metal species have been extensively 
explored in asymmetric carbonyl–ene cyclization reaction in the last 30 years. In 1986, 
Yamamoto and coworkers reported the first Lewis acid-catalyzed asymmetric carbonyl–
ene cyclization reaction (Scheme 2.27).71 Even though a good yield and 
enantioselelctivity of the trans-diastereoisomer were achieved, 3 equiv. of the Lewis 
acidic zinc-BINOL complex were required. This work is regarded as a milestone for 
asymmetric carbonyl–ene cyclizations and 3,3,7-trimethyloct-6-enal has been continually 
used as a standard substrate in carbonyl–ene cyclization reactions since then. 
 
Scheme 2.27 The first Lewis acid-promoted asymmetric carbonyl–ene cyclization. 
Later, the Mikami group reported the first catalytic asymmetric intramolecular carbonyl–
ene cyclization reaction using a chiral titanium-BINOL complex as the catalyst. Six- and 
seven-membered cyclic products were obtained with moderate diastereoselectivities and 
moderate to good enantioselectivities.72 
 
Scheme 2.28 The first catalytic asymmetric carbonyl–ene cyclization. 
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Recently, Hori, Mino, and coworkers reported a chiral aluminum-BINOL complex-
catalyzed asymmetric carbonyl–ene cyclization (Scheme 2.29).73 Compared to previous 
results, the cycloadduct of 3,3,7-trimethyloct-6-enal was obtained with an improved yield 
and stereoslelectivity using a reduced amount of the catalyst. Toste, Bergman, Raymond, 
and coworkers designed and synthesized a chiral amide-directed supramolecule and 
employed this supramolecule to the carbonyl–ene cyclization of 3,3,7-trimethyloct-6-enal 
with competitive results.74 
  
Scheme 2.29 Chiral Al-BINOL complex-catalyzed asymmetric carbonyl–ene cyclization. 
Lewis acids with other chiral ligands, e.g. BOX ligand and Pybox ligand, were also 
employed in asymmetric carbonyl–ene cyclizations.75–78 In 2003, the Yang group 
reported a highly enantioselective intramolecular carbonyl–ene reaction of olefinic keto 
esters, which was catalyzed by the chiral Lewis acid [Cu((S,S)-Ph-BOX)](OTf)2.
75 
Functionalized cycloadducts were obtained in good yields and excellent 
stereoselectivities, even though activated substrates bearing an electron deficient 
carbonyl were required. 
 
Scheme 2.30 Asymmetric carbonyl–ene cyclization of olefinic keto esters. 
Recently, Loh and coworkers reported a chiral Lewis acid [Sc-Pybox)](OTf)3, which 
catalyzed a highly enantioselective intramolecular carbonyl–ene reaction.76 This 
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methodology was applied to an enantioselective total synthesis of a natural terpenoid 
product (+)-triptophenolide.  
 
Scheme 2.31 Enantioselective carbonyl–ene cyclization. 
Steric acceleration has been exploited in intramolecular cyclization reactions for more 
than one century.79–81 One of the typical strategies to accelerate a reaction through steric 
accelerations is the gem-dialkyl effect, which is also known as Thorpe–Ingold effect. In 
the Thorpe–Ingold effect, hydrogen atoms are replaced with alkyl groups on the tethering 
carbon, which decreases the angel between the reacting ends and increases the interaction 
between each other.82,83 As shown in scheme 2.32, the C–C–C angle in propane is 112.2°, 
however, C–C–C angle in isobutane is reduced to 111.1°, while the angle is further 
reduced to 109.5° in neopentane, which is due to the replacement of hydrogens by methyl 
groups on the tethering carbon. This strategy has also been used in asymmetric 
intramolecular carbonyl–ene reactions. For example, the frequently used substrate 3,3,7-
trimethyloct-6-enal is an activated substrate due to the gem-dialkyl effect. 
 
Scheme 2.32 Thorpe–Ingold effect. 
Recently, Jacobsen and coworkers reported a highly enantioselective chiral dimeric 
chromium complex-catalyzed carbonyl−ene cyclization reaction.78 Cis-diastereoselective 
products were exclusively afforded in good yields with high stereoselectivities in this 
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case. However, reactive substrates with Thorpe−Ingold-type substitutions were used in 
this work.  
 
Scheme 2.33 Thorpe–Ingold effect in asymmetric carbonyl–ene cyclization. 
Even though it is very fruitful in Lewis acid-catalyzed enantioselective intramolecular 
carbonyl–ene reactions, chiral Brønsted acid catalysis has rarely been utilized in this field. 
There were several achiral Brønsted acid-catalyzed non-enantioselective carbonyl–ene 
cyclizations reported by Snaith and coworkers.84,85 Different diastereoselectivity was 
obtained using achiral Brønsted acids compared to previously reported Lewis acid-
catalyzed variants. This inspired us to investigate the relatively unexplored field of chiral 
Brønsted acid-catalyzed carbonyl–ene cyclization reactions. 
 
Scheme 2.34 Achiral acid-catalyzed carbonyl–ene cyclization 
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2.2.2 Asymmetric Hetero-Diels–Alder Reaction of Dienes and Aldehydes 
The Diels–Alder (DA) reaction between dienes and olefins (dienophiles) serves to 
construct functionalized cyclohexene compounds (Scheme 2.35). The DA reaction is 
mechanistically considered to proceed through a concerted and six-membered aromatic 
transition state.86–90 
 
Scheme 2.35 Diels–Alder reaction. 
This reaction was named after the German chemists Otto Diels and Kurt Alder. They 
pioneeringly investigated a cycloaddition reaction between benzoquinone and 
cyclopentadiene in 1928.91 After this milestone discovery, the Diels–Alder reaction 
immediately drew the attention of synthetic chemists.92,93 Tremendous progress has been 
made in this field, such as: 1. well-established reaction mechanisms and theories on the 
basis of both experiments and computational studies, including the Alder endo rule, 
molecular orbital theory, and frontier orbital theory;94,95 2. exploration and extension of 
the reaction scope, which has been widely used in academic and/or industrial area; 3. the 
recent development of DA reactions on exploration of asymmetric variants. In 1950, the 
Noble Prize in chemistry was awarded to Prof. Diels and Prof. Alder for their work on 
the Diels–Alder reaction.   
Likewise, the hetero-Diels–Alder (HDA) reaction between dienes and aldehydes is 
arguably the most efficient and atom economical approach to oxygen heterocycles.96 Six-
membered oxygen heterocycles are frequently found within carbohydrates, 
pharmaceuticals, agrochemicals, and fragrances.  However, it was not until 1949 that 
Gresham and Steadman reported the first HDA reaction between formaldehyde and 
methylpentadiene (Scheme 2.36). Valuable functionalized dihydropyran compounds were 
obtained from abundant feedstocks, such as formaldehyde and simple dienes.97 
 
Scheme 2.36 Pioneering HDA reaction of a diene with an aldehyde. 
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As mentioned above, the recent progress of HDA reactions between dienes and aldehydes 
has mainly focused on the development of asymmetric methodologies. In the past three 
decades, a variety of chiral Lewis acid complexes have been applied to asymmetric HDA 
reaction between dienes and aldehydes, including chiral boron, aluminum, indium, 
chromium, zinc and titanium complexes.98 Yamamoto and his coworkers reported the 
first highly enantioselective HDA reaction between dienes and aldehydes, which was 
catalyzed by a chiral BINOL-Al complex (Scheme 2.37).99 Good yields and excellent 
stereoselectivties were achieved using a highly reactive Danishefsky-type diene. 
 
Scheme 2.37 The first highly enantioselective HDA reaction of dienes with aldehydes. 
The discovery of Danishefsky’s diene boosted the applications of HDA reactions in 
organic synthesis.93,96 The introduction of this activated reagent, narrowing the energy 
gap between HOMOdiene and LUMOdienophile, enabled the performance of asymmetric 
HDA reactions under mild reaction conditions.100 Moreover, this reagent also contributed 
to the high regioselectivity. Several other activated dienes were developed subsequently, 
for example, Brassard’s diene, and Rawal’s diene (Scheme 2.38).101–103 
 
Scheme 2.38 Activated diens. 
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Complementary to Lewis acid catalysis, Brønsted acid-catalyzed HDA reactions between 
dienes and aldehydes have also been investigated recently. In 2003, Rawal and coworkers 
reported a TADDOL-catalyzed asymmetric HDA reaction between Rawal’s diene and 
aldehydes.102 They proposed a novel hydrogen bonding activation between the chiral 
alcohol catalyst and the carbonyl group. Functionalized dihydropyrones were obtained in 
generally good yields and enantioselectivities. 
 
Scheme 2.39 Organocatalytic cycloaddition of an activated diene with aldehydes. 
List and coworkers reported a highly enantioselelctive HDA reaction of substituted 1,3-
bis(silyloxy)-1,3-dienes with aldehydes in 2012, which was catalyzed by a highly acidic 
disulfonimide (DSI). High yields and enantioselectivities were generally achieved. The 
authors proposed a stepwise mechanism involving a Mukaiyama aldol reaction.  
 
Scheme 2.40 DSI-catalyzed cycloaddition of activated dienes with aldehydes. 
However, the successful enantioselective, catalytic variants of these asymmetric HDA 
reactions have been limited to activated and electronically engineered dienes. 
Unactivated and simple dienes, such as isoprene, were also explored in asymmetric 
Lewis acid catalyzed hetero-Diels–Alder reactions, although activated dienenophiles, 
such as glyoxylate, were required.104,105 
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In 1991, Mikami  and coworkers reported a chiral BINOL-Ti complex-catalyzed reaction 
between methyl glyoxylate and isoprene.104 As shown in Scheme 2.39, the carbonyl–ene 
adduct was obtained as the main product compared to the [4+2]-cycloadduct.  
 
Scheme 2.41 Asymmetric HDA reaction of glyoxylate with isoprene. 
Similar results were observed in a chiral Cu-BOX complex-catalyzed reaction between 
methyl glyoxylate and 2,3-dimethylbuta-1,3-diene reported in 1995 by Jørgensen  and 
coworkers.105 Compared to the report above, the amount of [4+2]-cycloadduct was 
increased, even though the enantioselectivty was moderate. So far, an efficient chiral 
Lewis acid-catalyzed HDA reaction of simple and unactivated dienes with aldehydes has 
remained unmet. 
MeO2C
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Scheme 2.42 Chiral Cu-BOX complex-catalyzed asymmetric HDA reaction. 
Compared to the progress in chiral Lewis acid catalysis, there are no reports on chiral 
Brønsted acid-catalyzed HDA reactions of simple and unactivated dienes with activated 
aldehydes due to several known side reactions, including Prins reactions106,107 and 
cationic oligomerization reactions.108 
The development of asymmetric HDA reactions of simple and unactivated dienes with 
activated aldehydes is still in its infancy. Unsurprisingly, asymmetric HDA reactions 
between simple and unactivated dienes and unactivated aldehydes are still unknown so 
far. In principle, this virgin field continuously attracts chemists’ interests. Ecouraged by 
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the achiral acid-catalyzed [4+2]-cycloaddition between simple and unactivated dienes 
and aldehydes (Scheme 2.43),107,109−111 we were determined to develop a general 
asymmetric variant in this doctoral thesis. 
 
Scheme 2.43 Achiral acid-catalyzed HDA reaction. 
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3 OBJECTIVES OF THIS THESIS 
3.1 Catalytic Asymmetric Reactions of Simple Alkenes with Aldehydes 
The goal of this doctoral work is to develop Brønsted acid-catalyzed asymmetric 
reactions between simple, unactivated alkenes and aldehydes. Highly fundamental, yet 
challenging enantioselective transformations including a carbonyl−ene cyclization, a 
Prins cyclization, an oxa-Pictet−Spengler reaction, and a hetero-Diels−Alder reaction 
were explored.  
This PhD work began with the intramolecular carbonyl−ene cyclization, which has been 
frequently used in natural product synthesis. Chiral Lewis acid-catalyzed asymmetric 
versions of the carbonyl−ene cyclization have been investigated since the 1980s. The first 
highly stereoselective version was reported by the Jacobsen group in 2008, and highly 
cis-diastereoselective cycloadducts were exclusively afforded. However, reactive 
substrates with Thorpe−Ingold-type substitutions were required in this work. 
Alternatively, an organocatalytic asymmetric intramolecular carbonyl−ene cyclization 
was rarely investigated. We envisioned that an appropriate Brønsted acid would be able 
to activate the aldehyde group through mono activation, thereby accelerating the 
intramolecular carbonyl−ene cyclization. The confined chiral microenvironment of the 
Brønsted acid could minimize alternative transition states to guarantee high 
stereoselectivities (Scheme 3.1). A general Brønsted acid-catalyzed asymmetric 
carbonyl−ene cyclization of unactived olefinic aldehydes without Thorpe−Ingold-type 
substitutions was targeted in this doctoral work. 
 
Scheme 3.1 Brønsted acid-catalyzed asymmetric carbonyl−ene cyclization. 
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Enantioselective intermolecular cyclizations between aldehydes and alkenes were also 
explored in this thesis. The Prins cyclization between an aldehyde and a homoallylic 
alcohol is an efficient approach to deliver tetrahydropyrans, via an in situ generated 
oxocarbenium ion. Surprisingly, only a few asymmetric Prins cyclizations have been 
reported thus far, probably due to the high reactivity of the intermediate oxocarbenium 
ion. In addition, the relatively low nucleophilicity of alkenes leads to undesirable side 
reactions, such as the formation of an acetal (Scheme 3.2). Our group realized the first 
highly enantioselective Prins cyclization in 2015, though highly activated 
salicylaldehydes were required to achieve reasonable reactivity. When benzaldehyde was 
used, the corresponding acetal was formed as the major product under the optimized 
reaction conditions. Herein, the first general asymmetric Prins cyclization of diverse 
aromatic and aliphatic aldehydes is presented. 
 
Scheme 3.2 Brønsted acid-catalyzed asymmetric Prins cyclization. 
In continuation of our studies on the asymmetric Prins cyclization, we hypothesized that 
the oxocarbenium ion intermediate could, in principle, be trapped by an even less 
nucleophilic group, such as an arene, effecting the so-called oxa-Pictet−Spengler 
reaction. A broad range of substrates such as diverse aromatic and aliphatic aldehydes 
were envisaged. In addition to the challenge of stereo- and regioselective control, the 
possibility of the formation of the side product acetal should be precluded. The rational 
design and synthesis of a new type of chiral Brønsted acid might enable a general 
asymmetric oxa-Pictet−Spengler reaction (Scheme 3.3). Potentially bioactive isochroman 
products would be obtained in this envisioned asymmetric oxa-Pictet−Spengler reaction 
between aldehydes and homobenzyl alcohols. 
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Scheme 3.3 Brønsted acid-catalyzed oxa-Pictet−Spengler Reaction. 
Following the fruitful success of asymmetric intramolecular carbonyl−ene cyclization and 
Prins cyclization, a direct intermolecular transformation was next explored as part of the 
overarching goal towards Brønsted acid-catalyzed asymmetric cycloaddition between simple 
alkenes and aldehydes. A general asymmetric [4+2]-cycloaddition of simple dienes with 
aldehydes was envisioned, providing an efficient approach to valuable dihydropyran 
compounds. A highly acidic and chiral acid would be required to lower the LUMO of 
aldehydes, due to the lower nucleophilicity of simple dienes. Moreover, several side reactions 
might occur, since acid-catalyzed Alder−Ene reactions, Aldol reactions and the cationic 
polymerization reactions were observed in the previously reported hetero-Diels−Alder 
reaction of aldehydes with dienes.  
 
Scheme 3.4 A general asymmetric [4+2]-cycloaddition of dienes with aldehydes. 
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3.2 Highly Acidic and Confined Brønsted Acids 
In the last decade, phosphoric acids had enabled a variety of highly enantioselective 
transformations and thereby effected a tremendous development in organic synthesis.33 
However, since the active site is relatively open, scarce progress has been made in the 
asymmetric reactions of small substrates in phosphoric acid catalysis. In 2012, the List 
group developed a new type of Brønsted acid, C2‐symmetric imidodiphosphate (IDP), 
which provided a highly compact chiral pocket for the asymmetric acetalization of small 
substrates (Scheme 3.5).59  
 
Scheme 3.5 Confined chiral Brønsted acid. 
Complementary to highly nucleophilic hydroxyl groups in well-studied IDP-catalyzed 
enantioselective acetalization reactions, 112−113 less nucleophilic alkenes were explored in 
this doctoral work (Scheme 3.6). We envisioned that highly acidic and confined Brønsted 
acids were required to achieve high yields and stereoselectivities in the asymmetric 
reactions between simple aldehydes and unactivated alkenes. 
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Scheme 3.6 Utilization of highly acidic and confined Brønsted acids. 
To enhance the acidity and steric hindrance of the confined imidodiphosphate (IDP) 
catalyst, three positions were mainly modulated in this thesis: (1) the active site, (2) the 
3,3'-positions, and (3) the 6,6'-positions of the BINOL backbones (Scheme 3.7). The 
development of the chiral Brønsted acid imidodiphosphate (IDP) and its derivatives made 
it possible to tackle extremely challenging asymmetric transformations in synthetic 
chemistry.  
 
    
Scheme 3.7 Highly acidic and confined chiral Brønsted acids. 
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4 RESULTS AND DISCUSSION 
4.1 Organocatalytic Asymmtric Carbonyl−Ene Cyclization 
4.1.1 Reaction Design and Initial Study 
The intramolecular carbonyl−ene cyclization provides an efficient and atom economic 
approach to diverse cyclic compounds.64,114 Activated substrates such as olefinic α-keto 
esters75,76 or olefinic aldehydes78 with Thorpe−Ingold-type substitutions were frequently 
in previously reported asymmetric carbonyl−ene cyclizations, due to the weak 
nucleophilicity of the alkene. As discussed in the background part, organocatalysis has 
been rarely developed in this field, compared to the fruitful Lewis acid-catalyzed 
asymmetric intramolecular carbonyl−ene cyclizations. 
We envisioned that confined chiral Brønsted acids would enable a general highly 
enantioselective carbonyl−ene cyclization (Scheme 4.1). Presumably, the hydrogen bond 
between the chiral bifunctional Brønsted acid and the carbonyl would accelerate the 
cyclization step. The compact microenvironment surrounding the active site of the chiral 
acid would be amenable to distinguish different confirmations of the cyclic ring in the 
transition state. 
  
Scheme 4.1 Brønsted acid-catalyzed carbonyl−ene cyclization reaction. 
We began our investigation with the chiral acid-catalyzed cyclization of olefinic 
aldehyde 1a to obtain pyrrolidine 2a. Different types of BINOL-derived Brønsted acids 
including phosphoric acid 3a,33,115,116 N-triflylphosphoramide 4a,51,117,118 and 
disulfonimide 5a,55,119 were explored. Gratifyingly, all these catalysts were able to afford 
the desired product with high trans-diastereoselectivities, but with low 
enantioselectivities (Table 4.1, entries 1−3). We reasoned that the active sites in chiral 
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acids 3a−5a were relatively open and might therefore not be amenable for high 
enantiocontrol of the small substrate 1a. Subsequently, a more confined Brønsted acid 
imidodiphosphate 6a120 was tested, giving a promising enantiomeric ratio (er) of 
74.5:24.5. After modulating the substituents at the 3,3'-postions of  the 
imidodiphosphates, catalyst 6c with 2,4,6- Et3C6H2 substituents fully converted 1a to 2a 
with an excellent diastereomeric ratio (dr) of 43:1 and a 97.5:2.5 er. The dr of 2a could 
reach 50:1 after optimizing the solvent. 
Table 4.1 Optimization of reaction conditions.a  
3-6 (5 mol%)
rt, 36 h
*
N
*
Ts
HO
1a
O
O
P
O
OH
SO2
SO2
NH
R = 3,5-(CF3)2C6H3 (6a)
Ph (6b)
2,4,6-Et3C6H2 (6c)
N
Ts
O H
2a
O
O
P
O
NHTf
F3C
CF3
CF3
F3C
F3C
CF3
CF3
F3C
CF3
F3C
F3C
CF3
phosphoric acid
3a
N-triflylphosphoramide
4a
disulfonimide
5a
imidodiphosphate (IDP)
O
P
O
O
O
PN
OH
R R
R R
O
conv.(%) ertrans
bentry catalyst solvent trans:cisb
1 3a CH2Cl2 >95 16:1 58:42
2 4a CH2Cl2 >95 12:1 64:36
3 5a CH2Cl2 >95 24:1 58.5:41.5
4 6a CH2Cl2 >95 18:1 75.5:24.5
5 6b CH2Cl2 56 19:1 53.5:46.5
6 6c CH2Cl2 >95 43:1 97.5:2.5
7 6c MeCy >95 50:1 97.5:2.5
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aUnless otherwise indicated, reactions were performed with 1a (0.1 mmol) and catalyst (5 
mol%) in 1.0 mL of solvent for 36 h at room temperature. bDetermined by HPLC. 
4.1.2 Substrate Scope 
With optimized reaction conditions at hand, the scope of this reaction was explored next. 
Different olefinic aldehydes could be obtained in two to four steps from commercially 
available amino acids, amino alcohols, or di-tert-butyl-malonate (Scheme 4.2).78,121 
 
 Scheme 4.2 Syntheses of substrates. 
Under optimized reaction conditions, functionalized pyrrolidines were obtained from α,α-
disubstituted α-amino olefinic aldehydes in generally high yields with excellent 
diastereoselectivities and good to excellent enantioselectivities (entries 1−4). Substrates 
with cyclic olefins were also explored (entries 5−6). Substrate 1f performed smoothly to 
product 2f with a >20:1 dr and a 95.5:4.5 er, but the enantioselectivity of 2e was slightly 
declined (92:8 er). Gratifyingly, products 2g and 2h could both be obtained with good 
diastereoselectivities, excellent enantioselectivities, and in good yields by slightly 
increased catalyst loadings and reaction temperatures, and by extending the reaction 
times (Table 4.2, entries 7−8). Moreover, 3,4-disubstituted tetrahydrofurans could be 
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obtained in moderate to good yields and high enantiopurities (entries 9−10). The reaction 
of non-Thorpe-Ingold-substrate 1i proceeded well under the neat conditions. A 
carbocyclic five-membered ring was also obtained smoothly when using di-tert-butyl-
malonate-derived substrate 1k (Table 4.2, entry 11).  
Table 4.2 Reaction scope.a 
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Continuing Table 4.2 Reaction scope.a 
  
aSubstrate 1 (0.1 mmol), catalyst 6c (5 mol%) in cyclohexane (1 mL) at rt. bDetermined 
by 1H-NMR. cDetermined by HPLC or GC analysis. dReaction at 10 °C. e6c (7.5 mol%). 
fReaction at rt, then at 50 °C. gNeat conditions. hNMR yield using an internal standard. 
i6c (10 mol%) 
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The absolute configuration of 2a was determined as 3S,4R using single-crystal X-ray 
diffraction analysis (Figure 4.1). The corresponding cis-3R,4R diastereomer was obtained 
using Jacobsen’s chiral Cr-dimer as the catalyst.  
     
Figure 4.1 X-ray crystal structure of 2a.  
4.1.3 Mechanistic Studies and Discussion 
Mechanistic Studies 
During our investigation, an interesting observation triggered us to uncover the 
mechanism of this Brønsted acid-catalyzed asymmetric carbonyl−ene cyclization of 1a. 
During the monitoring of the reaction process a weak new spot above the catalyst was 
observed on the thin layer chromatography (TLC) when irradiated with UV-light (λ = 
254 nm). However this newly generated weak spot disappeared along with the 
completion of the reaction. Presumably, the new species could be a reversible isomer of 
substrate 1a or a reversible side product, since the desired product 2a could be fully 
afforded. However, it was also possible that the new species was an intermediate in the 
catalytic cycle. 
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Figure 4.2 TLCs of reaction mixture.   
To figure out this interesting species and to elucidate the mechanism of this asymmetric 
intramolecular carbonyl−ene cyclization, we carefully investigated the cyclization of 1a 
catalyzed by 6b and 6c, respectively. ESI-MS and NMR studies of both reactions were 
carried out next. 
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ESI-MS Study 
As shown in Figure 4.3, in the initial electrospray ionization mass spectrometry (ESI-
MS) study a new peak at m/z 1291 appeared within minutes (Figure 4.3b) matching the 
mass of the catalyst 6b-1a (or 2a) adduct in the cyclization of 1a catalyzed by catalyst 
6b. Similarly, the new peak at m/z 1627 in the cyclization of 1a catalyzed by 6c matched 
the mass of catalyst 6c-1a (or 2a) adduct (Figure 4.3c). Presumably, a covalent 
intermediate was generated from the catalyst and substrate during the reaction. This 
exciting but unexpected result motivated us to determine the structure of the covalent 
adduct. 
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Figure 4.3 ESI-MS study of cyclization of 1a: (a) The MS of 1a. (b) Using catalyst 6b. 
(c) Using catalyst 6c. 
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NMR Kinetic Study 
NMR studies of the 6b-catalyzed cyclization of 1a were performed (Figure 4.4).122 
According to the NMR data analysis, the covalent adduct 7b was rapidly formed as soon 
as substrate 1a and catalyst 6b were dissolved in CD2Cl2 (Figure 4.4a). Interestingly, 
eight peaks were detected in the 31P NMR spectrum of 7b (Figure 4.4b). These peaks 
reflected two different diastereomeric intermediates containing two chemically non-
equivalent phosphorus atoms, that were coupling with each other, in line with the 
observed poor enantioselectivity and high trans-diastereoselectivity of 2a (53.5:46.5 er 
and >20:1 dr). Moreover, free catalyst 6b remained below the detection limit during the 
reaction. Presumably, the reaction proceeded via a covalent intermediate 7b and the 
release of catalyst 6b from 7b could be the rate-determining step.  
 
Figure 4.4 (a) Intermediate 7b. (b) 31P NMR spectra of reaction mixtures. 
NMR kinetic studies of the 6b-catalyzed cyclization of 1a were performed (Figure 4.5). 
As shown in Figure 4.5, the quasi-steady-state kinetic could be reached during the 
reaction. The reaction was zero-order with 1a, but first-order with intermediate 7b. 
Apparently, the continual transformation of 7b accomplished the regeneration of catalyst 
6b and afforded product 2a. As we speculated, the reaction indeed proceeded via a 
covalent intermediate 7b and the release of catalyst 6b from 7b turned out to be the rate-
determining step. 
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Figure 4.5 1H NMR kinetics of the cyclization of 1a to 2a using catalyst 6b. 
Similarly, 7c was observed as soon as substrate 1a and catalyst 6c were dissolved in 
CD2Cl2 (Figure 4.6a). Four peaks were observed in the 
31P NMR spectrum of 7c (Figure 
4.6b), which were different from the eight peaks in the 31P NMR spectrum of 7b (Figure 
4.4b). This was due to the high enantioselectivity and diastereoselectivity of 2a when 
using 6c as the catalyst (97.5:2.5 er and >20:1 dr). The observed AB spin system of two 
chemically non-equivalent 31P nuclei of one single diasteromer of 7c (Figure 4.6b) was 
also consistent with the high stereoselectivity. 
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Figure 4.6 (a) Intermediate 7c. (b) 31P NMR spectra of reaction mixtures. 
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Presumably, the quasi-steady-state kinetic could also be reached in the 6c-catalyzed 
cyclization of 1a. We assumed that a sufficient amount of 6c was likely to be fully 
converted into adduct 7c at the beginning of the reaction. With this assumption, we 
carried out a cyclization reaction of 1a with only 1 mol% of catalyst 6c at 294.2 K. An 
excellent 97:3 er and 30:1 dr of 2a were observed. According to the 1H NMR spectra 
(Figure 4.7) and 31P NMR spectra (Figure 4.8) of the reaction, catalyst 6c remained 
below the detection limit at the beginning of the reaction, while the concentration of 
adduct 7c kept essentially constant. The continual transformation of compound 7c 
accomplished the regeneration of catalyst 6c and afforded product 2a. The quasi-steady-
state kinetic of 6c was indeed reached and we could figure out that the release of catalyst 
6c from compound 7c was the rate-determining step of this transformation (Scheme 4.3).  
Scheme 4.3 Rate-determining step. 
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Figure 4.7 (a) 1H NMR kinetics of the cyclization of 1a to 2a using catalyst 6c. 
(b) 31P NMR spectra of reaction mixtures taken at different time. 
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Thermodynamic Kinetic Study 
The Eyring equation was generally used in NMR kinetic studies to determine the 
thermodynamic parameters in the 6c-catalyzed cyclization of 1a (equation 4.1).124 
 ln(kh/kBT) =  - ∆H/RT  + ∆S/R (4.1)  
We were able to manage the 6c-catalyzed cyclization of 1a to reach the quasi-steady-
state kinetic at different temperatures, for example, 280.6 K, 294.2 K, 301.2 K, 312.3 K, 
323.4 K.125,126 Collaborating with my colleague Dr. Markus Leutzsch, the reaction rate 
constants of the reactions could be readily calculated according to the 1H NMR kinetic 
measurements (Table 4.3).  
Table 4.3 Reaction rate constant at different temperature 
T (K) 280.6 294.2 301.2 312.3 323.4 
1/T (K-1) 0.003564 0.0034 0.00332 0.003202 0.003092 
k (s-1) 5.17372E-05 0.000301076 0.000493541 0.001958173 0.004711654 
ln(kh/kBT) -39.2662417 -37.5522139 -37.0815238 -35.7398133 -34.896584 
 
According to the Eyring plot, we were able to generate a function between the rate 
constant and the temperature (Figure 4.8). We could determine the activation enthalpy 
∆H≠ (18.47 ± 0.73 kcal/mol at 298.15 K) and the activation free energy ∆G≠ (22.08 ± 
1.46 kcal/mol at 298.15 K) of the rate-determining step of this reaction which referred to 
the release of catalyst 6c from the covalent adduct 7c (Table 4.4). 
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Figure 4.8 Eyring plot. 
4 RESULTS AND DISCUSSION 
 
43 
   
Table 4.4 Calculation of activation parameters at 298.15 K. 
∆H≠ 77258.88 ± 3072.25 J/mol 18.47 ± 0.73 kcal/mol 
∆S≠ −50.71 ± 10.20 J/(K⋅mol) −0.0121 ± 0.0024 kcal/(K⋅mol) 
∆G≠ 92377.84 ± 6112.89 J/mol 22.08 ± 1.46 kcal/mol 
 
Discussion 
In this part of the PhD work, the first organocatalytic asymmetric intramolecular 
carbonyl−ene reaction of olefinic aldehydes was successfully developed, and diverse 
trans-configured pyrrolidines, tetrahydrofuranes, and cyclopentanes were obtained in 
good yields, with good to excellent diastereoselectivities and enantioselectivities. To the 
best of our knowledge, for the first time, high trans-diastereoselectivities up to 50:1 dr 
were achieved in this asymmetric carbonyl−ene cyclization. Unactivated substrates such 
as 1g-i without Thorpe−Ingold-type substitutions were also compatible under the 
optimized reaction conditions.  
Moreover, we could show that this chiral imidodiphosphate catalyzed asymmetric 
intramolecular carbonyl−ene reaction proceeds through a covalent intermediate, which is 
generated from the catalyst and cyclized substrate. A subsequent release of free catalyst 
from this covalent intermediate afforded the desired product. It needs to be addressed that 
the bifunctional property of the catalyst plays a crucial role for the catalytic cycle. 
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4.2 Organolcatalytic Asymmetric Transformations via Oxocarbenium Ions 
As reactive intermediates, oxocarbenium ions are used in several types of 
transformations. Our confined chiral acid imidodiphophates (IDPs) have been 
successfully utilized in the asymmetric acetalization of small substrates via an 
oxocarbenium ion intermediate. Presumably, these confined acid IDPs offer potential for 
other asymmetric transformations. We hypothesized that the reactive oxocarbenium ions 
could be further trapped by a less nucleophilic sp2-hybridized alkene group or an arene 
group instead of a reactive hydroxyl group (Scheme 4.4). Probably, asymmetric 
reactions, such as enantioselective Prins cyclizations and oxa-Pictet−Spengler reactions 
could be realized using our confined chiral acids as catalysts. 
 
Scheme 4.4 IDP-catalyzed reactions between carbonyls and homoallylic alcohols. 
4.2.1 Catalytic Asymmetric Prins Cyclization 
(with Dr. Philip S. J. Kaib and Dr Gavin Chit Tsui) 
A highly enantioselective Prins cyclization between aldehydes and homoallylic alcohols 
was investigated, effecting functionalized tetrahydropyrans (THPs).127−129 Despite 
tremendous applications of the Prins cyclization in natural product synthesis, 130−133 a 
highly enantioselective catalytic Prins cyclization has not been reported.134,135 As shown 
in Scheme 4.5, we assumed that an oxocarbenium ion pair A could be readily formed 
according to our previous studies in IDP-catalyzed asymmetric acetalization. Probably, 
the oxocarbenium ion could be attracted by another intermolecular homoallylic alcohol, 
generating the undesired side product acetals. Presumably, the equilibrium between the 
oxocarbenium ion and the acetal could occur. The oxocarbenium ion could be trapped by 
the intramolecular nucleophilic alkene group generating another intermediate tertiary 
carbocation ion pair B. 136−138 An exocyclic or endocyclic alkene Prins product would be 
obtained after the release of the catalyst, since the deprotonation could proceed either at 
the primary or the secondary carbon.  
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Scheme 4.5 IDP-catalyzed Prins cyclization. 
4.2.1.1 Reaction Design and Initial Study 
We began our investigation of the Prins cyclization with aldehydes and 3-methyl-3-
buten-1-ol. Our confined IDP 6d showed a good enantiocontrol in the asymmetric Prins 
cyclization of salicylaldehydes with 3-methyl-3-buten-1-ol in high yields, with excellent 
regio- and enantioselectivities. (Scheme 4.6).  
              
Scheme 4.6 IDP-catalyzed Prins cyclization (with Dr Gavin Chit Tsui). 
Unfortunately, under the optimized reaction conditions, benzaldehyde gave a poor yield, 
but a good enantioselectivity (11% yield, 95:5 er) (Scheme 4.7a). Aliphatic 
isovaleraldehyde turned out to be even less reactive (7% yield), the acetal 8 was obtained 
as the main product (Scheme 4.7b). 
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Scheme 4.7 IDP-catalyzed Prins cyclization of simple aldehydes. 
We speculated that the poor activities of simple aldehydes could be due to the 
insufficient acidity of the IDP catalyst 6d. To address this issue, we presumed that the 
replacement of one oxo-group in IDP with a stronger electron withdrawing group, such 
as an NSO2CF3 (NTf)-group, would lead to a more acidic and confined imino-
imidodiphosphate (iIDP) 9 (Scheme 4.8). 
 
Scheme 4.8 Highly acidic and confined Brønsted acid iIDP (Dr. Philip S. J. Kaib). 
Both aromatic and aliphatic aldehydes proved suitable substrates for iIDP-catalyzed Prins 
cyclization, displaying high enantioselectivities and good yields (Scheme 4.9). 
        
Scheme 4.9 Exploration of Brønsted acid iIDPs. 
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4.2.1.2 Substrate Scope, Gram-Scale Synthesis, and Derivatizations 
Various linear, α-, and β-branched aliphatic aldehydes turned out to be suitable 
substrates for catalyst 9a under the optimized reaction conditions (Table 4.5, entries 1−8) 
and excellent enantioselectivities and good yields were generally obtained. THP products 
11 were obtained in good to excellent regiomeric ratios (rr; ratio of exo– to endocyclic 
isomers) of up to >20:1. 2-Phenylacetaldehyde (10h) was converted with reasonable 
enantioselectivity (90:10 er) (Table 4.5, entry 8). α,β-unsaturated aldehyde 10i required a 
higher catalyst loading of iIDP 9b and a prolonged reaction time to achieve high yield 
and enantioselectivity (Table 4.5, entry 9). Aromatic aldehydes, such as benzaldehyde, 
were selectively converted to the corresponding THPs, such as 11j, which was isolated in 
69%yield and with an excellent enantiomeric ratio of 96:4 (Table 4.5, entry 10). 
Systematic substitutions of the benzaldehyde core in ortho, meta, and para-position with 
electron donating and electron withdrawing groups were tolerated by catalyst 9b. For 
instance, THPs 11k−11p were obtained in good yields (65−86%), high to excellent 
enantiomeric ratios (up to 96.5:3.5 er) and high to excellent regioselectivities (up to 
>20:1) (Table 4.5, entries 11−16). Moreover, heterocyclic aromatic aldehydes 10q and 
10r successfully furnished the desired Prins cyclization products 11q and 11r (Table 4.5, 
entries 17−18). 
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Table 4.5 Reaction scope.a 
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Continuing Table 4.5 Reaction scope.a 
 
aUnless otherwise indicated, all reactions were carried out with 10 (0.12 mmol), 3-
methyl-3-buten-1-ol (0.1 mmol), iIDP catalyst 9 (5 mol%), and 50 mg of 5 Å molecular 
sieves in 1.0 mL of solvent (0.1 M); cyclohexane was used as solvent when T ≥10°C, 
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methylcyclohexane was used as solvent when T <10°C; catalyst 9b was used to afford 
products 11a−11h, catalyst 9a was used to afford 11i−11r;  bIsolated yields of 11h and 
11j−11r are given, yields of the volatile products 11a−11g and 11i were determined by 
1H-NMR of the reaction mixtures using CHCl2CHCl2 as internal standard. 
cDetermined 
by GC analysis. dThe regiomeric ratio (rr) between exo- and endocyclic alkenes was 
determined by GC analysis. e10 mol% catalyst was used. 
The absolute configuration of 11o was determined as R using single-crystal X-ray 
diffration analysis (Figure 4.9).  
 
Figure 4.9 X-ray crystal structure of 11o. 
This methodology is quite robust, and a gram-scale asymmetric Prins cyclization of 
pivalaldehyde 10g was achieved (Scheme 4.10a). 1.0 gram of 4-
methylenetetrahydropyran (R)-11g was obtained in a 83% yield and 98:2 er. With a 
variety of scented THPs in hand, we collaborated with the perfumery company Givaudan 
to explore the olfactory properties of our products. The olfactory investigation of 
undiscovered compoud 11g was carried out. Unfortunately, (R)-11g (odor threshold > 
500 ng/L air) proved to be too weak to serve in perfumery (Scheme 4.10a). (S)-11g could 
be furnished using the corresponding enantiomer of catalyst 9b (98:2 er). As shown in 
Scheme 4.10a, (S)-11g had a floral and slightly chocolate smell (odor threshold 47.6 ng/L 
air), which was more than ten times stronger compared to (R)-11g. After the 
hydrogenation process of (R)-11g, cis-12a was obtained as a major product with an 
excellent 97:3 er. Compared to (R)-11g, cis-12a was five times weaker (odor threshold 
250 ng/L air).  
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Scheme 4.10 Access to different scents. 
4.2.1.3 Discussion 
The first general catalytic asymmetric Prins cyclization was successfully developed 
(Scheme 4.11). Diverse scented THP products were obtained via the Prins cyclization of 
commercially available aldehydes and homoallylic alcohols, in good to excellent yields 
and with good to excellent regio- and enantioselectivities. This methodology is quite 
practical and scalable. Both enantiomerically enriched ennatiomers could be obtained 
using different enantiomers of imino-imidodiphosphates. It is worth mentioning that 
these newly developed, more acidic and confined imino-imidodiphosphates (iIDPs) 
catalysts were the key to this highly enantioselective Prins cyclization. 
 
Scheme 4.11 iIDP-catalyzed Prins cyclization. 
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The diverse tetrahydropyran products themselves already showed interesting olfactory 
properties. Valuable fragrant compounds such as rose oxide and doremox could be 
obtained, after a simple diastereoselective hydrogenation of the corresponding Prins 
cyclization products 11i and 11j. 
                               
Scheme 4.12 Derivatization to different scented compunds. 
A plausible mechanism of this asymmetric Prins cyclization was proposed (Scheme 
4.13). The imino-imidodiphosphate (iIDP) acid catalyzed the initial condensation of 
aldehyde 1a and a homoallylic alcohol affording an ion pair of the oxocarbenium ion A 
and a chiral imino-imidodiphosphate counteranion. Acetal 8 was detected as soon as all 
the reagents were mixed, because ion pair A could be trapped by another molecule of the 
homoallylic alcohol acting as a nucleophile. In the equilibrium, acetal 8 could be fully 
consumed since oxocarbenium ion A could be further attacked by an intramolecular 
alkene group forming the tertiary carbocation B. In the following deprotonation step, the 
confined imino-imidodiphosphate counteranion kinetically prefers removing a proton at 
the primary carbon so that the exocyclic alkene product 11a was furnished as the major 
product. 
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Scheme 4.13 Proposed catalytic cycle. 
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4.2.2 Catalytic Asymmetric Oxa-Pictet−Spengler Reaction 
(with Dr. Sayantani Das) 
Encouraged by the results of our imino-imidodiphosphate (iIDP) catalyzed asymmetric 
Prins cyclization, we envisioned an acid-catalyzed enantioselective oxa-Pictet−Spengler 
reaction between aldehydes and aryl ethanols.139−141 As shown in Scheme 4.14, 
presumably, the readily formed oxocarbenium ion of C could be attracted by an 
intramolecular arene, generating another ion pair D. Valuable bioactive enantiomerically 
enriched isochromans could be obtained after a subsequent rearomatization. 142−145 
Probably, the oxocabenium ion of C could be trapped by another intermolecular 
homobenzyl alcohol, and the undesirable side product acetal E would be generated.  
  
Scheme 4.14 iIDP-catalyzed oxa-Pictet−Spengler reaction. 
4.2.1.1 Reaction Design and Initial Study 
The investigation of chiral imidodiphosphate (IDP) catalyzed oxa-Pictet−Spengler 
reaction was carried out using isovaleraldehyde and phenylethanol 13a.146,147 
Unfortunately, the desired product was not obtained using IDP 6c as catalyst (Table 4.6, 
entry 1). We hypothesized that the introduction of a hydroxyl group at the meta position 
of phenylethanol 13a would increase the nucleophilicity of the arene. Indeed, using 3-(2-
hydroxyethyl) phenol 13b as substrate, the desired product 14b was obtained in a 
promising yield and with a high enantioselectivity (32%, 94:6 er). Remarkably, using 
imino-imidodiphosphate (iIDP) 9c as the catalyst, 14b was obtained with a high 
enantioselectivity (95:5 er) but a low yield of 53% (Table 4.6, entry 3). 
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Table 4.6 Optimization of reaction conditionsa 
 
entry substrate catalyst time yield(%)b er 
1c 13a 6c 72 h 0 N.D. 
2 13b 6c 72 h 32 94:6 
3 13b 9c 72 h 53 95:5 
aReactions on a 0.02 mmol scale (0.2 M). bNMR yield. cDCE was used as solvent. 
4.2.2.2 Catalyst Design, Synthesis, and Substrate Scope 
Catalyst Design 
As shown in Table 4.6, the modification of our confined IDP catalysts indeed improved 
the enantioselectivity of this Brønsted acid catalyzed oxa-Pictet−Spengler reaction. 148−151 
We speculated that a potential hydrogen bond would be formed between the hydroxyl 
group in 13b and the basic site of the IDP derivatives, under the assumption that the 
bifunctional property of IDP derivatives was crucial for this asymmetric oxa-
Pictet−Spengler reaction. We assumed that the basicity of iIDP 9c was not strong enough 
for the rearomatization step, which resulted in the low yield of this reaction. Probably, a 
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subtle modulation of IDP might enable both high yield and enantioselectivity of this oxa-
Pictet−Spengler reaction.  
  
Scheme 4.15 Rearomatization step. 
The acidity of the imidodiphosphates (IDPs) could be increased by introducing nitro 
groups on one side of the BINOL backbones. The chiral environment of this newly 
designed nitrated imidodiphosphates (nIDPs) would interact more closely with 
intermediates leading to a highly enatioselective control. Probably, the basicity of this 
new Brønsted acidic nIDPs would be enough for the rearomitization step resulting in an 
ideally high yield. 
Scheme 4.16 Stronger confined Brønsted acid. 
Catalyst Synthesis 
Compared to the synthesis of the corresponding IDP catalyst, an additional step of 
nitration of the corresponding BINOL was required. Starting from the laboratory 
available 3,3'-substituted BINOL derivatives, the corresponding nitrated BINOL 15 could 
be easily obtained in one step. The remaining steps were similar to the synthesis of IDP, 
and the nitrated imidodiphosphates could be rapidly formed through the coupling of 16 
and 17 under basic conditions. Subsequent to column chromatography, the mixture of 
nitrated imidodiphosphate and its salts were acidified by 6 M aqueous HCl. A class of 
nitrated imidodiphosphates 18a−18c were successfully obtained (Scheme 4.17). 
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Scheme 4.17 Synthesis of nitrated imidodiphosphates (nIDPs). 
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Application of nIDP in the Oxa-Pictet−Spengler Reaction 
Based on initial results, nitrated imidodiphosphate 18a with bulky 2,4,6-Et3C6H2-
substitutents at the 3,3'-positions of the BINOL backbones was  subsequently utilized in 
this asymmetric oxa-Pictet−Spengler reaction (Scheme 4.18). Gratifyingly, the desired 
product 14b was obtained with a high yield of 90% and with an excellent 
enantioselectivity 98:2 er. The rational design and synthesis of nIDP was crucial to 
realize this highly enantioselective oxa-Pictet−Spengler reaction. 
 
Scheme 4.18 Utilization of nitrated imidodiphosphate (nIDP). 
Reaction Scope 
Under the optimized reaction conditions, the scope of this reaction was explored next. As 
shown in Scheme 4.19, both aliphatic and aromatic aldehydes were compatible with this 
highly enantioselective oxa-Pictet−Spengler reaction (14b−14i). Other phenol derivatives 
were also explored and products 14g−14k were obtained in excellent yields (92–98%) 
and enantioselectivities (up to >99:1 er). 
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Scheme 4.19 Reaction scope. 
19a could be readily furnished after one simple derivatization of oxa-Pictet−Spengler 
reaction product 14g (Scheme 4.20). The absolute configuration of 19a was determined 
as R by single-crystal X-ray diffraction analysis (Figure 4.10).  
                                                  
Scheme 4.20 Derivatization. 
  
Figure 4.10 Absolute configuration of 19a. 
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4.2.2.3 Discussion 
In this part, the first highly enantioselective catalytic oxa-Pictet−Spengler reaction was 
successfully developed. A variety of potentially bioactive isochroman products were 
obtained in good to excellent yields and with good to excellent regio- and 
enantioselectivities. The rational design and the synthesis of chiral Brønsted acidic 
nitrated imidodiphosphate are of major importance to achieve high yields and 
selectivities in this transformation.  We demonstrated the possibility to introduce the 
electron deficient nitro group to the BINOL backbone of imidodiphosphate IDP. The 
nIDP proved to be quite stable during the silica column chromatography and the process 
of acidification. The bifunctionality of nitrated imidodiphosphate (nIDP) was crucial to 
the reaction process (Scheme 4.20). 
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Scheme 4.20 Interactions between nIDP and reactants. 
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4.3 Asymmetric [4+2]-Cycloaddition Reaction of Dienes with Aldehydes 
4.3.1 Reaction Design and Initial Study 
Encouraged by the work on the asymmetric intramolecular carbonyl−ene cyclization, Prins 
cyclization, and oxa-Pictet−Spengler reaction during my PhD study, we recognized the 
potential for Brønsted acids in a direct intermolecular asymmetric cycloaddition between 
simple alkenes and aldehydes. As shown in Scheme 4.21, a fundamental [4+2]-cycloaddition 
of dienes with aldehydes is equally efficient to deliver valuable dihydropyran compounds.152  
 
Scheme 4.21 Brønsted acid-catalyzed [4+2]-cycloaddition of dienes with aldehydes. 
Catalytic and enantioselective variations of the [4+2]-cycloaddition of dienes with aldehydes 
have been investigated during the last 30 years, but current methodologies are limited to 
electron-biased substrates and therefore lack generality.153 Despite the enormous potential of a 
general catalytic asymmetric [4+2]-cycloaddition of simple and electron-unbiased dienes with 
any type of aldehyde, such a process is entirely unknown. We reasoned that this is due to the 
inability of current catalysts to simultaneously reduce the large energy difference between the 
involved frontier orbitals of unactivated dienes and aldehydes, and due to various potential 
side reactions, such as Prins, carbonyl–ene, aldol, and/or cationic oligomerization reactions.  
Strong Brønsted acids would be required to significantly lower the LUMO of the aldehyde 
(dienophile) and thereby narrowing the energy gap between the involved frontier orbitals154 
(Scheme 4.22). We further hypothesized that a highly confined chiral microenvironment of 
the catalyst would be essential to enable efficient stereocontrol with small and 
unfunctionalized substrates, and to preclude side reactions. 
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Scheme 4.22 FMOs of [4+2]-cycloaddition of diene with aldehyde. 
We initially started with a chiral Brønsted acid catalyzed [4+2]-cycloaddition of 2,3-
dimethyl-1,3-butadiene 20a with benzaldehyde. Different chiral Brønsted acids, 
including phosphoric acid 3a,33 N-triflylphosphoramide 4a,51 disulfonimide 5a,55 and 
imidodiphosphate 6a59 with the same electron withdrawing substituents 3,5-(CF3)2C6H3 
at the 3,3'-postions of the BINOL backbone were explored. However, the desired product 
21a (Table 4.7, entries 1, 3, and 4) was not observed due to the less nucleophilicity of 
2,3-dimethyl-1,3-butadiene, when using phosphoric acid 3a, disulfonimide 5a and 
imidodiphosphate 6a. Only trace of the desired [4+2]-cycloaddition product was detected 
using catalyst triflylphosphoramide 4a, even though a poor enantioselectivity of 64:36 er 
was observed (Table 4.7, entry 2). My colleague Dr. Philip S. J. Kaib creatively 
developed a method to replace both oxo groups with N-triflyl groups at the active site of 
imidodiphosphate, affording a new type of extremely acidic and confined Brønsted acid 
imidodiphosphorimidate (IDPi),155 which would probably address both issues, the 
reactivity and the stereoselectivity in the [4+2]-cycloaddition.  Imidodiphosphorimidate 
22a with 3,5-(CF3)2C6H3 substituents at the 3,3'-postions of BINOL backbones was 
directly tested. The obtained results were quite gratifying, a reaction with full conversion 
and hardly any side products was performed at room temperature with a promising 
enantioselectivity of 79:21 er (Table 4.7, entry 5).  
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Table 4.7 Screening of different chiral Brønsted acidsa  
 
conv. (%)b erc
n.r. -
n.r. -
HX* (mol%)catalyst
53a
54a
55a
56a
T/°C
22
22
22
22
t/h
24
24
24
24
entry
1
3
2
4 n.r. -
522a 22 245 >95 79:21
10.5 64:36
 
aUnless otherwise indicated, reactions were performed with benzaldehyde (0.02 mmol), 
2,3-dimethyl-1,3-butadiene (0.1 mmol),  and catalyst (5 mol%) in 0.2 mL of solvent for 
24 h at room temperature. bDetermined by 1H NMR.  cDetermined by HPLC analysis on 
chiral stationary phase.  
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4.3.2 Catalyst Design and Synthesis 
Catalyst Design 
Encouraged by the promising results obtained with catalyst IDPi 22a, we set out to 
modulate the IDPi catalyst. To enhance the acidity and the sterical hindrance of IDPi, we 
introduced bulkier electron withdrawing groups, such as 3,5-(CnF2n+1)2C6H3, 3,5-
(SF5)2C6H3, 3,5-(NO2)2C6H3 substituents to the 3,3'-postions of imidodiphosphorimidate 
(IDPi) (Scheme 4.23).  
 
Scheme 4.23 Modulation of IDPi. 
Catalyst Synthesis 
As mentioned above, the introduction of 3,5-(CnF2n+1)2C6H3 substituents were exploited. 
IDPi 22b with 3,5-(nC3F7)2C6H3 substituents were successfully synthesized by my 
colleague Dr. Hyejin Kim (Scheme 4.24). The characterization of 22b will be disclosed in 
the upcoming publication.  
22b
R =3, 5-(nC3F7)2C6H3
O
P
O
O
O
PN
NH N
R R
R R
Tf Tf
 
Scheme 4.24 IDPi 22b (Dr. Hyejin Kim). 
According to the procedure for the synthesis of IDPi,156 we started with the preparation 
of the corresponding BINOL. Even though it was reported the preparation of BINOL 23a 
with 3,5-(SF5)2C6H3 substituents at the 3,3'-postions from the starting material 3,5-
bis(pentafluorothio)bromo benzene, the yield was quite low around 22.5%. An 
optimization of the preparation of this BINOL was preformed, and an improved yield of  
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Scheme 4.25 Synthesis of IDPi 22c−22e. 
66% was achieved from the starting material boronic ester, available in our laboratory157 
(Scheme 4.25a). Following the procedures of the IDPi catalyst synthesis, the new type of 
IDPi 22c was afforded with an isolated yield of 80%. Similarly, using boronic acid 
available in our laboratory, the corresponding BINOL 23b with 3,5-(NO2)2C6H3 
substituents and 23c with 3,5-(NO2)2-4-Me-C6H3 substituents could be obtained after the 
4 RESULTS AND DISCUSSION 
 
65 
   
Suzuki coupling respectively. Imidodiphosphorimidate 22d and 22e could be readily 
obtained after a further step (Scheme 4.25b). 
4.3.3 Utilization of New Catalysts 
We directly utilized these newly synthesized catalysts in the [4+2]-cycloaddition of 2,3-
dimethyl-1,3-butadiene (20a) with benzaldehyde. Gratifyingly, all IDPis were able to 
catalyze the [4+2]-cycloaddition of 2,3-Dimethyl-1,3-butadiene with benzaldehyde 
(Table 4.8, entries 1−4). Excellent enantioselectivity of 98:2 er and >95% conv. could be 
achieved using catalyst 22c at −20 °C (Table 4.8, entry 5). The reaction concentration 
could be increased to 0.3 M without diminishing the enantioselectivity (98:2 er) or the 
reactivity (> 95% conv.) for this [4+2]-cycloaddition of 20a with benzaldehyde (Table 
4.8, entry 6). The catalyst loading could be reduced to 0.2 mol%, and identically 
excellent results were achieved (Table 4.8, entry 7). 
Table 4.8 Utilization of catalysts IDPis 22b-22ea 
 
 
aUnless otherwise indicated, reactions were performed with benzaldehyde (0.02 mmol), 
2,3-dimethyl-1,3-butadiene (0.1 mmol), catalyst and 5 Å molecular sieves (70mg/mL) in 
solvent at −20 °C for 24 h. bDetermined by 1H NMR.  cDetermined by HPLC analysis on 
chiral stationary phase. dThe reaction was preformed within 4 h.  
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Optimization of the Amount of Diene 
The amount of diene was optimized and could be reduced to 1.2 equiv. with an excellent 
enantiomeric ratio 98:2 and full conversion (Table 4.9, entry 3). The reaction was also 
performed well with excess amount of benzaldehyde. 21a was obtained with similarly 
excellent enantioselectivity and conversion (Table 4.9, entry 4).  
Table 4.9 The ratio of substratesa 
 
aUnless otherwise indicated, reactions were performed with benzaldehyde, 2,3-dimethyl-
1,3-butadiene, catalyst and 5 Å molecular sieves (70mg/mL) in solvent at −20 °C for 24 
h. bDetermined by 1H NMR.  cDetermined by HPLC analysis on chiral stationary phase.  
The Role of Molecular Sieves  
Apparently 5 Å molecular sieves with a formula of 0.7CaO•0.30Na2O•Al2O3•2.0SiO2 
•4.5H2O contain a lot of metal sources, a possible Brønsted acid assisted Lewis acid 
activation or the reverse way, a Lewis acid assisted Brønsted acid activation might 
happen. Comparative reactions were carried out (Table 4.10). According to the excellent 
results shown  in Table 4.10, we could give a conclusion that a pure Brønsted acid 22c 
could catalyze this highly enantioselective [4+2]-cycloaddition of 2,3-dimethyl-1,3-
butadiene 20a with benzaldehyde.  
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Table 4.10 Comparative reactionsa 
 
aUnless otherwise indicated, reactions were performed with benzaldehyde (0.1 mmol), 
2,3-dimethyl-1,3-butadiene (0.5 mmol), catalyst and 21 mg of 5 Å molecular sieves in 
0.3 mL of MeCy at −20 °C for 24 h. bDetermined by 1H NMR. cDetermined by HPLC 
analysis on chiral stationary phase.  
4.3.4 Substrate Scope of Aromatic Aldehydes 
With the optimized reaction conditions, various aromatic aldehydes were explored. Since 
fluorinated compounds have attacted the interest of chemists already for a long time due 
to their potential bio-activity, aldehydes with systematic fluoride substition at ortho, 
meta, and para-position of the benzaldehyde ring were mainly exploited (Table 4.11, 
entries 2−4). All of them turned out to be suitable substrates for catalyst 22c with 
excellent enantioselectivities and high yields except the moderate 92.5:7.5 er of 22b 
(Table 4.11, entry 2). Both, the electron-deficient 4-Br benzaldehyde and electron-rich 4-
Me benzaldehyde delivered the desired products with high enantioselectivities, even 
though a slightly higher catalyst loading of 3 mol% was used (Table 4.11, entries 5−6). 
We tried to optimize the reaction conditions to achieve a high yield of 21e but failed. 
This low yield might be probably due to the low solubility of 4-Br benzaldehyde at −60 
°C (Table 4.11, entry 5). However, traces of product 21g were detected with the 
optimized reaction conditions using 4- MeO benzaldehyde as the substrate. We reasoned 
the poor reactivity to the high basicity of 4-MeO benzaldehyde, which might inhibit the 
activity of Brønsted acid 22c (Table 4.11, entry 7).  Heterocyclic aromatic aldehyde 2-
thiophenecarboxaldehyde also successfully furnished the desired [4+2]-cycloaddition 
product with an excellent 99.5:0.5 enantiomeric ratio (Table 4.11, entry 8). Moderate 
yield was obtained, even though we extended the reaction time. The absolute 
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configuration of 21e was determined as R by single-crystal X-ray diffraction analysis 
(Figure 4.11).  
Table 4.11 Scope of aromatic aldehydesa 
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aUnless otherwise indicated, reactions were performed with aldehyde (0.1 mmol), 2,3-
dimethyl-1,3-butadiene (0.12−1.0 mmol), 22c (0.2−3 mol%) and 5 Å molecular sieves 
(70mg/mL) in MeCy at −20 °C for 24 h. bIsolated yield.  cDetermined by HPLC analysis 
on chiral stationary phase. dThe reaction was performed at −10 °C for 3 days. eThe 
reaction was performed at −60 °C for 6 days. 
  
Figure 4.11 X-ray crystal structure of 21e.  
4.3.5 Substrate Scope of Aliphatic Aldehydes 
Subsequently, aliphatic aldehydes were investigated next. Using the optimized conditions 
for aromatic aldehydes, the desired [4+2]-cycloaddition product could be obtained in 
generally high enantioselectivity but with low conversion in the reaction between 
isovaleraldehyde and 20a (Table 4.12, entry 1). The trimerization of isovaleraldehyde 
turned out to be the main product. But the trimerization of isovaleraldehyde was 
reversible and no obvious trimerization product 25a was observed when we performed 
the reaction at room temperature (Table 4.12, entry 2). Good enantioselectivity and 
conversion could be achieved when we reduced the catalyst loading to 1 mol% and 
increased the diene amount to 10 equiv. (Table 4.12, entry 3).  
Table 4.12 Initial exploration with 22ca 
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aUnless otherwise indicated, reactions were performed with isovaleraldehyde (0.02 
mmol), 2,3-dimethyl-1,3-butadiene (0.1 mmol), 22c (3 mol%) and 5 Å molecular sieves 
(70mg/mL) in MeCy at −20 °C for 24 h. bDetermined by 1H NMR. cDetermined by HPLC 
analysis on chiral stationary phase. dThe reaction was performed with 1 mol% catalyst 
loading and  10 equiv. of 2,3-dimethyl-1,3-butadiene. 
In order to increase the enantioseletivity in the [4+2]-cycloaddition between 
isovaleraldehyde and 2,3-dimethyl-1,3-butadiene, we screened other IDPis. Gratifyingly, 
using the catalyst IDPi 22b with 3,5-(C3F7)2C6H3 substituents, we were able to increase 
the enantioselectivity to 94.4:5.6 er with excellent 91% isolated yield (Table 4.13, entry 
1). Various aliphatic aldehydes were explored using 22b as the catalyst. Both linear 
aldehydes valeraldehyde and decyl aldehyde, proved to be suitable substrates under the  
Table 4.13 Scope of aliphatic aldehydesa 
 
aUnless otherwise indicated, reactions were performed with aldehyde (0.3 mmol), 2,3-
dimethyl-1,3-butadiene (3.0 mmol), 22b (1.0 mol%) and 5 Å molecular sieves (70mg/mL) 
in MeCy. bIsolated yield.  cDetermined by HPLC analysis on chiral stationary phase.  
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optimized reaction conditions, and the desired products 21j and 21k were obtained in 
excellent enantioselectivities and yields (Table 4.13, entries 2 and 3).  The α-branched 
aliphatic aldehyde isobutyraldehyde was compatible with 22b and furnished the product 
21l with 83% yield and 97.4:2.6 er after increasing the reaction temperature to −10 °C 
(Table 4.13, entry 4). The slightly larger aliphatic substrate 3-phenylpropionaldehyde 
was next exploited. The trimerization product of 3-phenylpropionaldehyde was detected 
as the main product when the reaction was performed at −20 °C. Nevertheless, 21m could 
be obtained in good enantioselectivity of 95.5:4.5 er (Table 4.13, entry 5). 
4.3.6 Diene Scope 
The initial objective of this part of the doctoral work was to achieve a highly 
enantioselective asymmetric [4+2]-cycloaddition of simple dienes with aldehydes. Both 
aliphatic and aromatic aldehydes were compatible in this asymmetric [4+2]-cycloaddition 
as shown above under the optimized reaction conditions. The scope of dienes was 
investigated next. Inexpensive and commercially available simple dienes, such as 
butadiene, isoprene, 1,3-pentadiene and trisubstituted diene 2,4-dimethyl-1,3-pentadiene 
were all explored (Scheme 4.26).  
  
Scheme 4.26 Scope of dienes. 
Starting with butadiene, however, the desired product was not obtained even after 
increasing the reaction temperature to 50 °C with an increased catalyst loading (Table 
4.14, entry 1). We also performed the reaction at high pressure which was known to 
accelerate the HDA reaction of butadiene, but the desired [4+2]-cycloaddition product 
was not observed except the polymerization of butadiene. Other new types of catalyst 
motifs might be required regarding the reactivity of butadiene, for example, a 
combination of IDPi with Lewis acid. Isoprene was investigated next, whose 
nucleophilicity is similar to the standard diene 2,3-dimethyl-1,3-butadiene. Excellent 
yield and enantioselectivity were achieved using 22c as catalyst (98:2 er, 87% yield). 
Using trans-1,3-pentadiene as substrate, the trans-diastereoselective [4+2]-cycloaddition 
product was obtained with high enantioselectivity >99.5:0.5 er (Table 4.14, entry 3). But 
the isolated yield was quite low despite a full convertion of the benzaldehyde. This was 
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due to the side reaction, the Prins reaction. Trisubstituted 2,4-dimethyl-1,3-pentadiene 
was tested next. After reducing the concentration and lowering the temperature, 82% 
yield and 96:4 er were achieved (Table 4.14, entry 4). Another trans-2-methyl-1,3-
pentadiene was also investigated, affording the desired cycloadduct in good yield and 
enantioselectivity, yet moderate diastereoselectivity. The absolute configuration of 21o 
was determined as trans-2R,6S, and the absolute configuration of 21q was determined as 
cis-2R,6R by comparison with the reported specific rotation values.158 
Table 4.14 Scope of dienea 
aUnless otherwise indicated, reactions were performed with aldehyde (0.1 mmol), diene 
(0.12−1.0 mmol), 22b (1.0 mol%) and 70mg/mL 5 Å molecular sieves in MeCy. bIsolated 
yield.  cDetermined by 1H NMR. dDetermined by HPLC analysis on chiral stationary 
phase.  
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4.3.7 Gram-Scale Synthesis and Derivatization 
This methodology is quite practical and scalable as shown in scheme 4.27. Gram-scale 
[4+2]-cycloaddition reactions proceeded well for both cases 2,3-dimethyl-1,3-butadiene 
20a and isoprene 20b with benzaldehyde. Excellent enantioselectivity of 98:2 er was 
generally obtained and high yields (Scheme 4.27). Additionally, the catalyst 22c could be 
easily recovered in a high yield of 97% through column chromatography without losing 
activity after acidification with 6 M HCl aq.  
 
Scheme 4.27 Gram-scale synthesis. 
Doremox is one of the most common commercial fragrances. (2R,4S)-cis-doremox could 
be readily afforded as main product with one simple hydrogenation step of the [4+2]-
cycloaddition product 21n (Scheme 4.28). (2S,4R)-cis-doremox is the nicest and 
strongest scent among the four diastereoisomers. The precursor of (2S,4R)-cis-doremox 
could be obtained from ent-21n. 
Scheme 4.28 Derivatization. 
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4.3.8 Discussion 
The first highly enantioselective [4+2]-cycloaddition between simple dienes and 
aldehydes was presented in this chapter (Scheme 4.29). For the first time, a general 
asymmetric catalytic [4+2]-cycloaddition between dienes and aldehydes was achieved. 
Valuable dihydropyrans could be readily obtained in high stereo selectivities and yields 
from inexpensive commercial aldehydes and naturally abundant dienes. This 
methodology was quite practical and could be easily performed on a gram scale. The 
catalyst could be recovered and acidified with a high yield of 97%. This methodology 
provided the most straight forward and atom-economical synthesis of valuable 
fragrances. Since dihydropyran compounds were important scaffolds in natural products 
and pharmaceuticals, this methodogy could in principle be utilized in organic synthesis.  
 
Scheme 4.29 Asymmetric catalytic HDA reaction. 
Although the substrate scope of this reaction is quite general, the basic aldehyde is not 
compatible with the reaction conditions (Table 4.11, entry 7). We reasoned this to a 
potential hydrogen bond between IDPi and the basic substituents of the aldehydes which 
might reduce the high acidity of IDPi.  Another assumption is that the energy of the 
LUMO of the aldehyde was too high. To solve this problem, either the development of 
new catalysts or the optimization of the reaction conditions might be necessary. Large 
dienes were also investigated, for example beta-myrcene which is one of the common 
terpenes (Scheme 4.30). The enantioselectivity was very good, but the isolated yield was 
quite low, which is due to the side Prins reaction. 
 
Scheme 4.30 Large diene. 
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Aliphatic aldehydes were well tolerated under the optimized reaction conditions (Table 
4.13). To investigate the potential of this confined catalyst 22b further, large substrate, 
such as dihydrocholesterol-derivatized aldehyde 27 synthesized. Subsequently, aldehyde 
27 was performed with 2,3-dimethyl-1,3-butadiene 20a using catalyst 22b. The desired 
[4+2]-cycloadduct was afforded in a good yield of 81% with excellent 
diastereoselectivity. 
 
Scheme 4.31 Large aldehyde. 
Despite the important synthetic value of this Brønsted acid-catalzyed asymmetric [4+2]-
cycloaddition reaction, the different diastereoselectivities were obtained by the variation 
of the dienes (21o and 21q), which triggered closer investigations to achieve a 
mechanistic understanding of this reaction.  
 
Scheme 4.32 Asymmetric catalytic [4+2]-cycloaddition. 
Mechanistic Studies 
We initially envisioned two mechanistic scenarios for the described Brønsted acid-
catalyzed [4+2]-cycloaddition reaction: a concerted, pericyclic reaction or a stepwise, 
carbocationic pathway (Scheme 4.33). The protonation of benzaldehyde will result in the 
lowering of its LUMO promoting an electronically-matched interaction with the HOMO 
of the diene. A subsequent concerted [4+2]-cycloaddition could furnish the 
corresponding hetero-Diels–Alder adduct 21a after deprotonation. Alternatively, a 
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stepwise pathway proceeding via a carbocation intermediate, which undergoes an 
intramolecular nucleophilic attack, can be envisioned.159−161  
 
Scheme 4.33 Proposed reaction mechanism 
The precise determination of the kinetic isotope effect (KIE), which is defined as the 
ratio of the rate constant of the lighter isotope (kL) to the rate constant of the heavier 
isotope (kH), can provide some detailed information about the reaction mechanism.
162 In 
1995, the Singleton group reported a practical KIE measurement at natural isotopic 
abundance, which has been successfully used to elucidate the mechanism of many 
reactions.163-165 To elucidate the reaction mechanism, an intramolecular 13C kinetic 
isotope effect (KIE, k12C/k13C) experiment of the reaction leading to product 21a was 
conducted at the natural isotopic abundance.166,167 The relative 13C compositions of 20a 
at C3 and C4 were respectively assigned to be 1.000 in this intramolecular KIE 
measurement. The 13C KIE at C2 of 0.998(3)−0.999(4) indicated that the NMR 
measurements were accurately performed, since a negligible 13C KIE at C2 would be 
expected for either of the envisioned mechanisms. We observed a substantial 13C KIE at 
C1 of 1.022(3)−1.025(4), which suggested that the reaction proceeds via a stepwise 
mechanism. However, the observed KIE is also consistent with a concerted, though 
highly asynchronous pathway.  
4 RESULTS AND DISCUSSION 
 
77 
   
 
Scheme 4.34 Intramolecular 13C KIEs. (The values above were measured at 15 ± 0.6% 
completion of 20a, the values below were measured at 16 ± 0.8% completion of 20a.)  
 
A series of highly acidic and confined IDPis were synthesized in this hetero-Diels−Alder 
reaction between dienes and aldehydes, which could be utilized in other challenging 
asymmetric transformations. The main effort of the modulation of IDPi here is the 
introduction of 3,5-(EWG)2C6H3 substituents at the 3,3'-postions of the BINOL 
backbones. The reactivity and stereoselectivity of this [4+2]-cycloaddition was 
dramatically improved using 3,5-(SF5)2C6H3 substituents. This indicated that the 
replacement of the oxo group at the active site of IDPi with N-SO2SF5 would make the 
active site even more compact and acidic. In principle, we could also replace the active 
“H” site with metal species, which might enable us to perform more fascinating 
asymmetric transformations. 
 
Scheme 4.35 Highly acidic confined acids. 
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5 SUMMARY 
5.1 Organolcatalytic Asymmtric Carbonyl−Ene Cyclization 
Intramolecular carbonyl-ene cyclizations are widely used in the synthesis of cyclic 
compounds. Complementary to Jacobsen’s work on an asymmetric cis-diasteroselective 
intramolecular carbonyl−ene cyclization reaction catalyzed by a chiral dimeric chromium 
complex, this PhD work describes the first organocatalytic highly enantioslective and 
trans-diasteroselective intramolecular carbonyl−ene cyclization of olefinic aldehydes 
without Thorpe−Ingold-type substitutions.  
Mechanistic studies including ESI-MS, NMR, DFT calculations, unanimously supported 
an unexpected step-wise mechanism, suggesting that the reaction proceeds via a 
“catalyst-substrate” covalent intermediate. 
 
Scheme 5.1 Brønsted acid-catalyzed asymmetric carbonyl−ene cyclization. 
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5.2 Organolcatalytic Asymmetric Transformations via Oxocarbenium Ions 
5.2.1 A General Organolcatalytic Asymmetric Prins Cyclization  
(with Dr. Philip S. J. Kaib) 
Functionalized chiral tetrahydropyrans (THPs) are valuable motifs in natural products 
and fragrances, which could potentially be readily synthesized using the Prins cyclization 
between aldehydes and homoallylic alcohols. Alhough the Prins cyclization has been 
frequently used in organic synthesis, enantioselective variants of the Prins cyclization 
have been rarely investigated. In 2015, the first highly enantioselective Prins cyclization 
was developed in the List group utilizing activated salicylaldehydes as substrates. In this 
part of the presented doctoral work, a new chiral Brønsted acid imino-imidodiphosphate 
(iIDP) was developed to realize a broad range of substrate scope, representing the first 
general and highly enantioselective Prins cyclization. This methodology provides a 
straightforward access to a variety of fragrances, including rose oxide and doremox. 
 
Scheme 5.2 A general Brønsted acid-catalyzed asymmetric Prins cyclization. 
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5.2.2 Organolcatalytic Asymmetric Oxa-Pictet−Spengler Reaction  
(with Dr. Sayantani Das) 
Chiral isochromans are important scaffolds in many natural bio-active compounds and 
could be efficiently afforded through an enantioselective oxa-Pictet−Spengler reaction 
between aldehydes and aryl ethanols. Our newly developed Brønsted acid, nitrated 
imidodiphosphate (nIDP), proved to be a suitable catalyst for this enantioselective oxa-
Pictet−Spengler reaction. Diverse isochromans were obtained in high yields with 
excellent regio- and enantioselectivities. Interestingly, the bifunctional property of the 
nIDP catalyst was crucial in this transformation.  
 
Scheme 5.3 Brønsted acid-catalyzed asymmetric oxa-Pictet−Spengler reaction. 
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5.3 Catalytic Asymmetric [4+2]-Cycloaddition of Dienes with Aldehydes 
The [4+2]-cycloaddition between dienes and aldehydes is a direct and elegant approach 
to construct dihydropyrans. To achieve good yields and stereoselectivities, either highly 
activated aldehydes or engineered dienes were required in previous reports. In this thesis, 
the first highly general, efficient and enantioselective [4+2]-cycloaddition of simple 
dienes with aldehydes was developed, using our newly-developed 
imidodiphosphorimidates (IDPis) as catalysts. This methodology is very practical, 
scalable and atom-economical. A broad range of substrates are compatible with the 
optimized reaction conditions, including aliphatic and aromatic aldehydes as well as a 
variety of simple dienes. A diverse set of functionalized dihydropyran compounds were 
obtained in moderate to high yields and high stereoselectivities. Significantly, this 
method provided the most elegant and enantioselective access to valuable scented 
dihydropyran compounds. 
 
Scheme 5.4 Catalytic asymmetric [4+2]-cycloaddition of dienes with aldehydes. 
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5.4 Highly Acidic and Confined Brønsted Acids 
Highly acidic and confined Brønsted acids were designed and synthesized in this doctoral 
work to achieve a variety of highly enantioselective cyclization reactions of unactivated 
aldehydes and inactive nucleophilic alkenes. The effort has mainly been put in 
modulating the skeleton of our previously-developed confined Brønsted acidic 
imidodiphosphates (IDPs), which showed their privilege in asymmetric reactions of 
small-sized substrates.  
As demonstrated in this dissertation, imidodiphosphates proved to be quite tunable. We 
successfully introduced electron withdrawing groups at the 6,6' positions of the BINOL 
backbone of imidodiphosphate (IDP), resulting in the nitrated imidodiphosphate (nIDP) 
(Scheme 5.5). Remarkably, this novel catalyst nIDP turned out to be more acidic without 
diminishing the inherent confinement of its parent IDP. Nitrated imidodiphosphate 
(nIDP) has been applied to a highly enantioselective oxa-Pictet−Spengler reaction of 
aldehydes and homobenzyl alcohol. 
 
Scheme 5.5 Highly acidic and confined Brønsted acid nIDP. 
The modulation of the 3,3'-positions of the BINOL backbone has been extensively 
studied in phosphoric acid catalysis, which has proven to be closely related to the acidity 
and sterical hindrance of chiral acids. Throughout this doctoral investigation, the 
substituents at the 3,3'-positions of the BINOL backbone of IDP are crucial to the 
reactivity and stereoselectivity in the reactions. The ideal substituents are supposed to 
improve both acidity and confinement of the chiral acid. Strong electron-withdrawing 
substituents, for example, 3,5-(SF5)2C6H3, emerged as excellent candidates. In 
combination with my colleagues’ intelligent design of the replacement of the oxo group 
with a N-Tf group, super acidic but sterically hindered imidodiphosphorimidates (IDPis) 
have been developed in this doctoral work (Scheme 5.6). These rationally designed 
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imidodiphosphorimidates (IDPis) enabled a general and highly enantioselective [4+2]-
cycloaddition of simple dienes with aldehydes.  
 
Scheme 3.7 Highly acidic and confined Brønsted acid IDPi. 
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6 OUTLOOK 
6.1 A Highly Enantioselective Synthesis of Menthol 
In our initial exploration of asymmetric intramolecular carbonyl−ene cyclizations, I focused 
on the construction of six-membered all carbon rings and aimed at an entioselective access to 
menthol. The initial results demonstrated that the chiral pockets of imidodiphosphates (IDPs) 
were not compact enough to differentiate and minimize the transition states of six membered 
rings, so that moderate enantioselectivity was achieved (Scheme 6.1a). Later, using newly 
developed imino-imidodiphosphates (iIDPs) as catalysts, high enantio- and 
diastereoselectivity were achieved (Scheme 6.1a). However the reaction time is relatively 
long. High diastereoselectivty was also obtained using (R)-citronellal as the substrate after 7 
days (Scheme 6.1b). On the basis of these intial results, we presumed that chiral Brønsted 
acids would enable a highly enantioselective intramolecular carbonyl−ene cyclization to 
construct optically active six-membered cyclic compounds.  
 
Scheme 6.1 Brønsted acid-catalyzed asymmetric carbonyl−ene cyclization. 
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6.2 An Organolcatalytic Asymmetric Allylation of Aldehydes 
Encouraged by the success of the asymmetric Prins cyclization in our laboratory, we 
hypothesized an asymmetric allylation of aldehydes via oxa-Cope rearrangement between 
aldehydes and tertiary homoallylic alcohols (Scheme 6.2). Gratifying, the desired product 
could be obtained with stronger Brønsted acids disulfonimide (DSI) and binaphthyl-allyl-
tetrasulfones C−H acid (BALT), even though enantioselectivties were poor. Presumably, a 
highly enantioselective oxa-Cope rearrangement could be achieved with the development of 
new types of chiral Brønsted acids.  
 
Scheme 6.2 Catalytic asymmetric allylation of aldehydes. 
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7 EXPERIMENTAL PART 
7.1 General Experimental Conditions 
Solvents and Reagents 
All solvents were obtained by distillation over appropriate drying agent and then kept 
under an atmosphere of argon with the help of technicians in our laboratory: diethyl 
ether, tetrahydrofuran, toluene, cyclohexane, methylcyclohexane and methylcyclohexane 
(sodium), chloroform, dichloromethane, triethylamine (calcium hydride), ethanol 
(magnesium). 1,4-dioxane, MTBE, di(n-butyl)ether, DMF, acetonitrile, and DMSO were 
purchased from Sigma-Aldrich and used as received. Aldehydes were distilled and stored 
under argon in flame‐dried Schlenk flasks prior to use. Other commercial reagents were 
purchased from different commercial suppliers and used without further purification 
unless indicated. 
Inert Gas Atmosphere 
Air and moisture-sensitive reactions were conducted in flame‐dried round-bottom or 
Schlenk flasks under argon atmosphere. Argon was obtained from Air Liquide with 
higher than 99.5% purity.  
Thin Layer Chromatography (TLC) and Preparative Thin Layer Chromatography 
Silica gel pre-coated plastic sheets (Polygram SIL G/UV254, 0.2 mm, with fluorescent 
indicator; Macherey-Nagel) plastic sheets or silica gel pre-coated glass plates SIL G-25 
UV254 and SIL G-100 UV254 with 0.25 mm and 1.0 mm SiO2 layers (Macherey-Nagel) 
were used. The visualization was accomplished by irradiation with UV-light (λ = 254 nm 
or 366 nm) and/or by staining reagents. Phosphomolybdic acid (PMA) stain: PMA (10 g) 
was dissolved in EtOH (100 mL). Anisaldehyde stain: Anisaldehyde (0.5 mL) and glacial 
acetic acid (10 mL) were dissolved in MeOH (85 mL), then concentrated H2SO4 (5.0 mL) 
was added carefully to the mixture.  
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Flash Column Chromatography  
Column chromatography was performed under Merck silica gel (60 Å, 230−400 mesh, 
particle size 0.040−0.063 mm) or aluminum oxide (neutral, activated, Brockmann I, 
Sigma‐Aldrich) using technical grade solvents. Elution was accelerated using compressed 
air.  
Nuclear Magnetic Resonance Spectroscopy (NMR) 
Proton and carbon NMR spectra were recorded on Bruker AV-500, Bruker AV-400 or 
Bruker AV-300 spectrometer in deuterated solvents. Proton chemical shifts are reported 
in ppm (δ) relative to tetramethylsilane (TMS) with the solvent resonance employed as 
the internal standard (CDCl3 δ 7.26 ppm; CD2Cl2 δ 5.32 ppm). Data are reported as 
follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, p = 
pentet, s = sextet, h = heptet, m = multiplet, br = broad), coupling constants (Hz) and 
integration. 13C chemical shifts are reported in ppm from tetramethylsilane (TMS) with 
the solvent resonance as the internal standard (CDCl3 δ 77.16 ppm; CD2Cl2 δ 53.84 ppm). 
15N, 19F, and 31P NMR spectra were referenced in ppm from MeNO2, CCl3F, and H3PO4, 
respectively. 
High Pressure Liquid Chromatography (HPLC) 
Shimadzu LC−20AD liquid chromatograph (SIL−20AC auto sampler, CMB−20A 
communication bus module, DGU−20A5 degasser, CTO−20AC column oven, 
SPD−M20A diode array detector), Shimadzu LC−20AB liquid chromatograph 
(SIL−20ACHT auto sampler, DGU−20A5 degasser, CTO−20AC column oven, 
SPD−M20A diode array detector), or Shimadzu LC−20AB liquid chromatograph 
(reversed phase, SIL−20ACHT auto sampler, CTO−20AC column oven, SPD−M20A 
diode array detector) using Daicel columns with a chiral stationary phase. All solvents 
used were HPLC-grade solvents purchased from Sigma-Aldrich. The enantiomeric ratios 
were determined by comparing the samples with the appropriate racemic mixtures. The 
enantiomeric ratios of chiral molecules were determined using corresponding chiral 
columns. Detail conditions are given in the individual experiment. 
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Gas Chromatography (GC) 
Gas chromatography (GC) was performed on HP 6890 and 5890 Series instruments 
(carrier gas: hydrogen) equipped with a split-mode capillary injection system and a flame 
ionization detector (FID). The enantiomeric ratios were determined by comparing the 
samples with the appropriate racemic mixtures. The enantiomeric ratios of chiral 
molecules were determined using corresponding chiral columns. Detail conditions are 
given in the individual experiment.  
Mass Spectrometry (MS) 
Electron impact (EI) mass spectrometry (MS) was performed on a Finnigan MAT 8200 
(70 eV) or MAT 8400 (70 eV) spectrometer. Electrospray ionization (ESI) mass 
spectrometry was conducted on a Bruker ESQ 3000 spectrometer. High resolution mass 
spectrometry (HRMS) was performed on a Finnigan MAT 95 (EI) or Bruker APEX III 
FTMS (7T magnet, ESI). The ionization method and mode of detection employed is 
indicated for the respective experiment and all masses are reported in atomic units per 
elementary charge (m/z) with an intensity normalized to the most intense peak.  
Specific Rotation ([α]) 
Optical rotations were measured with a Rudolph RA Autopol IV Automatic Polarimeter 
at 20 or 25 °C with a sodium lamp (sodium D line, λ = 589 nm). Measurements were 
performed in an acid resistant 1 mL cell (50 mm length) with concentrations (g/(100 
mL)) reported in the corresponding solvent .  
X‐Ray Crystallography 
The crystals were grown as specified in the synthetic protocol. X‐ray crystal structure 
analyses were performed on a Bruker-AXS Kappa Mach2 APEX-II diffractometer, 
equipped with an Incoatec Microfocus lµS Mo radiation X-ray source. Data were face-
indexed absorption corrected and scaled using the program SADABS (Bruker AXS, 
2014). The structure was refined using the programs SHELXS and SHELXL, both 
programs from G. M. Sheldrick (Göttingen, 2014). The X‐ray crystal structure analyses 
were performed by the X‐ray department of the Max‐Planck‐Institut für 
Kohlenforschung. 
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7.2 Organolcatalytic Asymmtric Carbonyl−Ene Cyclization 
7.2.1 Substrates Synthesis 
Synthesis of 1b-1f and 1h 
 
General procedure: The corresponding aminoalcohol compound (1 equiv.) was dissolved 
in DMF (0.5 M), and NaH (60% dispersion in mineral oil, 1 equiv.) was added 
portionwise at 0 °C under argon atmosphere. The bubbling solution was stirred for 30 
min at room temperature before allyl bromide (1.1 equiv) was added. The solution was 
stirred at room temperature until full consumption of the starting material. After the 
addition of H2O, the aqueous phase was extracted with CH2Cl2. The combined organic 
layers were washed with H2O, brine and dried by Na2SO4, then concentrated with a 
rotary evaporator. The crude mixture was purified by column chromatography on silica 
gel using EtOAc/hexane as the eluent. The obtained alcohol was used for the next Swern 
oxidation step. To a solution of DMSO (2.6 equiv.) in CH2Cl2 (0.5 M) at −78°C was 
added oxalyl chloride (1.3 equiv.). After 30 min, the solution of alcohol (1 equiv) in 
CH2Cl2 (1.0 M) was added. After another 30 min, triethylamine (6 equiv.) was added. 
The cold bath was removed and the reaction was quenched by the addition of H2O. The 
reaction mixture was extracted with CH2Cl2 and the combined organic layer was washed 
with H2O, brine and dried over Na2SO4,
 then concentrated with a rotary evaporator. The 
desired aldehyde was purified by column chromatography on silica gel using 
EtOAc/hexane as the eluent. 
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N-(1-Formylcyclobutyl)-4-methyl-N-(3-methylbut-2-en-1-yl)benzenesulfonamide.  
Prepared according to general procedure. White solid, 54%.  
1H NMR (300 MHz, CD2Cl2): δ 9.68 (s, 1H), 7.70 (d, J = 8.3 Hz, 2H), 7.34 (d, J = 8.0 
Hz, 2H), 7.30 (d, J = 8.0 Hz, 2H), 5.11 (app. t, J = 6.8 Hz, 1H), 3.91 (d, J = 6.8 Hz, 2H), 
2.43 (s, 3H), 2.37−2.20 (m, 4H), 1.88−1.68 (m, 2H), 1.67 (d, J = 1.1 Hz, 3H), 1.60 (s, 
3H).  
13C NMR (75 MHz, CD2Cl2): δ 199.8, 144.0, 139.7, 136.8, 130.1, 127.4, 121.4, 68.6, 
44.7, 29.3, 25.8, 21.7, 18.0, 14.3.  
HRMS (ESI+) (m/z): calculated for C17H23N1O3S1Na1 [M+Na]
+: 344.129085; found: 
344.129100. 
  
N-(1-Formylcyclopentyl)-4-methyl-N-(3-methylbut-2-en-1-yl)benzenesulfonamide.  
Prepared according to general procedure. White solid, 50%. 
 1H NMR (500 MHz, CD2Cl2): δ 9.60 (s, 1H), 7.70 (d, J = 8.3 Hz, 2H), 7.32 (d, J = 8.1 
Hz, 2H), 5.15 (app. t, J = 6.2 Hz, 1H), 3.90 (d, J = 6.2 Hz, 2H), 2.42 (s, 3H), 2.10−2.05 
(m, 2H), 1.78−1.73 (m, 2H), 1.67 (d, J = 1.1 Hz, 3H), 1.59 (s, 3H), 1.57−1.51 (m, 4H).  
13C NMR (126 MHz, CD2Cl2): δ 198.0, 144.2, 138.3, 134.9, 130.0, 128.0, 122.5, 77.1, 
45.1, 32.5, 25.7, 24.0, 21.6, 18.0.  
 HRMS (ESI+) (m/z): calculated for C18H25 N1O3S1Na1 [M+Na]
+: 358.144735; found: 
358.144700. 
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N-(1-Formylcyclohexyl)-4-methyl-N-(3-methylbut-2-en-1-yl)benzenesulfonamide.  
Prepared according to general procedure. White solid, 73%.  
1H NMR (500 MHz, CDCl3): δ 9.69 (s, 1H), 7.72 (d, J = 8.3 Hz, 2H), 7.28 (d, J = 8.3 
Hz, 2H), 5.15 (app. t, J = 6.2 Hz, 1H), 3.84 (d, J = 6.2 Hz, 2H), 2.41 (s, 3H), 2.17 (d, J = 
13.4 Hz, 2H), 1.69 (td, J = 12.6, 3.8 Hz, 2H), 1.64 (s, 3H), 1.60−1.49 (m, 8H), 1.17−1.07 
(m, 1H). 
 13C NMR (126 MHz, CDCl3): δ 200.0, 143.4, 138.1, 133.8, 129.5, 127.8, 122.6, 68.8, 
43.4, 31.1, 25.6, 24.8, 22.5, 21.5, 17.8.  
HRMS (ESI+) (m/z): calculated for C19H27N1O3S1Na1 [M+Na]
+: 372.160386; found: 
372.160520. 
 
N-(2-Cyclohexylideneethyl)-4-methyl-N-(2-methyl-1-oxopropan-2-
yl)benzenesulfonamide.  
Prepared according to general procedure. White solid, 41%.  
1H NMR (500 MHz, CD2Cl2): δ 9.60 (s, 1H), 7.75 (d, J = 8.3 Hz, 2H), 7.34 (d, J = 8.0 
Hz, 2H), 5.05 (app. t, J = 6.5 Hz, 1H), 3.83 (d, J = 6.5 Hz, 2H), 2.42 (s, 3H), 2.05 (td, J = 
24, 6.1 Hz, 4H), 1.52−1.43 (m, 6H), 1.36 (s, 6H).  
13C NMR (126 MHz, CD2Cl2): δ 198.8, 144.4, 142.3, 137.8, 130.0, 128.3, 119.1, 67.3, 
42.8, 37.2, 29.0, 28.5, 27.5, 26.9, 22.4, 21.6. 
 HRMS (ESI+) (m/z): calculated for C19H27N1O3S1Na1 [M+Na]
+: 372.160385; found: 
372.160090. 
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N-(2-Cycloheptylideneethyl)-4-methyl-N-(2-methyl-1-oxopropan-2-
yl)benzenesulfonamide.  
Prepared according to general procedure. White solid, 42%. 
 1H NMR (500 MHz, CD2Cl2): δ 9.63 (s, 1H), 7.77 (d, J = 8.3 Hz, 2H), 7.36 (d, J = 8.0 
Hz, 2H), 5.10 (app. t, J = 6.0 Hz, 1H), 3.83 (d, J = 6.0 Hz, 2H), 2.45 (s, 3H), 2.16−2.12 
(m, 4H), 1.52−1.47 (m, 8H),  1.36 (s, 6H).  
13C NMR (126 MHz, CD2Cl2): δ 198.8, 144.4, 143.9, 137.7, 130.0, 128.3, 122.7, 67.3, 
43.2, 37.8, 30.5, 30.1, 29.7, 29.4, 27.0, 22.4, 21.6. 
 HRMS (ESI+) (m/z): calculated for C20H29N1O3S1Na1 [M+Na]
+: 386.176035; found: 
386.176120. 
 
Benzyl (3-methylbut-2-en-1-yl)(2-oxoethyl)carbamate.  
Prepared according to general procedure. White oil, 46%.  
The NMR signals are reported as observed . The signals belong to two different 
rotamers. 
1H NMR (500 MHz, CD2Cl2):  δ 9.53−9.52 (m, 1H), 7.38−7.29 (m, 5H), 5.16−5.10 (m, 
3H), 3.99−3.91 (m, 4H), 1.71−1.72 (m, 3H), 1.64−1.57 (m, 3H).  
13C NMR (75 MHz, CD2Cl2): δ 199.2, 156.8, 156.1, 138.1, 137.5, 137.2, 136.2, 128.9, 
128.4, 128.2, 120.5, 119.7, 119.6, 67.8, 57.0, 56.3, 46.2, 25.8, 18.0, 17.9. 
HRMS (ESI+) (m/z): calculated for C15H19 N1O3Na1 [M+Na]
+: 284.125713; found: 
284.125770. 
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Synthesis of 1k 
 
General procedure: To a solution of di-tert-butyl-malonate (4 mL, 15 mmol) in DMF (75 
mL), sodium hydride (719 mg, 18 mmol) was added at 0 °C. After stirring for one hour, 
10 mmol of methylbromacetate was added to this reaction mixture.The reaction was 
stirred at r.t. for 6 h, then was diluted with 30 mL a.q. NaHCO3 and extracted by 2 x 90 
mL MTBE. The organic layer was rinsed with H2O (2 x 150 mL) and brine (2 × 150 mL), 
then dried over Na2SO4, filtered, and concentrated in vacuo. The product was isolated by 
flash chromatography (2−5% ethyl acetate/hexanes) as a colorless and viscous oil (780 
mg, 2.19 mmol, 44% yield). To a solution of 2,2-di-tert-butyl 1-methyl 5-methylhex-4-
ene-1,2,2-tricarboxylate (749 mg, 2.1 mmol) in CH2Cl2 (20 mL, 0.1 M), 
diisobutylaluminum hydride (4.6 mL, 4.6 mmol, 1M in hexane) was added at −78 °C. 
The reaction mixture was stirred for 4 h at −78 °C. The reaction was quenched by adding 
0.1 mL H2O, 0.1 mL 15% aqueous NaOH, and 0.4 mL H2O waiting 5 minutes between 
each addition. The resulting suspension was carefully dried over Mg2SO4 and filtered, 
rinsed with CH2Cl2 then concentrated with a rotary evaporator. The product was obtained 
by flash chromatography (hexane/ether = 95/5) as an clear oil (200 mg, 0.61 mmol, 29% 
yield).  
 
Di-tert-butyl 2-(3-methylbut-2-en-1-yl)-2-(2-oxoethyl)malonate. 
1H NMR (500 MHz, CD2Cl2): δ 9.68 (t, J = 2.0 Hz, 1H), 5.0 (app. t, J = 7.8 Hz, 1H), 
2.72 (d, J = 2.0 Hz, 2H), 2.59 (d, J = 7.7 Hz, 2H), 1.69 (d, J = 0.9 Hz, 3H), 1.59 (s, 3H), 
1.43 (s, 18H). 
 13C NMR (126 MHz, CD2Cl2): δ 200.3, 169.8, 136.5, 118.3, 82.4, 56.5, 46.7, 33.0, 27.9, 
26.1, 18.2. HRMS (ESI+) (m/z): calculated for C18H30O5Na1 [M+Na]
+: 349.198544; 
found: 349.19841.  
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7.2.2 Products 
 
 
Unless specified otherwise, aldehyde 1 (0.1 mmol) was added to catalyst 6d (0.005 
mmol, 5 mol%) in cyclohexane (0.1 M). The mixture was stirred vigorously at room 
temperature. Purification was performed by column chromatography or preparative thin 
layer chromatography on silica gel using EtOAc/hexane as the eluent. 
 
(3S,4R)-2,2-Dimethyl-4-(prop-1-en-2-yl)-1-tosylpyrrolidin-3-ol.  
Prepared according to general procedure. 30.0 mg white solid, 97%.  
1H NMR (500 MHz, CDCl3): δ 7.73 (d, J = 8.3 Hz, 2H), 7.29 (d, J = 8.1 Hz, 2H), 4.92 (t, 
J = 1.4 Hz, 1H), 4.89 (s, 1H), 3.63 (d, J = 10.4 Hz, 1H), 3.57 (t, J = 9.1 Hz, 1H), 3.06 (t, 
J = 10.1 Hz, 1H), 2.62 (q, J = 10.2 Hz, 1H), 2.41 (s, 3H), 1.71 (s, 3H), 1.50 (s, 3H), 1.27 
(s, 3H).  
13C NMR (126 MHz, CDCl3): δ 143.0, 141.3, 138.2, 129.5, 127.2, 113.9, 80.4, 65.9, 
48.6, 48.1, 26.5, 21.6, 21.5, 19.8.  
HRMS (ESI+) (m/z): calculated for C16H23N1O3S1Na1 [M+Na]
+: 332.129130; found: 
332.129085.  
HPLC The enantiomeric ratio was measured by HPLC analysis using Chiralpak AS-3R, 
CH3CN/ H2O = 35:65, Flow rate = 1.0 mL/min, λ = 220 nm, tR = 17.7 min (minor) and 
tR= 18.9 min (major). er = 97.5:2.5. 
[α]D
25 = −19.1 (c 0.70, CH2Cl2).  
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(7R,8S)-7-(prop-1-en-2-yl)-5-tosyl-5-azaspiro[3.4]octan-8-ol.  
Prepared according to general procedure. 26 mg white solid, 81%.  
1H NMR (500 MHz, CDCl3): δ 7.73 (d, J = 8.3 Hz, 2H), 7.30 (d, J = 7.5 Hz, 2H), 
4.92−4.90 (m, 2H), 3.84 (d, J = 8.7 Hz, 1H), 3.60 (dd, J = 9.6,  8.2 Hz, 1H), 3.19−3.13 
(m, 2H), 2.65−2.61 (m, 1H), 2.52 (q, J = 8.6 Hz, 1H), 2.42 (s, 3H), 2.29−2.23 (m, 1H), 
2.09−2.03 (m, 1H),  1.82 (tq, J = 10.8,  3.6 Hz, 1H), 1.72 (s, 3H), 1,70−1,64 (m, 1H).  
13C NMR (126 MHz, CDCl3): δ 143.1, 141.1, 138.2, 129.7, 126.9, 113.7, 79.8, 67.7, 
49.3, 49.0, 32.5, 29.9, 21.5, 20.3, 13.5.  
HRMS (ESI+) (m/z): calculated for C17H23N1O3S1Na1 [M+Na]
+: 344.129085; found: 
344.128960.  
HPLC The enantiomeric ratio was measured by Heart-Cut HPLC analysis using 
Chiralpak OJ-3R , CH3CN/ H2O = 40:60, Flow rate = 1.0 mL/min, λ = 220 nm, tR = 9.3 
min (major) and tR= 10.8 min (minor). er = 97:3. 
[α]D
25 = −8.8 (c 0.80, CH2Cl2). 
 
(3R,4S)-3-(Prop-1-en-2-yl)-1-tosyl-1-azaspiro[4.4]nonan-4-ol.  
Prepared according to general procedure. 27.8 mg white solid, 83%.  
1H NMR (500 MHz, CDCl3): δ 7.72 (d, J = 8.3 Hz, 2H), 7.30 (d, J = 8.1 Hz, 2H), 
4.92−4.91 (m, 1H), 4.89−4.88 (m, 1H), 3.78 (d, J = 10.0 Hz, 1H), 3.58 (t, J = 9.1 Hz, 
1H), 3.10 (t, J = 9.9 Hz, 1H), 2.62−2.52 (m, 2H), 2.42 (s, 3H), 2.02−1.89 (m, 3H), 
1.86−1.79 (m, 1H),  1.71 (s, 3H), 1.69−1.58 (m, 3H),  1.53−1.45 (m, 1H).   
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13C NMR (126 MHz, CDCl3): δ 143.0, 141.3, 138.3, 129.6, 127.1, 113.9, 81.2, 75.7, 
49.6, 48.7, 36.7, 33.3, 25.9, 25.3, 21.5, 19.9.  
HRMS (ESI+) (m/z): calculated for C18H25N1O3S1Na1 [M+Na]
+: 358.144735; found: 
358.144700.  
HPLC The enantiomeric ratio was measured by Heart-Cut HPLC analysis using 
Chiralpak OJ-3R , CH3CN/ H2O = 40:60, Flow rate = 1.0 mL/min, λ = 220 nm, tR = 15.2 
min (minor) and tR= 15.5 min (major). er = 95.5:4.5. 
[α]D
25 = −11.6 (c 0.78, CH2Cl2). 
 
(3R,4S)-3-(prop-1-en-2-yl)-1-tosyl-1-azaspiro[4.5]decan-4-ol.  
The reaction was performed at 10°C for 5 days. 27.0 mg white solid, 77%.  
1H NMR (500 MHz, CDCl3): δ 7.73 (d, J = 8.3 Hz, 2H), 7.28 (d, J = 8.0 Hz, 2H), 
4.91−4,89 (m, 1H), 4.89−4,88 (m, 1H), 4.00 (d, J = 7.0 Hz, 1H), 3.55 (dd, J = 9.7, 7.8 
Hz, 1H), 3.24 (dd, J = 9.7, 8.9 Hz, 1H), 2.62 (q, J = 7.9 Hz, 1H), 2.41 (s, 3H), 2.27−2.39 
(m, 2H), 1.91 (d, J = 12.1 Hz, 1H), 1.74 (s, 3H), 1.70−1.61 (m, 6H), 1.44 (tq, J = 13.4, 
3.2 Hz, 1H), 1.33−1.27 (m, 1H).   
13C NMR (126 MHz, CDCl3): δ 142.8, 141.7, 138.7, 129.5, 127.2, 113.2, 81.1, 70.2, 
51.2, 48.4, 36.4, 31.7, 24.7, 23.9, 23.7, 21.5, 20.7.  
HRMS (ESI+) (m/z): calculated for C19H27N1O3S1Na1 [M+Na]
+: 372.160386; found: 
372.160520.  
HPLC The enantiomeric ratio was measured by Heart-Cut HPLC analysis using 
Chiralpak OJ-3R, CH3CN/ H2O = 50:50, Flow rate = 1.0 mL/min, λ = 220 nm, tR = 38.4 
min (minor) and tR= 38.9 min (major). er = 95:5. 
[α]D
25 = −1.8 (c 0.33, CH2Cl2). 
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(3S,4R)-4-(Cyclohex-1-en-1-yl)-2,2-dimethyl-1-tosylpyrrolidin-3-ol.  
Prepared according to general procedure. 28.0 mg white solid, 80%.  
1H NMR (500 MHz, CDCl3): δ 7.72 (d, J = 7.0 Hz, 2H), 7.28 (d, J = 8.5 Hz, 2H), 5.61 
(br. s, 1H), 3.63 (d, J = 10.4 Hz, 1H), 3.55 (t, J = 9.5 Hz, 1H), 3.01 (dt, J = 10.6, 1.2 Hz, 
1H), 2.51 (q, J = 9.8 Hz, 1H), 2.41 (s, 3H), 2.00 (d, J = 1.6 Hz, 2H), 1.89 (br. s, 2H), 1.72 
(br. s, 1H), 1.64−1.55 (m, 4H), 1.49 (s, 3H), 1.27 (s, 3H).  
13C NMR (126 MHz, CDCl3): δ 142.8, 138.3, 133.3, 129.5, 127.2, 125.3, 79.9, 65.8, 
49.0, 48.1, 26.6, 25.6, 25.2, 22.7, 22.3, 21.5, 21.4. 
HRMS (ESI+) (m/z): calculated for C19H27N1O3S1Na1 [M+Na]
+: 372.160385; found: 
372.160500.  
HPLC The enantiomeric ratio was measured by HPLC analysis using Chiralpak AS-3R, 
CH3CN/ H2O = 70:30, Flow rate = 1.0 mL/min, λ = 220 nm, tR = 3.4 min (major) and tR= 
3.7 min (minor). er = 92:8. 
[α]D
25 = −15.3 (c 0.34, CH2Cl2). 
 
(3S,4R)-4-(Cyclohept-1-en-1-yl)-2,2-dimethyl-1-tosylpyrrolidin-3-ol.  
Prepared according to general procedure. 35.0 mg white solid, 96%.  
1H NMR (500 MHz, CDCl3): δ 7.73 (d, J = 8.3 Hz, 2H), 7.29 (d, J = 8.0 Hz, 2H), 5.77 (t, 
J = 6.6 Hz, 1H), 3.55 (d, J = 10.2 Hz, 1H), 3.48 (t, J = 9.3 Hz, 1H), 3.02 (t, J = 9.9 Hz, 
1H), 2.52 (q, J = 9.8 Hz, 1H), 2.42 (s, 3H), 2.11 (q, J = 6.5 Hz, 2H), 2.05 (dd, J = 5.8, 4.1 
Hz, 2H), 1.77−1.72 (m, 3H), 1.63 (br. s, 1H), 1.50 (s, 3H), 1.48−1.40 (m, 4H),  1.23 (s, 
3H).  
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13C NMR (126 MHz, CDCl3): δ 142.9, 140.0, 138.3, 131.5, 129.5, 127.2, 79.8, 65.6, 
51.0, 47.9, 32.7, 28.8, 28.3, 27.1, 26.9, 26.7, 21.5, 21.1.  
HRMS (ESI+) (m/z): calculated for C20H29N1O3S1Na1 [M+Na]
+: 386.176035; found: 
386.175930.  
HPLC The enantiomeric ratio was measured by HPLC analysis using Chiralpak OJ-3R, 
CH3CN/ H2O = 50:50, Flow rate = 1.0 mL/min, λ = 220 nm, tR = 9.2 min (major) and tR= 
9.9 min (minor). er = 95.5:4.5. 
[α]D
25 = −23.4 (c 1.0, CH2Cl2).  
 
(3S,4R)-4-(Prop-1-en-2-yl)-1-tosylpyrrolidin-3-ol. 
 The reaction was performed at room temperature for 3 days then at 50 °C for 2 days in 
the presence of 6d (7.5 mol%). 24.0 mg white solid, 85%. Running the reaction at 50 °C 
from the start gave lower enantioselectivity.  
1H NMR (500 MHz, CDCl3): δ 7.74 (d, J = 8.3 Hz, 2H), 7.34 (d, J = 7.9 Hz, 2H), 
4.84−4.83 (m, 1H), 4.75−4.73 (m, 1H), 4.10 (p, J = 5.0 Hz, 1H), 3.60 (dd, J = 10.4, 6.1 
Hz, 1H), 3.52 (dd, J = 10.1, 8.1 Hz, 1H), 3.21 (dd, J = 10.1, 7.4 Hz, 1H), 3.12 (dd, J = 
10.4, 5.5 Hz, 1H), 2.55 (q, J = 7.3 Hz, 1H), 2.44 (s, 3H), 1.69 (s, 3H).  
13C NMR (126 MHz, CDCl3): δ143.7, 141.6, 133.6, 129.74, 129.73, 127.6, 112.9, 73.1, 
54.0, 53.4, 49.7, 21.5, 20.7.  
HRMS (ESI+) (m/z): calculated for C14H19N1O3S1Na1 [M+Na]
+: 304.097786; found: 
304.097580.  
HPLC The enantiomeric ratio was measured by HPLC analysis using Chiralpak OJ-3R, 
CH3CN/ H2O = 25:75, Flow rate = 1.0 mL/min, λ = 220 nm, tR = 22.8 min (major) and 
tR= 25.4 min (minor). er = 98:2. 
 [α]D
25 = −13.0 (c 1.0, CH2Cl2).  
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Benzyl (3S,4R)-3-hydroxy-4-(prop-1-en-2-yl)pyrrolidine-1-carboxylate.  
The reaction was performed at room temperature for 3 days then at 50 °C for 8 days in 
the presence of 6d (7.5 mol%). 19.0 mg White solid, 73%.  
The NMR signals of major diastereomer are reported as observed . The signals belong to 
two different rotamers (ratio ~ 1:1). 
1H NMR (500 MHz, CDCl3): δ 7.36−7.31 (m, 5H), 5.13 (s, 2H), 4.90 (d, J = 3.6 Hz, 1H), 
4.84 (d, J = 11.8 Hz, 1H), 4.23 (ddd, J = 12.1, 6.1, 2.2 Hz, 1H), 3.77−3.86 (m, 2H), 
3.42−3.36 (m, 1H), 3.33−3.27 (m, 1H), 2.68 (s, J = 8.8 Hz, 1H), 2.30 (br. s, 1H), 1.76 (s, 
3H).  
13C NMR (126 MHz, CDCl3): δ154.9, 142.3, 142.2, 136.8, 128.5, 128.0, 127.9, 127.8, 
112.6, 112.5, 73.1, 72.4, 66.9, 66.8, 53.1, 52.6, 52.5, 52.2, 48.2, 48.0, 23.0, 21.0, 20.9. 
HRMS (ESI+) (m/z): calculated for C15H19N1O3Na1 [M+Na]
+: 284.125713; found: 
284.125710.  
HPLC The enantiomeric ratio was measured by Heart-Cut HPLC analysis using 
Chiralpak OJ-3R , CH3CN/ H2O = 70:30, Flow rate = 1.0 mL/min, λ = 220 nm, tR = 17.1 
min (major) and tR= 17.8 min (minor). er = 98:2. 
 [α]D
25 = −8.6 (c 0.95, CH2Cl2). 
 
(3S,4R)-4-(Prop-1-en-2-yl)tetrahydrofuran-3-ol.  
The reaction was performed under neat condition. White oil, 78% NMR yield using 
1,1,2,2-tetrachloroethane used as internal standard.  
1H NMR (500 MHz, CD2Cl2): δ 4.84−4.83 (m, 1H), 4.81−4.80 (m, 1H), 4.29−4.26 (m, 
1H), 4.05 (dd, J = 9.2, 7.5 Hz, 1H), 3.90 (dd, J = 9.6, 5.3 Hz, 1H), 3.68 (dd, J = 8.8, 6.3 
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Hz, 1H), 3.65 (dd, J = 9.5, 3.2 Hz, 1H), 2.69 (dt, J = 6.8, 3.8 Hz, 1H), 1.93 (d, J = 5.0 
Hz, 1H), 1.77 (t, J = 1.1 Hz, 3H).  
13C NMR (126 MHz, CD2Cl2): δ144.1, 111.5, 76.4, 75.1, 71.3, 56.2, 21.5.  
HRMS (ESI+) (m/z): calculated for C7H12O2Na1 [M+Na]
+: 151.072949; found: 
151.073020.  
GC The enantiomeric ratio was measured by GC analysis on Hydrodex-gamma-TBDAc-
CD column: tR = 11.1 min (major) and tR= 12.1 min (minor). er = 97:3. 
[α]D
25 = −20 (c 0.33, CH2Cl2). 
 
(3S,4R)-2,2-Dimethyl-4-(prop-1-en-2-yl)tetrahydrofuran-3-ol.  
The reaction was performed under neat condition. 14mg white oil, 90%.  
1H NMR (500 MHz, CDCl3): δ 4.89−4.87 (m, 2H), 3.96 (t, J = 8.9 Hz, 1H), 3.80 (dd, J = 
8.6, 5.1 Hz, 1H), 3.65 (t, J = 9.1 Hz, 1H), 2.83 (q, J = 9.0 Hz, 1H), 1.77 (s, 3H), 1.75 (d, 
J = 5.4 Hz, 1H), 1.29 (s, 3H), 1.18 (s, 3H).  
13C NMR (126 MHz, CDCl3): δ 142.6, 112.6, 81.1, 80.9, 66.7, 54.1, 26.6, 21.4, 19.9.  
HRMS (ESI+) (m/z): calculated for C9H16O2Na1 [M+Na]
+: 179.104249; found: 
179.104430.  
GC The enantiomeric ratio was measured by GC analysis on Hydrodex-BTBDAC-G-589 
column: tR = 33.0 min (minor) and tR= 36.0 min (major).  
[α]D
25 = −30.5 (c 0.42, CH2Cl2). er = 98:2. 
2k
HO
tBuO2C CO2tBu  
Di-tert-butyl (3R,4S)-3-hydroxy-4-(prop-1-en-2-yl)cyclopentane-1,1-dicarboxylate.  
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The reaction was performed at room temperature for 3 days then at 50 °C for 2 days in 
the presence of 6d (7.5 mol%). 26.5 mg white oil, 81%. 
1H NMR (500 MHz, CDCl3): δ 4.81 (br s, 2H), 4.04 (q, J = 7.1 Hz, 1H), 2.52−2.38 (m, 
3H), 2.23 (br. s, 1H), 2.09 (dd, J = 13.3, 10.8 Hz, 1H), 2.02−1.98(m, 1H), 1.75 (t, J = 0.9 
Hz, 3H), 1.46 (s, 9H), 1.44 (s, 9H).  
13C NMR (126 MHz, CDCl3): δ 172.2, 171.1, 144.4, 111.5, 81.6, 81.3, 74.9, 58.3, 54.8, 
41.2, 35.9, 27.8, 20.3. 
HRMS (ESI+) (m/z): calculated for C18H30O5Na1 [M+Na]
+: 349.198544; found: 
349.198320.  
GC The enantiomeric ratio was measured by GC analysis on BGB-176/BGB-15-G-618 
column: tR = 53.3 min (minor) and tR= 53.8 min (major). er = 98:2. 
 [α]D
25 = −6.0 (c 0.6, CH2Cl2). 
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7.2.3 Mechainsitic Studies  
ESI-MS Studies 
In order to elucidate the reaction mechanism, we performed electrospray ionization mass 
spectroscopy (ESI-MS) studies using the cyclization of olefinic aldehyde 1a as a model 
reaction. For this purpose, we carried out two reactions: One experiment was the 
cyclization of 1a in the presence of catalytic amounts of catalyst 6b under the optimized 
reaction conditions, and the other experiment was performed in the presence of catalytic 
amounts of catalyst 6c. General procedure: substrate 1a (15.5 mg, 0.05mmol) and dry 
cyclohexane (0.5 mL) were added to a vial, then catalyst 6b (2.5 mg, 2.5 µmol) or 6c (3.3 
mg, 2.5 µmol) were added at 22 °C. Samples of the reaction mixtures were monitored at 
different time during the initial 24h. The selected spectra Figure S1, Figure S2, and the 
HRMS data of the catalyst 6b, 6c, and intermediate 7b, 7c were sumerized in Table S1 
and Table S2. The ESI-MS obtained revealed the characteristic signals of free catalysts 
6b and 6c. As soon as substrate 1a, catalyst 6b were combined under the optimized 
reaction conditions, the new peak at m/z 1291.3 could be detected which matches the 
mass of the covalent the intermediate [7b + H]+ generated from substrate 1a and the 
corresponding catalyst 6b. Interestingly, the fact that the intermediate 7b could be easily 
detected under the reaction conditions, while the catalyst 6b remained below the 
detection limit, suggested that the elimination of catalyst 6b from 7b could be the rate-
determining step of the whole reaction.    
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Table 7.1 High-Resolution Mass Dataa 
species formula 
HRMS 
calcd 
HRMS 
found 
deviation 
[ppm] 
   
 
C64H42NO6P2 982.24819 982.24816 0.03 
 C80H65N2O9P2S 1291.38805     1291.38801 0.03 
aThe reaction was performed using catalyst 6b (2.45 mg, 2.5 µmol), 1a (15.5 mg, 
0.05mmol)  in dry cyclohexane (0.5 mL) at room temperature and samples of the reaction 
mixtures were monitored at different time during the initial 24 h. 
As soon as substrate 1a, catalyst 6c were combined under the optimized reaction 
conditions, the new peak at m/z 1627.7 could be detected which match the masses of the 
covalent the intermediate [7c + H]+ generated from substrate 1a and the corresponding 
catalyst 6c.  
Table 7.2 High-Resolution Mass Dataa 
species formula 
HRMS 
calcd 
HRMS 
found 
deviation 
[ppm] 
   
 
C88H90NO6P2 1318.62379 1318.62370 0.07 
 C104H113N2O9P2S 1627.76365 1627.76362 0.02 
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aThe reaction was performed using catalyst 6c (3.3 mg, 2.5 µmol), 1a (15.5 mg, 0.05 
mmol)  in dry cyclohexane (0.5 mL) at room temperature and samples of the reaction 
mixtures were monitored at different time during the initial 24 h. 
Characterization of Intermediate 7b 
 
The detected intermediate 7b were futher characterized by 1H, 13C, 1H-1H NOESY, 
1H−13C HMBC, 1H−31P HMBC and 1H−15N HMBC NMR experiments of  reaction 
mixture. The 15N, 13C and 31P spectra of intermediate 7b were referenced indirectly to the 
referenced proton frequency with the ∈-scale with the factors 0.10136767 for 15N 
(δ(MeNO2) = 0 ppm), 0.25145020 for 
13C  (δ(Me4Si) = 0 ppm)) and 0.40480742 for 
31P  (δ(H3PO0) = 0 ppm)). The 
15N chemical shifts were determined from the indirect 
dimension of a 1H−15N HMBC. The abosolute configuration of two diastereomers of 7b 
was not determined.  
HRMS (ESI+) (m/z): calculated for C80H65N2O9P2S1 [M+H]
+: 1291.38805; found: 
1291.38801. 
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Selected NMR spectra of intermediate 7b 
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Selected NMR spectra of intermediate 7b 
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Characterization of Intermediate 7c 
 
The detected intermediate 7c were futher characterized by 1H, 13C, 1H−1H NOESY, 
1H−13C HMBC, 1H−31P HMBC and 1H−15N HMBC NMR experiments of  reaction 
mixture. The 15N, 13C- and 31P spectra of intermediate 7c were referenced indirectly to 
the referenced proton frequency with the ∈-scale with the factors 0.10136767 for 15N 
(δ(MeNO2) = 0 ppm), 0.25145020 for 
13C  (δ(Me4Si) = 0 ppm)) and 0.40480742 for 
31P  (δ(H3PO0) = 0 ppm)). The 
15N chemical shifts were determined from the indirect 
dimension of a 1H−15N HMBC. The abosolute configuration of two diastereomers of 7c 
was not determined.  
HRMS (ESI+) (m/z): calculated for C104H113N2O9P2S1 [M+H]
+: 1627.76365; found: 
1627.76362. 
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Selected NMR spectra of intermediate 7c 
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Selected NMR spectra of intermediate 7c 
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Eyring Equation Studies 
The activation parameters of the elimination of catalyst 6c from 7c were determined by 
measuring the rate constant as a function of temperatures on the basis of Eyring equation 
(equation 4.1). By reducing the loading of the catalyst 6c to 1 mol%, all the catalyst 6c 
could be saturated to the intermediate 7c. Subsequently, the concentration of 7c did not 
change in the beginning of the reaction, so the reaction rate to generate the product 2a 
reached Vmax in the beginning of the reaction (d[2a] = k [7c] dt). We carried out the 
following reactions: substrate 1a (235.2 mg, 0.76 mmol) and dry CD2Cl2 (0.5 mL) were 
added to a dry NMR tube, then catalyst 6c (10 mg, 7.6 µmol) was added at -78°C. Then 
the reaction was performed at various temperatures. The total volume of sample was 0.7 
ml at 22°C and we ignored the changes of volume at different temperatures.  1H and 31P 
NMR spectra of the reaction mixtures were monitored at different time. The kinetic data 
of time versus [2a] were provided, and the [2a] was determined by several different 
signals. Vmax = k [7c], [7c] = 0.01086 M. The obtained NMR data was analyzed with the 
reaction monitoring plugin of MestReNova 9.1 and Origin 2015G 32Bit. 
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Temperature 280.6 K:  
Substrate 1a (235.2 mg, 0.76 mmol) and dry CD2Cl2 (0.5 mL) were added to a dry NMR 
tube, then catalyst 6c (10 mg, 7.6 µmol) was added at −78°C. The reaction was 
conducted at 280.6 K as internally monitored.3 1H NMR spectra of the reaction mixtures 
were monitored at different time. The kinetic datas of time versus [2a] were provided, 
and the [2a] was determined by several different signals. Vmax = k [7c], [7c] = 0.01086 M. 
k  =  5.17372E-05 s-1 
 1 2 3 average 
Vm 5.69E-07 5.57E-07 5.59E-07 5.61718E-07 
R
2 0.99524 0.99024 0.99921 0.994897 
0.02
0.025
0.03
0.035
0.04
0.045
0.05
0.055
0.06
0.065
0.07
0 20000 40000 60000 80000 100000
 
time/s [2a]/M 
1 2 3 
383 0.026207 0.028453 0.021714 
2183 0.026207 0.028453 0.022463 
3983 0.026207 0.029202 0.023212 
5783 0.028453 0.029951 0.024709 
7583 0.0307 0.031448 0.026207 
9383 0.029951 0.031448 0.026956 
11183 0.032197 0.034443 0.028453 
12983 0.032946 0.035192 0.029202 
14783 0.032946 0.035192 0.029951 
16583 0.032946 0.037438 0.0307 
18383 0.03669 0.038187 0.032197 
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20183 0.037438 0.040433 0.033695 
21983 0.038187 0.041931 0.034443 
23783 0.038187 0.040433 0.035192 
25583 0.038936 0.041931 0.035941 
27383 0.041182 0.04268 0.037438 
29183 0.041182 0.044177 0.038187 
30983 0.043429 0.045675 0.039685 
32783 0.043429 0.045675 0.040433 
34583 0.044177 0.049419 0.041182 
36383 0.047172 0.050167 0.04268 
38183 0.047172 0.049419 0.043429 
39983 0.04867 0.050916 0.044177 
41783 0.049419 0.051665 0.045675 
43583 0.050167 0.051665 0.046424 
45383 0.051665 0.053163 0.047172 
47183 0.052414 0.056158 0.04867 
48983 0.052414 0.055409 0.049419 
50783 0.053911 0.058404 0.050167 
52583 0.05466 0.058404 0.050916 
54383 0.056906 0.056158 0.052414 
56183 0.056906 0.06065 0.053163 
57983 0.059901 0.062148 0.05466 
59783 0.06065 0.06065 0.055409 
61583 0.06065 0.062897 0.056158 
63383 0.061399 0.062148 0.057655 
65183 0.062897 0.065143 0.058404 
66983 0.064394 0.065143 0.059153 
68783 0.064394 0.067389 0.059901 
70583 0.062897 0.064394 0.06065 
72383 0.064394 0.065892 0.061399 
74183 0.067389 0.068138 0.062897 
75983 0.069635 0.068138 0.064394 
77783 0.068887 0.072631 0.065143 
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Temperature 294.2 K: 
Substrate 1a (235.2 mg, 0.76 mmol) and dry CD2Cl2 (0.5 mL) were added to a dry NMR 
tube, then catalyst 6c (10 mg, 7.6 µmol) was added at −78°C. The reaction was 
conducted at 294.2 K measured by thermometer. 1H NMR spectra of the reaction 
mixtures were monitored at different time. The kinetic datas of time versus [2a] were 
provided, and the [2a] was determined by several different signals. Vmax = k [7c], [7c] = 
0.01086 M. 1H NMR kinetics study also followed. 
k  =  0.000301 s-1 
 1 2 3 average 
Vm 3.25E-06 3.29E-06 
 
3.27E-06 
 
3.26883E-06 
R
2 0.99988 0.9999 
 
0.99988 
 
0.999887 
 
0
0.05
0.1
0.15
0.2
0.25
0.3
0.35
0.4
0.45
0.5
0 20000 40000 60000 80000 100000 120000 140000
 
time/s [2a]/M 
1 2 3 
0 0.010483 0.013478 2.097E-02 
360 0.012729 0.015724 2.471E-02 
780 0.014227 0.016473 2.471E-02 
1200 0.014975 0.01797 2.621E-02 
1560 0.016473 0.018719 2.621E-02 
1980 0.01797 0.020217 2.845E-02 
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2340 0.018719 0.020966 2.920E-02 
2760 0.020217 0.022463 3.070E-02 
3120 0.020966 0.023212 3.145E-02 
5280 0.029202 0.031448 4.043E-02 
8040 0.038187 0.040433 4.867E-02 
10080 0.045675 0.047921 5.616E-02 
19830 0.078621 0.081616 8.985E-02 
23880 0.092099 0.094345 1.026E-01 
27060 0.10333 0.105576 1.138E-01 
30660 0.114562 0.117557 1.250E-01 
34260 0.125793 0.129537 1.363E-01 
37860 0.137025 0.14002 1.475E-01 
41460 0.149005 0.152749 1.595E-01 
45060 0.160236 0.163232 1.707E-01 
48660 0.171468 0.175212 1.820E-01 
52260 0.181951 0.185695 1.924E-01 
55860 0.193931 0.198424 2.044E-01 
59460 0.205163 0.209655 2.164E-01 
63060 0.216394 0.220887 2.276E-01 
66660 0.227626 0.232118 2.381E-01 
70320 0.238857 0.244099 2.508E-01 
74580 0.253084 0.258325 2.643E-01 
77580 0.262069 0.266562 2.733E-01 
85860 0.291271 0.297261 3.033E-01 
93060 0.315232 0.32197 3.280E-01 
100620 0.339941 0.34668 3.527E-01 
107460 0.362404 0.369892 3.751E-01 
121980 0.408079 0.416315 4.208E-01 
122340 0.408828 0.417064 4.223E-01 
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Temperature 301.2 K:  
Substrate 1a (235.2 mg, 0.76 mmol) and dry CD2Cl2 (0.5 mL) were added to a dry NMR 
tube, then catalyst 6c (10 mg, 7.6 µmol) was added at −78°C. The reaction was 
conducted at 301.2 K as internally monitored.4 1H NMR spectra of the reaction mixtures 
were monitored at different time. The kinetic datas of time versus [2a] were provided, 
and the [2a] was determined by several different signals. Vmax = k [7c], [7c] = 0.01086 M. 
k  =  0.000493541 s-1 
 1 2 3 average 
Vm 5.38E-06 5.38E-06 5.31E-06 5.35845E-06 
R
2 0.99904 0.99888 0.99867 0.998863 
 
0
0.1
0.2
0.3
0.4
0.5
0 20000 40000 60000 80000 100000
 
time/s [2a]/M 
1 2 3 
0 0.026956 0.014975 0.013478 
780 0.033695 0.021714 0.019468 
1680 0.041931 0.028453 0.026207 
2580 0.046424 0.034443 0.032946 
3480 0.052414 0.040433 0.038936 
4380 0.059153 0.046424 0.044926 
5280 0.063645 0.051665 0.050167 
6180 0.071133 0.057655 0.056158 
7080 0.075626 0.063645 0.062148 
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7980 0.080867 0.068887 0.067389 
8880 0.086108 0.074877 0.072631 
9780 0.092847 0.080118 0.078621 
10680 0.09734 0.086857 0.084611 
11580 0.10333 0.090601 0.089103 
12480 0.108571 0.096591 0.095094 
13380 0.113064 0.101833 0.100335 
14280 0.118305 0.106325 0.105576 
15180 0.123547 0.112315 0.110818 
16080 0.128788 0.117557 0.116059 
16980 0.13403 0.122798 0.1213 
17880 0.139271 0.128039 0.126542 
18780 0.143764 0.132532 0.131034 
19680 0.149005 0.137773 0.136276 
20580 0.154246 0.143015 0.141517 
21480 0.159488 0.148256 0.14601 
22380 0.16398 0.153498 0.151251 
23280 0.169222 0.158739 0.156493 
24180 0.175212 0.165478 0.161734 
25080 0.178956 0.168473 0.166227 
25980 0.184946 0.175212 0.171468 
26880 0.18869 0.178207 0.175961 
27780 0.19468 0.183448 0.181202 
28680 0.201419 0.189438 0.186443 
29580 0.205163 0.193931 0.190936 
30480 0.211153 0.199172 0.196177 
31380 0.214897 0.204414 0.20067 
32280 0.220887 0.208906 0.205911 
33180 0.223133 0.21265 0.210404 
34080 0.228374 0.217143 0.214897 
34980 0.233616 0.222384 0.220138 
35880 0.239606 0.226877 0.224631 
36780 0.24335 0.232118 0.229872 
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37680 0.247094 0.236611 0.233616 
38580 0.253833 0.241103 0.238857 
39480 0.259074 0.246345 0.24335 
40380 0.263567 0.250837 0.248591 
41340 0.266562 0.256079 0.253084 
42180 0.2733 0.260571 0.257576 
43080 0.276296 0.265813 0.262069 
43980 0.281537 0.270305 0.26731 
44940 0.287527 0.275547 0.271803 
45840 0.29202 0.280039 0.276296 
46680 0.296512 0.284532 0.281537 
47640 0.301005 0.289773 0.28603 
48540 0.305498 0.294266 0.290522 
49440 0.30999 0.299507 0.295015 
50340 0.315232 0.304 0.299507 
51240 0.320473 0.308493 0.304749 
52140 0.324966 0.312985 0.308493 
53040 0.329458 0.318227 0.313734 
53940 0.333951 0.322719 0.318227 
54840 0.337695 0.327212 0.322719 
55740 0.342936 0.331704 0.327212 
56640 0.348926 0.336946 0.332453 
57540 0.353419 0.341438 0.336197 
58440 0.357163 0.345931 0.34069 
59340 0.362404 0.350424 0.345931 
60240 0.366897 0.354916 0.350424 
61140 0.371389 0.359409 0.354167 
62040 0.375882 0.36465 0.359409 
62940 0.381123 0.369892 0.363901 
63840 0.385616 0.372887 0.368394 
64740 0.390108 0.377379 0.372138 
65640 0.394601 0.382621 0.377379 
66540 0.399094 0.387113 0.381872 
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67440 0.404335 0.391606 0.386365 
68340 0.408079 0.396099 0.390857 
69240 0.411823 0.400591 0.394601 
70140 0.417064 0.406581 0.399842 
71040 0.421557 0.410325 0.404335 
71940 0.426049 0.414818 0.408828 
72840 0.430542 0.41931 0.41332 
73740 0.435034 0.423054 0.417064 
74640 0.440276 0.428296 0.421557 
75540 0.444768 0.432788 0.426798 
76440 0.449261 0.436532 0.430542 
77340 0.453754 0.441773 0.435034 
78240 0.458246 0.446266 0.439527 
79140 0.462739 0.450759 0.44402 
80040 0.467232 0.455251 0.448512 
80940 0.471724 0.458995 0.452256 
81840 0.476217 0.463488 0.456749 
82740 0.480709 0.46798 0.461241 
83640 0.485202 0.473222 0.465734 
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Temperature 312.3 K:  
Substrate 1a (235.2 mg, 0.76 mmol) and dry CD2Cl2 (0.5 mL) were added to a dry NMR 
tube, then catalyst 6c (10 mg, 7.6 µmol) was added at −78°C. The reaction was 
conducted at 312.3 K.4 1H NMR spectra of the reaction mixtures were monitored at 
different time. The kinetic datas of time versus [2a] were provided, and the [2a] was 
determined by several different signals. Vmax = k [7c], [7c] = 0.01086 M. 
k  =  0.001958173 s-1 
 1 2 3 average 
Vm 2.15E-5 2.13E-05 2.10E-05 0.0000212602 
 
R
2 0.99963 0.99967 0.99964 0.999647 
0
0.1
0.2
0.3
0.4
0.5
0.6
0 5000 10000 15000 20000 25000
 
time/s [2a]/M 
1 2 3 
0 0.051665 0.068887 0.050916 
840 0.071882 0.087606 0.071133 
1740 0.093596 0.107074 0.092099 
2640 0.113813 0.128039 0.111567 
3540 0.132532 0.149005 0.131034 
4440 0.152 0.166975 0.150502 
5340 0.172966 0.187192 0.170719 
6240 0.192433 0.207409 0.190187 
7140 0.21265 0.226877 0.208906 
8040 0.232118 0.245596 0.228374 
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8940 0.252335 0.265813 0.247094 
9840 0.271054 0.284532 0.265813 
10740 0.289025 0.304 0.284532 
11640 0.309241 0.323468 0.304 
12540 0.328709 0.342187 0.322719 
13440 0.347429 0.361655 0.341438 
14340 0.367645 0.379626 0.359409 
15240 0.386365 0.399842 0.378128 
16140 0.404335 0.417813 0.396099 
17040 0.423803 0.435783 0.414818 
17940 0.441025 0.453754 0.432788 
18840 0.458995 0.473222 0.450759 
19740 0.476217 0.488946 0.46798 
20640 0.495685 0.507665 0.485951 
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Temperature 323.4 K:  
Substrate 1a (235.2 mg, 0.76 mmol) and dry CD2Cl2 (0.5 mL) were added to a dry NMR 
tube, then catalyst 6c (10 mg, 7.6 mmol) was added at −78°C.4 1H NMR spectra of the 
reaction mixtures were monitored at different time. The kinetic datas of time versus [2a] 
were provided, and the [2a] was determined by several different signals. Vmax = k [7c], 
[7c] = 0.01086 M. 
k  =  0.004711654 s-1 
 1 2 3 average 
Vm 5.32E-05 5.03E-05 5.00E-05 5.11551E-05 
R
2 0.99835 0.99831 1 0.998887 
 
0
0.1
0.2
0.3
0.4
0.5
0.6
0 2000 4000 6000 8000 10000 12000
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time/s [2a]/M 
1 2 3 
720 0.059153 0.04867 0.059153 
1380 0.096591 0.083862 0.092099 
1980 0.132532 0.117557 0.122049 
2580 0.166975 0.149754 0.152 
3180 0.199921 0.181202 0.181951 
3780 0.232867 0.211901 0.211901 
4380 0.264315 0.241852 0.241852 
4980 0.295015 0.271054 0.271803 
5580 0.324966 0.299507 0.301754 
6180 0.355665 0.327961 0.331704 
6780 0.384867 0.355665 0.361655 
7380 0.41332 0.383369 0.392355 
7980 0.442522 0.410325 0.422305 
8580 0.470975 0.437281 0.452256 
9180 0.524887 0.489695 0.482207 
9780 0.55334 0.515153 0.512158 
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Eyring Plot  
ln(kh/kBT) =  −∆H/RT  + ∆S/R 
Boltzmann Constant kB = 1.3806488 × 10
J/K,  
Planck Constant h = 6.62606957 × 10
 J⋅s.                               
1 kcal = 4184 J, R = 8.314462175 J/(K⋅ mol).  
T (K) 280.6 294.2 301.2 312.3 323.4 
1/T (K-1) 0.003564 0.0034 0.00332 0.003202 0.003092 
k (s-1) 5.17372E-05 0.000301076 0.000493541 0.001958173 0.004711654 
ln(kh/kBT) −39.2662417 −37.5522139 −37.0815238 −35.7398133 −34.896584 
 
-39.5
-39
-38.5
-38
-37.5
-37
-36.5
-36
-35.5
-35
-34.5
0.003 0.0031 0.0032 0.0033 0.0034 0.0035 0.0036
 
slope =  − ∆H/R = −9292.10851 ± 369.50685,  intercept = ∆S/R = −6.09892 ± 1.22658. 
Calculation of activation parameters at 298.15 K 
∆H 77258.88 ± 3072.25 J/mol 18.47 ± 0.73 kcal/mol 
∆S −50.71 ± 10.20 J/(K⋅mol) −0.0121 ± 0.0024 kcal/(K⋅mol) 
∆G 92377.84 ± 6112.89 J/mol 22.08 ± 1.46 kcal/mol 
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7.2.4 X-Ray Data  
X-ray structural analysis parameter for 2a: 
 
Crystal data and structure refinement. 
Identification code  9037sadabs 
Empirical formula  C13 H23 N O3 S1 
Color  colourless 
Formula weight  309.41  g·mol-1  
Temperature  100 K 
Wavelength  1.54178 Å 
Crystal system  TRICLINIC 
Space group  p 1,  (no. 1)  
Unit cell dimensions a = 8.8573(4) Å α= 100.3631(12)°. 
 b = 11.7268(5) Å β= 92.9867(11)°. 
 c = 15.6313(7) Å γ = 90.2474(12)°. 
Volume 1594.78(12) Å3 
Z 4 
Density (calculated) 1.289  Mg·m-3 
Absorption coefficient 1.883 mm-1 
F(000) 664 e 
Crystal size 0.8 x 0.2 x 0.16 mm3 
θ range for data collection 3.832 to 67.596°. 
Index ranges −10 ≤ η ≤ 10, −13≤ κ ≤ 14, −18≤ λ ≤ 18 
Reflections collected 72019 
Independent reflections 9536 [Rint = 0.0369] 
Reflections with I>2σ(I) 9493 
Completeness to θ = 67.596° 96.7 %  
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Absorption correction Gaussian 
Max. and min. transmission 0.80136 and 0.36318 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 9536 / 3 / 809 
Goodness-of-fit on F2 1.020 
Final R indices [I>2σ(I)] R1 = 0.0402 wR
2 = 0.1049 
R indices (all data) R1 = 0.0403 wR
2 = 0.1050 
Absolute structure parameter 0.010(12) 
Extinction coefficient 0 
Largest diff. peak and hole 0.493 and -0.435 e·Å-3 
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 Selected bond lengths [Å] and angles [°]. 
______________________________________________________________________ 
C(1)-C(2) 1.559(4) C(1)-C(8) 1.523(5)
C(1)-C(9) 1.517(5) C(1)-N(1) 1.506(4)
C(2)-C(3) 1.522(4) C(2)-O(1) 1.418(4)
C(3)-C(4) 1.535(4) C(3)-C(5) 1.511(4)
C(4)-N(1) 1.480(4) C(5)-C(6) 1.314(6)
C(5)-C(7) 1.511(5) C(6)-H(6A) 0.89(5)
C(6)-H(6B) 0.95(6) C(10)-C(11) 1.396(4)
C(10)-C(15) 1.398(5) C(10)-S(1) 1.761(4)
C(11)-C(12) 1.381(5) C(12)-C(13) 1.398(5)
C(13)-C(14) 1.401(5) C(13)-C(16) 1.506(6)
C(14)-C(15) 1.376(5) N(1)-S(1) 1.613(3)
O(2)-S(1) 1.432(2) O(3)-S(1) 1.442(2)
C(33)-C(34) 1.544(5) C(33)-C(40) 1.532(4)
C(33)-C(41) 1.525(4) C(33)-N(3) 1.503(4)
C(34)-C(35) 1.528(4) C(34)-O(7) 1.415(4)
C(35)-C(36) 1.528(5) C(35)-C(37) 1.504(5)
C(36)-N(3) 1.483(4) C(37)-C(38) 1.505(5)
C(37)-C(39) 1.313(6) C(39)-H(39A) 0.93(5)
C(39)-H(39B) 1.02(7) C(42)-C(43) 1.398(4)
C(42)-C(47) 1.397(5) C(42)-S(3) 1.765(3)
C(43)-C(44) 1.381(5) C(44)-C(45) 1.400(5)
C(45)-C(46) 1.397(4) C(45)-C(48) 1.508(5)
C(46)-C(47) 1.379(5) N(3)-S(3) 1.611(3)
O(8)-S(3) 1.443(2) O(9)-S(3) 1.431(2)
C(17)-C(18) 1.564(5) C(17)-C(24) 1.519(5)
C(17)-C(25) 1.521(4) C(17)-N(2) 1.509(4)
C(18)-C(19) 1.521(5) C(18)-O(4) 1.409(4)
C(19)-C(20) 1.537(4) C(19)-C(21) 1.512(5)
C(20)-N(2) 1.484(4) C(21)-C(22) 1.324(6)
C(21)-C(23) 1.501(5) C(22)-H(22A) 0.98(5)
C(22)-H(22B) 0.97(7) C(26)-C(27) 1.397(4)
C(26)-C(31) 1.393(5) C(26)-S(2) 1.772(3)
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C(27)-C(28) 1.380(5) C(28)-C(29) 1.403(5)
C(29)-C(30) 1.393(5) C(29)-C(32) 1.505(5)
C(30)-C(31) 1.386(5) N(2)-S(2) 1.622(3)
O(5)-S(2) 1.444(2) O(6)-S(2) 1.430(3)
C(49)-C(50) 1.565(4) C(49)-C(56) 1.522(5)
C(49)-C(57) 1.521(4) C(49)-N(4) 1.508(4)
C(50)-C(51) 1.516(4) C(50)-O(10) 1.412(4)
C(51)-C(52) 1.534(5) C(51)-C(53) 1.517(4)
C(52)-N(4) 1.486(4) C(53)-C(54) 1.324(5)
C(53)-C(55) 1.490(5) C(54)-H(54A) 0.95(5)
C(54)-H(54B) 0.98(5) C(58)-C(59) 1.391(5)
C(58)-C(63) 1.395(4) C(58)-S(4) 1.775(3)
C(59)-C(60) 1.381(5) C(60)-C(61) 1.404(4)
C(61)-C(62) 1.387(5) C(61)-C(64) 1.510(5)
C(62)-C(63) 1.383(5) N(4)-S(4) 1.615(3)
O(11)-S(4) 1.433(2) O(12)-S(4) 1.446(3) 
 
C(8)-C(1)-C(2) 110.1(3) C(9)-C(1)-C(2) 112.7(3)
C(9)-C(1)-C(8) 110.6(3) N(1)-C(1)-C(2) 99.8(2)
N(1)-C(1)-C(8) 114.8(3) N(1)-C(1)-C(9) 108.5(3)
C(3)-C(2)-C(1) 104.8(2) O(1)-C(2)-C(1) 111.6(3)
O(1)-C(2)-C(3) 113.5(3) C(2)-C(3)-C(4) 100.7(2)
C(5)-C(3)-C(2) 118.1(3) C(5)-C(3)-C(4) 111.2(3)
N(1)-C(4)-C(3) 102.9(2) C(3)-C(5)-C(7) 114.0(3)
C(6)-C(5)-C(3) 123.9(4) C(6)-C(5)-C(7) 122.1(4)
C(5)-C(6)-H(6A) 119(3) C(5)-C(6)-H(6B) 128(4)
H(6A)-C(6)-H(6B) 113(5) C(11)-C(10)-C(15) 120.1(3)
C(11)-C(10)-S(1) 120.4(3) C(15)-C(10)-S(1) 119.5(2)
C(12)-C(11)-C(10) 119.3(3) C(11)-C(12)-C(13) 121.5(3)
C(12)-C(13)-C(14) 118.1(3) C(12)-C(13)-C(16) 121.5(3)
C(14)-C(13)-C(16) 120.4(3) C(15)-C(14)-C(13) 121.2(3)
C(14)-C(15)-C(10) 119.8(3) C(1)-N(1)-S(1) 125.1(2)
C(4)-N(1)-C(1) 112.4(2) C(4)-N(1)-S(1) 119.1(2)
N(1)-S(1)-C(10) 107.83(15) O(2)-S(1)-C(10)
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108.57(15) O(2)-S(1)-N(1) 108.06(14) O(2)-
S(1)-O(3) 119.10(14) O(3)-S(1)-C(10)
106.38(15) O(3)-S(1)-N(1) 106.45(13) C(40)-
C(33)-C(34) 113.1(3) C(41)-C(33)-C(34) 110.0(3)
C(41)-C(33)-C(40) 110.0(3) N(3)-C(33)-C(34) 100.3(2)
N(3)-C(33)-C(40) 108.4(3) N(3)-C(33)-C(41) 114.9(3)
C(35)-C(34)-C(33) 104.6(3) O(7)-C(34)-C(33) 111.7(3)
O(7)-C(34)-C(35) 113.8(3) C(36)-C(35)-C(34) 100.6(2)
C(37)-C(35)-C(34) 118.4(3) C(37)-C(35)-C(36) 112.0(3)
N(3)-C(36)-C(35) 103.1(3) C(35)-C(37)-C(38) 114.1(3)
C(39)-C(37)-C(35) 123.9(3) C(39)-C(37)-C(38) 122.0(4)
C(37)-C(39)-H(39A) 123(3) C(37)-C(39)-H(39B) 125(4)
H(39A)-C(39)-H(39B) 111(5) C(43)-C(42)-S(3) 120.3(2)
C(47)-C(42)-C(43) 120.1(3) C(47)-C(42)-S(3) 119.5(2)
C(44)-C(43)-C(42) 119.5(3) C(43)-C(44)-C(45) 121.1(3)
C(44)-C(45)-C(48) 121.2(3) C(46)-C(45)-C(44) 118.3(3)
C(46)-C(45)-C(48) 120.4(3) C(47)-C(46)-C(45) 121.4(3)
C(46)-C(47)-C(42) 119.5(3) C(33)-N(3)-S(3) 125.5(2)
C(36)-N(3)-C(33) 111.9(3) C(36)-N(3)-S(3) 119.1(2)
N(3)-S(3)-C(42) 108.05(16) O(8)-S(3)-C(42)
106.21(15) O(8)-S(3)-N(3) 106.32(14) O(9)-
S(3)-C(42) 108.41(14) O(9)-S(3)-N(3)
107.90(15) O(9)-S(3)-O(8) 119.49(15) C(24)-
C(17)-C(18) 109.8(3) C(24)-C(17)-C(25) 110.3(3)
C(25)-C(17)-C(18) 112.6(3) N(2)-C(17)-C(18) 99.0(2)
N(2)-C(17)-C(24) 111.0(3) N(2)-C(17)-C(25) 113.7(3)
C(19)-C(18)-C(17) 105.8(3) O(4)-C(18)-C(17) 113.8(3)
O(4)-C(18)-C(19) 114.8(3) C(18)-C(19)-C(20) 101.7(3)
C(21)-C(19)-C(18) 115.8(3) C(21)-C(19)-C(20) 113.1(3)
N(2)-C(20)-C(19) 104.0(3) C(22)-C(21)-C(19) 119.2(3)
C(22)-C(21)-C(23) 121.1(3) C(23)-C(21)-C(19) 119.7(3)
C(21)-C(22)-H(22A) 124(3) C(21)-C(22)-H(22B) 126(4)
H(22A)-C(22)-H(22B) 111(5) C(27)-C(26)-S(2) 119.4(3)
C(31)-C(26)-C(27) 120.6(3) C(31)-C(26)-S(2) 120.0(2)
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C(28)-C(27)-C(26) 119.3(3) C(27)-C(28)-C(29) 121.2(3)
C(28)-C(29)-C(32) 120.5(3) C(30)-C(29)-C(28) 118.3(3)
C(30)-C(29)-C(32) 121.3(3) C(31)-C(30)-C(29) 121.4(3)
C(30)-C(31)-C(26) 119.1(3) C(17)-N(2)-S(2) 125.2(2)
C(20)-N(2)-C(17) 113.0(2) C(20)-N(2)-S(2) 117.6(2)
N(2)-S(2)-C(26) 108.65(15) O(5)-S(2)-C(26)
105.82(15) O(5)-S(2)-N(2) 106.10(13) O(6)-
S(2)-C(26) 108.45(15) O(6)-S(2)-N(2)
108.06(15) O(6)-S(2)-O(5) 119.38(15) C(56)-
C(49)-C(50) 112.2(3) C(57)-C(49)-C(50) 109.4(3)
C(57)-C(49)-C(56) 110.4(3) N(4)-C(49)-C(50) 99.3(2)
N(4)-C(49)-C(56) 113.9(3) N(4)-C(49)-C(57) 111.2(3)
C(51)-C(50)-C(49) 105.3(3) O(10)-C(50)-C(49) 113.7(3)
O(10)-C(50)-C(51) 114.7(3) C(50)-C(51)-C(52) 102.1(3)
C(50)-C(51)-C(53) 116.4(3) C(53)-C(51)-C(52) 112.5(3)
N(4)-C(52)-C(51) 103.8(3) C(54)-C(53)-C(51) 119.0(3)
C(54)-C(53)-C(55) 122.0(3) C(55)-C(53)-C(51) 118.9(3)
C(53)-C(54)-H(54A) 120(3) C(53)-C(54)-H(54B) 121(3)
H(54A)-C(54)-H(54B) 120(4) C(59)-C(58)-C(63) 120.6(3)
C(59)-C(58)-S(4) 119.2(2) C(63)-C(58)-S(4) 120.1(3)
C(60)-C(59)-C(58) 119.5(3) C(59)-C(60)-C(61) 120.8(3)
C(60)-C(61)-C(64) 119.9(3) C(62)-C(61)-C(60) 118.5(3)
C(62)-C(61)-C(64) 121.6(3) C(63)-C(62)-C(61) 121.6(3)
C(62)-C(63)-C(58) 118.9(3) C(49)-N(4)-S(4) 125.8(2)
C(52)-N(4)-C(49) 112.7(3) C(52)-N(4)-S(4) 117.4(2)
N(4)-S(4)-C(58) 108.42(15) O(11)-S(4)-C(58) 108.40(15)
O(11)-S(4)-N(4) 107.89(14) O(11)-S(4)-O(12) 119.51(15)
O(12)-S(4)-C(58) 106.07(15) O(12)-S(4)-N(4)          106.14(14)  
_____________________________________________________________________ 
Symmetry transformations used to generate equivalent atoms 
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7.3 Organolcatalytic Asymmetric Transformations via Oxocarbenium Ions  
7.3.1 Prins Cyclization  
 7.3.1.1 Products  
  
Unless specified otherwise, aldehyde 10 (0.12 mmol) and 3-methyl-3-buten-1-ol (0.10 
mmol) were added to a mixture of catalyst 9 (0.005 mmol, 5 mol%) and 50 mg 5Å 
molecular sieves in anhydrous solvent (0.1 M). Purification was performed by column 
chromatography or preparative thin layer chromatography on silica gel using 
pentane/diethyl ether = 95/5 as the eluent. Due to the concentration and separation issue, 
only the enantiomeric ratios of minor endocyclic alkene isomers of 11e, 11f, 11i, 11l, 
11m, 11p−11r were provided. 
O
O
H
8
 
2-methyl-4-(3-methyl-1-((3-methylbut-3-en-1-yl)oxy)butoxy)but-1-ene  
1H NMR (500 MHz, CDCl3): δ 4.77–4.78 (m, 2H), 4.73–4.74 (m, 2H), 4.59 (t, J = 6.0 
Hz, 1 H), 3.66–3.70 (m, 2H), 3.52–3.57 (m, 2H), 2.29 (t, J = 7.0 Hz, 4H), 1.75 (br s, 6H), 
1.69–1.73 (m, 1H), 1.50 (dd, J = 6.9Hz, J = 6.0 Hz, 2H), 0.91 (s, 3H), 0.90 (s, 3H). The 
spectra is not clean because a little amount of impurity 11a was exist, which is similar 
polarity to 8 during column chromatography.   
13C NMR (126 MHz, CDCl3): δ 143.0, 111.6, 101.9, 63.7, 42.2, 38.1, 24.5, 23.0, 22.9. 
The spectra is not clean because a little amount of impurity 3a was exist, which is similar 
polarity to B during column chromatography.   
HRMS (ESI+) (m/z): calculated for C15H28O2Na1 [M+Na]
+: 263.1981; found: 263.1979.  
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(S)-2-Isobutyl-4-methylenetetrahydro-2H-pyran 
Prepared at 22 °C in cyclohexane. A colorless oil was obtained. Due to the volatile nature 
of the product, the yield was determined by 1H NMR spectroscopy of the reaction 
mixture using CHCl2CHCl2 as internal standard. The major isomer was obtained in 89% 
NMR yield. The regiomeric ratio of the isolated compound is 9:1 which was determined 
by GC analysis.  
1H NMR (500 MHz, CDCl3): δ 4.72–4.70 (m, 2H), 4.05 (ddd, J = 10.9Hz, 5.6Hz, 1.6Hz, 
1H), 3.4–3.2 (m, 2H), 2.34–2.10 (m, 3H), 1.99–1.91 (m, 1H), 1.83–1.74 (m, 1H), 1.56–
1.46 (m, 1H), 1.25–1.16 (m, 1H), 0.91 (d, J = 3.3 Hz, 3H), 0.89 (d, J = 3.3 Hz, 3H). 
13C NMR (126 MHz, CDCl3): δ 145.0, 108.1, 68.7, 45.5, 41.6, 35.3, 24.3, 23.2, 22.3. 
HRMS (EI) (m/z): calculated for C10H18O1 [M]: 154.1357; found: 154.1356.  
GC The enantiomeric ratio was measured by GC analysis on Hydrodex-gamma-TBDAc-
CD column: tR = 32.17 min (major) and tR= 34.50 min (minor), er = 95.5:4.5. 
 
(S)-4-Methylene-2-propyltetrahydro-2H-pyran  
Prepared at 10 °C in cyclohexane. A colorless oil was obtained. Due to the volatile nature 
of the product, the yield was determined by 1H NMR spectroscopy of the reaction 
mixture using CHCl2CHCl2 as internal standard. The major isomer was obtained in 60% 
NMR yield. The regiomeric ratio of the isolated compound is 10:1 which was determined 
by GC analysis.  
1H NMR (300 MHz, CD2Cl2): δ 4.71–4.68 (m, 2H), 4.01 (ddd, J = 10.9 Hz, 5.5 Hz, 1.7 
Hz, 1H), 3.32 (ddd, J = 13.7 Hz, 10.9 Hz, 2.9 Hz, 1H), 3.24–3.16 (m, 1H), 2.32–2.09 (m, 
3H), 1.98–1.89 (m, 1H), 1.49–1.30 (m, 4H), 0.91 (t, J = 7.1 Hz, 3H). 
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13C NMR (75 MHz, CD2Cl2): δ 145.9, 108.0, 79.0, 69.0, 41.6, 38.9, 35.8, 19.1, 14.3. 
HRMS (EI) (m/z): calculated for C9H17O1 [M]: 141.1273; found: 141.1275.  
GC The enantiomeric ratio was measured by GC analysis on Lipodex-G/in G-566 
column: tR = 10.38 min (minor) and tR= 11.27 min (major), er = 95:5. 
 
(S)-2-Butyl-4-methylenetetrahydro-2H-pyran  
Prepared at 0 °C in methylcyclohexane. A colorless oil was obtained. Due to the volatile 
nature of the product, the yield was determined by 1H NMR spectroscopy of the reaction 
mixture using CHCl2CHCl2 as internal standard. The major isomer was obtained in 85% 
NMR yield. The regioisomeric ratio of the isolated compound is >20:1 which was 
determined by GC analysis.  
1H NMR (500 MHz, CDCl3): δ 4.72–4.69 (m, 2H), 4.06 (ddd, J = 10.9 Hz, 5.6 Hz, 1.4 
Hz, 1H), 3.36 (ddd, J = 13.6 Hz, 10.9 Hz, 2.7 Hz, 1H), 3.24–3.19 (m, 1H), 2.32–2.26 (m, 
1H), 2.22 (td, J = 13.3 Hz, 1.9 Hz, 1H), 2.15–2.11 (m, 1H), 1.99–1.94 (m, 1H), 1.48–1.28 
(m, 6H), 0.90 (t, J = 7.0 Hz, 3H). 
13C NMR (126 MHz, CDCl3): δ 145.1, 108.3, 79.0, 68.8, 41.3, 36.1, 35.4, 27.8, 22.9, 
14.2. 
HRMS (EI) (m/z): calculated for C10H18O1 [M]: 154.1357; found: 154.1355.  
GC The enantiomeric ratio was measured by GC analysis on Hydrodex-beta-TBDAc-CD 
column: tR = 13.51 min (major) and tR= 14.80 min (minor), er = 95:5. 
 
(S)-4-Methylene-2-neopentyltetrahydro-2H-pyran  
Prepared at 22 °C in cyclohexane. A colorless oil was obtained. Due to the volatile nature 
of the product, the yield was determined by 1H NMR spectroscopy of the reaction 
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mixture using CHCl2CHCl2 as internal standard. The major isomer was obtained in 60% 
NMR yield. The regiomeric ratio of the isolated compound is >20:1 which was 
determined by GC analysis.  
1H NMR (500 MHz, CDCl3): δ 4.71–4.69 (m, 2H), 4.03 (ddd, J = 11.1 Hz, 5.7 Hz, 1.1 
Hz, 1H), 3.4–3.3 (m, 2H), 2.31–2.24 (m, 1H), 2.14–2.11 (m, 2H), 2.04–1.99 (m, 1H), 
1.53 (q, 8.0 Hz, 1H),  1.25 (dd, 14.5 Hz, 2.6 Hz, 1H), 0.93 (s, 9H). 
13C NMR (126 MHz, CDCl3): δ 145.3, 108.1, 76.8, 68.4, 49.9, 42.8, 35.0, 30.2, 30.1. 
HRMS (EI) (m/z): calculated for C11H20O1 [M]: 168.1514; found: 168.1512.  
GC The enantiomeric ratio was measured by GC analysis on Hydrodex-gamma-TBDAc-
CD column: tR = 14.86 min (major) and tR= 16.37 min (minor), er = 98:2. 
 
(R)-2-Isopropyl-4-methylenetetrahydro-2H-pyran  
Prepared at 22 °C in cyclohexane. A colorless oil was obtained. Due to the volatile nature 
of the product, the yield was determined by 1H NMR spectroscopy of the reaction 
mixture using CHCl2CHCl2 as internal standard. The major isomer was obtained in 94% 
NMR yield. The regioisomeric ratio of the isolated compound is 9:1 which was 
determined by GC analysis. 
1H NMR (300 MHz, CD2Cl2): δ 4.71–4.70 (m, 2H), 4.03 (ddd, J = 10.9 Hz, 5.6 Hz, 1.6 
Hz, 1H), 3.03 (ddd, J = 13.7 Hz, 10.8 Hz, 2.9 Hz, 1H), 2.91 (ddd, J = 11.1 Hz, 6.2 Hz, 
2.4 Hz, 1H), 2.31–2.19 (m, 2 H), 2.15–2.09 (m, 1H), 2.01–1.92 (m, 1H), 1.66 (q, 6.6 Hz, 
1H),  0.92 (d, 6.8 Hz, 3H), 0.90 (d, 6.8 Hz, 3H). 
13C NMR (126 MHz, CD2Cl2): δ 146.2, 108.1, 84.3, 69.2, 38.4, 35.9, 33.6, 18.7, 18.5. 
HRMS (EI) (m/z): calculated for C9H16O1 [M]: 140.1201; found: 140.1200.  
GC The enantiomeric ratio was measured by GC analysis on Cyclodextrin-H/in OV-1701 
column: tR  = 11.34 min (minor) and tR= 13.50 min (major), er (exocylic alkene isomer) = 
95:5; tR  = 15.53 min (minor) and tR= 16.87 min (major), er (endocylic alkene isomer 1) = 
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77:23; tR  = 23.18 min (minor) and tR= 25.19 min (major), er (endocylic alkene isomer 2) 
= 76:24. 
 
(R)-4-Methylene-2-(pentan-3-yl)tetrahydro-2H-pyran  
Prepared at 22 °C in cyclohexane. A colorless oil was obtained. Due to the volatile nature 
of the product, the yield was determined by 1H NMR spectroscopy of the reaction 
mixture using CHCl2CHCl2 as internal standard. The major isomer was obtained in 85% 
NMR yield. The regiomeric ratio of the isolated compound is 13:1 which was determined 
by GC analysis.  
1H NMR (500 MHz, CD2Cl2): δ 4.71–4.69 (m, 2H), 4.02 (ddd, J = 10.8 Hz, 5.7 Hz, 1.2 
Hz, 1H), 3.29 (ddd, J = 13.5 Hz, 10.8 Hz, 2.7 Hz, 1H), 3.16 (ddd, J = 11.2 Hz, 5.4 Hz, 
2.3 Hz, 1H), 2.28–2.21 (m, 1H), 2.18 (td, J = 13.1 Hz, 1.9 Hz, 1H), 2.14–2.10 (m, 1H), 
2.04–1.99 (m, 1H), 1.51–1.25 (m, 5H), 0.89–0.85 (m, 6H). 
13C NMR (126 MHz, CD2Cl2): δ 146.4, 108.1, 80.9, 69.3, 46.3, 38.3, 35.9, 22.0, 21.8, 
11.69, 11.65. 
HRMS (EI) (m/z): calculated for C11H20O1 [M]: 168.1514; found: 168.1513.  
GC The enantiomeric ratio was measured by GC analysis on C-DEXTRIN-H/in G-632 
column: tR = 10.92 min (minor) and tR= 11.71 min (major), er (exocylic alkene isomer) = 
95:5; tR  = 12.18 min (minor) and tR= 13.26 min (major), er (endocylic alkene isomer 1) = 
80:20; tR  = 16.24 min (minor) and tR= 17.27 min (major), er (endocylic alkene isomer 2) 
= 77:23. 
 
(R)-2-(tert-Butyl)-4-methylenetetrahydro-2H-pyran  
Prepared at 22 °C in cyclohexane. A colorless oil was obtained. Due to the volatile nature 
of the product, the yield was determined by 1H NMR spectroscopy of the reaction 
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mixture using CHCl2CHCl2 as internal standard. The major isomer was obtained in 90% 
NMR yield. The regiomeric ratio of the isolated compound is 20:1 which was determined 
by GC analysis. The corresponding enantiomer could be achieved using ent-9b. 
1H NMR (500 MHz, CD2Cl2): δ 4.71–4.69 (m, 2H), 4.05 (ddd, J = 13.5 Hz, 10.8 Hz, 1.0 
Hz, 1H), 3.29 (ddd, J = 13.5 Hz, 10.8 Hz, 2.7 Hz, 1H), 2.8 (dd, J = 11.5 Hz, 2.2 Hz, 1H), 
2.27–2.19 (m, 2H), 2.13–2.09 (m, 1H), 2.01–1.96 (m, 1H), 0.89 (s, 9H). 
13C NMR (126 MHz, CD2Cl2): δ 146.7, 108.1, 87.2, 69.5, 35.94, 35.88, 34.4, 26.1. 
HRMS (EI) (m/z): calculated for C10H18O1 [M]: 154.1357; found: 154.1356.  
GC The enantiomeric ratio was measured by GC analysis on Lipodex-G/in G-566 
column: using catalyst 9b tR = 9.07 min (minor) and tR= 9.73 min (major), er = 98:2; 
using catalyst ent-9b tR = 9.14 min (major) and tR= 10.21 min (minor), er = 98:2. 
 
(S)-4-Methylene-2-phenethyltetrahydro-2H-pyran  
Prepared at 22 °C in cyclohexane. A colorless oil was obtained. 80% Isolated yield was 
obtained using pentane/diethylether = 95/5 as the eluents. The regiomeric ratio of the 
isolated compound is >20:1 which was determined by GC analysis.  
1H NMR (500 MHz, CDCl3): δ 7.30–7.27 (m, 2H), 7.22–7.17 (m, 3H), 4.70 (qd, J = 10.3 
Hz, 1.8 Hz, 2H), 4.10 (ddd, J = 10.9 Hz, 5.6 Hz, 1.5 Hz, 1H), 3.38 (ddd, J = 13.6 Hz, 
11.0 Hz, 2.7 Hz, 1H), 3.27–3.22 (m, 1H), 2.82–2.76 (m, 1H),  2.70–2.64 (m, 1H), 2.35–
2.28 (m, 1H), 2.22 (td, J = 13.2 Hz, 1.8 Hz, 1H), 2.17–2.13 (m, 1H), 2.05–2.00 (m, 1H), 
1.92–1.84 (m, 1H), 1.77–1.70 (m, 1H). 
13C NMR (126 MHz, CDCl3): δ 144.8, 142.3, 128.6, 128.5, 125.9, 108.5, 77.9, 68.8, 
41.3, 38.1, 35.4, 31.9. 
HRMS (ESI+) (m/z): calculated for C19H28O2Na1 [M+Na]
+: 311.1981; found: 311.1980.  
GC The enantiomeric ratio was measured by GC analysis on Hydrodex-beta-TBDAc-CD 
column: tR = 23.11 min (major) and tR= 23.68 min (minor), er = 90:10. 
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(R)-4-Methylene-2-(2-methylprop-1-en-1-yl)tetrahydro-2H-pyran  
Prepared at –30 °C in methylcyclohexane. A colorless oil was obtained. Due to the 
volatile nature of the product, the yield was determined by 1H NMR spectroscopy of the 
reaction mixture using CHCl2CHCl2 as internal standard. The major isomer was obtained 
in 87% NMR yield. The regiomeric ratio of the isolated compound is 11:1 which was 
determined by GC analysis.  
1H NMR (500 MHz, CDCl3): δ 5.23–5.19 (m, 1H), 4.75–4.71 (m, 2H), 4.07 (ddd, J = 
10.9 Hz, 5.6 Hz, 1.5 Hz, 1H), 3.97 (ddd, J = 10.9 Hz, 8.2 Hz, 2.8 Hz, 1H), 3.43 (ddd, J = 
13.6 Hz, 11.0 Hz, 2.7 Hz, 1H), 2.34–2.27 (m, 1H), 2.20–2.06 (m, 3H), 1.73 (d, J = 1.3 
Hz, 3H), 1.69 (d, J = 1.3 Hz, 3H). 
13C NMR (126 MHz, CDCl3): δ 144.6, 136.2, 125.6, 108.5, 75.8, 68.5, 41.3, 35.0, 25.7, 
18.5. 
HRMS (ESI+) (m/z): calculated for C10H16O1Na1 [M+Na]
+: 175.1093; found: 175.1095.  
GC The enantiomeric ratio was measured by GC analysis on Hydrodex-gamma-TBDAc-
CD column: tR = 14.90 min (major) and tR= 16.20 min (minor), er (exocylic alkene 
isomer) = 95:5; tR = 21.77 min (major) and tR= 22.44 min (minor), er (endocylic alkene 
isomer 1) = 52:48; tR = 24.52 min and tR= 25.41 min, er (endocylic alkene isomer 2) = 
50:50. 
 
(R)-4-Methylene-2-phenyltetrahydro-2H-pyran  
Prepared at 10 °C in cyclohexane. A colorless oil was obtained. 69% isolated yield was 
obtained using pentane/diethylether = 95/5 as the eluents (due to the volatile nature of the 
product, the yield was also determined by 1H NMR spectroscopy of the reaction mixture 
using CHCl2CHCl2 as internal standard. The major isomer was obtained in 97% NMR 
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yield). The regiomeric ratio of the isolated compound is >20:1 which was determined by 
GC analysis.  
1H NMR (500 MHz, CDCl3): δ 7.39–7.34 (m, 4H), 7.30–7.26 (m, 1H), 4.81 (qd, J = 7.3 
Hz, 1.8 Hz, 2H), 4.30 (dd, J = 11.3 Hz, 2.5 Hz, 1H), 4.24 (ddd, J = 10.8 Hz, 5.7 Hz, 1.0 
Hz, 1H), 3.56 (ddd, J = 13.5 Hz, 11.0 Hz, 2.7 Hz, 1H), 2.48–2.40 (m, 2H),  2.36–2.30 (m, 
1H), 2.25–2.22 (m, 1H). 
13C NMR (126 MHz, CDCl3): δ 144.6, 142.5, 128.5, 127.7, 126.0, 109.0, 81.1, 69.3, 
43.3, 35.1. 
HRMS (EI) (m/z): calculated for C12H14O1 [M]: 174.1044; found: 174.1041.  
GC The enantiomeric ratio was measured by GC analysis on Hydrodex-beta-TBDAc-CD 
column: tR = 15.02 min (major) and tR= 15.94 min (minor), er = 96:4.  
 
(R)-2-(4-Methylenetetrahydro-2H-pyran-2-yl)phenol Prepared at 0 °C in 
methylcyclohexane. A colorless oil was obtained. 80% Isolated yield was obtained using 
pentane:diethyl ether 95:5 as the eluents. The regiomeric ratio of the isolated compound 
is >20:1 which was determined by GC analysis.  
HRMS (ESI+) (m/z): calculated for C12H14O2Na1 [M+Na]
+: 213.0885; found: 213.0888.  
GC The enantiomeric ratio was measured by GC analysis on Hydrodex-gamma-TBDAc-
CD column: tR = 16.04 min (major) and tR= 16.53 min (minor), er = 95.5:4.5. 
 
(R)-2-(3-Methoxyphenyl)-4-methylenetetrahydro-2H-pyran  
Prepared at 0 °C in methylcyclohexane. A colorless oil was obtained. 65% Isolated yield 
was obtained using pentane/diethylether = 95/5 as the eluents. The regiomeric ratio of the 
isolated compound is 12:1 which was determined by GC analysis.  
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1H NMR (500 MHz, CDCl3): δ 7.28–7.24 (m, 1H), 6.95–6.94 (m, 2H), 6.82 (dd, J = 8.2 
Hz, 0.95 Hz, 1H), 4.81 (qd, J = 3.2 Hz, 1.8 Hz, 2H), 4.27 (dd, J = 11.2 Hz, 2.5 Hz, 1H), 
4.23 (ddd, J = 11.0 Hz, 5.7 Hz, 1.1 Hz, 1H), 3.82 (s, 3H), 3.55 (ddd, J = 13.6 Hz, 11.0 
Hz, 2.6 Hz, 1H), 2.48–2.40 (m, 2H),  2.34–2.29 (m, 1H), 2.24–2.21 (m, 1H). 
13C NMR (126 MHz, CDCl3): δ 159.8, 144.6, 144.1, 129.5, 118.3, 113.4, 111.3, 109.1, 
80.9, 69.2, 55.4, 43.3, 35.1. 
HRMS (ESI+) (m/z): calculated for C13H16O2Na1 [M+Na]
+: 227.1042; found: 227.1044.  
GC The enantiomeric ratio was measured by GC analysis on Hydrodex-beta-TBDAc-CD 
column column: tR = 80.12 min (major) and tR= 82.53 min (minor), er (exocylic alkene 
isomer) = 95:5; tR = 101.56 min (minor) and tR= 113.69 min (major), er (endocylic alkene 
isomer) = 54:46. 
 
(R)-2-(3-bromophenyl)-4-methylenetetrahydro-2H-pyran  
Prepared at 10 °C in cyclohexane. A colorless oil was obtained. 73% Isolated yield was 
obtained using pentane/diethylether = 95/5 as the eluents. The regiomeric ratio of the 
isolated compound is 15:1 which was determined by GC analysis.  
1H NMR (500 MHz, CDCl3): δ 7.55 (t, J = 1.7 Hz, 1H), 7.40 (qd, J = 7.9 Hz, 1.2 Hz, 
1H), 7.29–7.28 (m, 1H), 7.23–7.20 (m, 1H), 4.82 (qd, J = 7.8 Hz, 1.7 Hz, 2H), 4.28–4.21 
(m, 2H), 3.54 (ddd, J = 13.6 Hz, 11.0 Hz, 2.6 Hz, 1H), 2.47–2.38 (m, 2H),  2.29–2.21 (m, 
2H).  
13C NMR (126 MHz, CDCl3): δ 144.8, 144.1, 130.7, 130.1, 129.1, 124.5, 122.7, 109.4, 
80.1, 69.3, 43.2, 35.0. 
HRMS (ESI+) (m/z): calculated for C12H13Br1O1Na1 [M+Na]
+: 275.0042; found: 
275.0042.  
GC The enantiomeric ratio was measured by GC analysis on Hydrodex-beta-TBDAc-CD 
column column: tR = 38.84 min (major) and tR= 40.29 min (minor), er (exocylic alkene 
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isomer) = 95:5; tR = 46.66 min (minor) and tR= 49.94 min (major), er (endocylic alkene 
isomer) = 57:43. 
 
(R)-2-(4-chlorophenyl)-4-methylenetetrahydro-2H-pyran  
Prepared at 10 °C in cyclohexane. A colorless oil was obtained. 81% Isolated yield was 
obtained using pentane/diethylether = 95/5 as the eluents. The regiomeric ratio of the 
isolated compound is >20:1 which was determined by GC analysis.  
1H NMR (500 MHz, CDCl3): δ 7.33–7.29 (m, 4H), 4.82 (qd, J = 7.1 Hz, 1.8 Hz, 2H), 
4.27 (dd, J = 11.3 Hz, 2.6 Hz, 1H), 4.22 (ddd, J = 11.0 Hz, 5.7 Hz, 1.1 Hz, 1H), 3.54 
(ddd, J = 13.6 Hz, 11.0 Hz, 2.7 Hz, 1H), 2.45–2.38 (m, 2H),  2.29–2.21 (m, 2H). 
13C NMR (126 MHz, CDCl3): δ 144.2, 141.0, 133.3, 128.7, 127.4, 109.3, 80.2, 69.2, 
43.3, 35.0. 
HRMS (ESI+) (m/z): calculated for C12H13Cl1O1Na1 [M+Na]
+: 208.0654; found: 
208.0653.  
GC The enantiomeric ratio was measured by GC analysis on Hydrodex-beta-TBDAc-CD 
column column: tR = 71.63 min (minor) and tR= 72.40 min (major), er = 96:4. 
 
(R)-2-(4-bromophenyl)-4-methylenetetrahydro-2H-pyran 
Prepared at 10 °C in cyclohexane. A colorless oil was obtained. 86% Isolated yield was 
obtained using pentane/diethylether = 95/5 as the eluents. The regiomeric ratio of the 
isolated compound is >20:1 which was determined by GC analysis.  
1H NMR (500 MHz, CDCl3): δ 7.49–7.46 (m, 2H), 7.26–7.24 (m, 2H), 4.82 (qd, J = 8.8 
Hz, 1.7 Hz, 2H), 4.26–4.20 (m, 2H), 3.54 (ddd, J = 13.6 Hz, 11.1 Hz, 2.6 Hz, 1H), 2.45–
2.38 (m, 2H), 2.28–2.21 (m, 2H). 
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13C NMR (126 MHz, CDCl3): δ 144.1, 141.6, 131.6, 127.7, 121.4, 109.3, 80.2, 69.2, 
43.2, 35.0. 
HRMS (EI) (m/z): calculated for C12H13Br1O1 [M]: 252.0149; found: 252.0150.  
GC The enantiomeric ratio was measured by GC analysis on Hydrodex-beta-TBDAc-CD 
column column: tR = 97.26 min (minor) and tR= 98.48 min (major), er = 96.5:3.5. 
 
(R)-5-(4-methylenetetrahydro-2H-pyran-2-yl)benzo[d][1,3]dioxole  
Prepared at 0 °C in methylcyclohexane. A colorless oil was obtained. 68% Isolated yield 
was obtained using pentane/diethylether = 95/5 as the eluents. The regiomeric ratio of the 
isolated compound is 16:1 which was determined by GC analysis.  
1H NMR (500 MHz, CDCl3): δ 6.90 (d, J = 1.6 Hz, 1H), 6.83–6.81 (m, 1H), 6.78–6.77 
(m, 1H), 5.94 (s, 2H), 4.80 (qd, J = 9.5 Hz, 1.8 Hz, 2H), 4.22–4.19 (m, 2H), 3.53 (ddd, J 
= 13.6 Hz, 11.0 Hz, 2.7 Hz, 1H), 2.44–2.37 (m, 2H),  2.32–2.26 (m, 1H), 2.23–2.19 (m, 
1H). 
13C NMR (126 MHz, CDCl3): δ 147.8, 147.0, 144.6, 136.6, 119.4, 109.0, 108.2, 106.8, 
101.1, 80.9, 69.2, 43.3, 35.1. 
HRMS (ESI+) (m/z): calculated for C13H14O3Na1 [M+Na]
+: 241.0835; found: 241.0836.  
GC The enantiomeric ratio was measured by GC analysis C-DEXTRIN H/in G-632 
column column: tR = 55.76 min (minor) and tR= 57.22 min (major), er (exocylic alkene 
isomer) = 94:6; tR = 73.98 min (major) and tR= 86.96 min (minor), er (endocylic alkene 
isomer) = 51:49. 
 
(R)-2-(furan-2-yl)-4-methylenetetrahydro-2H-pyran  
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Prepared at 10 °C in cyclohexane. A colorless oil was obtained. 73% Isolated yield was 
obtained using pentane/diethylether = 95/5 as the eluents. The regiomeric ratio of the 
isolated compound is 13:1 which was determined by GC analysis.  
1H NMR (500 MHz, CDCl3): δ 7.40 (dd, J = 1.8 Hz, 0.85 Hz, 1H), 6.34 (dd, J = 3.3 Hz, 
1.9 Hz, 1H), 6.31–6.30 (m, 1H), 4.82 (q, J = 1.7 Hz, 2H), 4.40 (dd, J = 10.8 Hz, 2.9 Hz, 
1H), 4.12 (ddd, J = 11.0 Hz, 5.5 Hz, 2.1 Hz, 1H), 3.56 (ddd, J = 13.9 Hz, 11.1 Hz, 2.8 
Hz, 1H), 2.61–2.56 (m, 1H),  2.52–2.49 (m, 1H), 2.44–2.37 (m, 1H), 2.23 (qd, J = 13.6 
Hz, 2.3 Hz, 1H). 
13C NMR (126 MHz, CDCl3): δ 154.4, 143.5, 142.4, 110.2, 109.7, 106.9, 73.7, 68.7, 
38.8, 35.0. 
HRMS (EI) (m/z): calculated for C10H12O2 [M]: 164.0837; found: 164.0835.  
GC The enantiomeric ratio was measured by GC analysis on Hydrodex-beta-TBDAc-G-
589 column: tR = 19.24 min (major) and tR= 24.92 min (minor), er (exocylic alkene 
isomer) = 95:5; tR = 27.47 min (minor) and tR= 28.44 min (major), er (endocylic alkene 
isomer 1) = 58:42; tR = 28.97 min (major) and tR= 29.58 min (minor), er (endocylic 
alkene isomer 2) = 51:49. 
 
(R)-2-(furan-3-yl)-4-methylenetetrahydro-2H-pyran  
Prepared at 0 °C in methylcyclohexane. A colorless oil was obtained. 82% Isolated yield 
was obtained using pentane/diethylether = 95/5 as the eluents. The regiomeric ratio of the 
isolated compound is 14:1 which was determined by GC analysis.  
1H NMR (500 MHz, CDCl3): δ 7.41–7.39 (m, 2H), 6.43–6.42 (m, 1H), 4.81–4.79 (m, 
2H), 4.30 (dd, J = 10.8 Hz, 2.7 Hz, 1H), 4.13 (ddd, J = 10.9 Hz, 5.4 Hz, 1.7 Hz, 1H), 
3.53 (ddd, J = 13.8 Hz, 10.0 Hz, 2.8 Hz, 1H), 2.48–2.44 (m, 1H),  2.39–2.34 (m, 2H), 
2.23–2.19 (m, 1H). 
13C NMR (126 MHz, CDCl3): δ 144.1, 143.3, 139.3, 127.0, 109.3, 108.9, 73.6, 68.8, 
41.5, 35.1. 
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HRMS (EI) (m/z): calculated for C10H12O2 [M]: 164.0837; found: 164.0835.  
GC The enantiomeric ratio was measured by GC analysis on Cyclodextrin-H/OV-1701 
column: tR = 7.29 min (minor) and tR= 7.77 min (major), er (exocylic alkene isomer) = 
95:5; tR = 8.46 min (minor) and tR= 8.66 min (major), er (endocylic alkene isomer 1) = 
91:9; tR = 11.41 min (minor) and tR= 14.11 min (major), er (endocylic alkene isomer 2) = 
57:43. 
Synthesis of Both Enantiomers 
 
Aldehyde 10g (0.12 mmol) and 3-methyl-3-buten-1-ol (0.1 mmol) were added to a 
mixture of catalyst 9b (5 µmol, 5 mol%) and 50 mg 5 Å molecular sieves in anhydrous 
solvent (0.1 M). Purification was performed by chromatography on silica gel using 
pentane/diethylether = 95/5 as the eluent. The olfactory property of (R)-11g was 
measured by Givaudan (Switzerland). Using ent-9b, the corresponding enantiomer (S)-
11g could be obtained. 
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Gram-Scale Reaction 
 
At room temperature, 4 g of 5 Å molecular sieves and catalyst 9b (0.53 g/0.4 mmol) were 
added to 16 mL anhydrous cyclohexane and the mixture was stirred for 20 min. Then 
aldehyde 10g (0.82 g/9.6 mmol) and 3-methyl-3-buten-1-ol (0.68 g/8.0 mmol) were 
added subsequently. The reaction was completed after 2 days. Purification of product 11g 
was performed by column chromatography on silica gel using pentane/diethylether = 
95/5 as the eluent. 11g (1.02 g/6.6 mmol) was obtained after further distillation. The 
catalyst 9b could be recycled by column chromatography on silica gel using hexane/ethyl 
acetate = 70:30 as the eluent giving a pale solid. The solid was dissolved in CH2Cl2 (5 
mL) and stirred with 6 N aqueous HCl (5 mL) for 30 min. The organic layer was 
separated, washed with 6 N aqueous HCl (5 mL) and concentrated under reduced 
pressure to give the recycled catalyst 9b (0.51 g, 95%). 
The recycled catalyst 9b was further used for another gram scale reaction. At room 
temperature, 4 g 5 Å molecular sieves and catalyst 9b (0.10 g/0.08 mmol) were added to 
16 ml anhydrous cyclohexane and the mixture was stirred for 20 min. Then aldehyde 10g 
(0.82 g/9.6 mmol) and 3-methyl-3-buten-1-ol (0.68 g/8.0 mmol) were added 
subsequently. The reaction was completed after 7 days. Purification of product 11g was 
performed by column chromatography on silica gel using pentane/diethylether = 95/5 as 
the eluent. 11g (1.01 g/6.58 mmol) was obtained after further distillation. 
 Derivatization 
11g
OtBu
Pd/C, H2, EtOH
12a
OtBu
 
11g (100 mg, 0.65 mmol) was dissolved in dry, degassed ethanol (4 mL) at room 
temperature, then palladium (10%) on charcoal (40 mg) was added. An atmosphere of 
hydrogen was introduced and the resulting suspension was stirred at room temperature 
for 2 h. The reaction mixture was filtered over Celite, then concentrated with a rotary 
evaporator. The product 12a was obtained by flash chromatography (pentane/diethylether 
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= 95/5) as a clear oil (83 mg, 0.83 mmol, 82% yield). The cis-diastereomer was obtained 
as the major product, with a ratio of cis:trans = 8:1 which was determined by 1H NMR 
spectroscopy. The olfactory property of 12a was measured by Givaudan (Switzerland). 
The main isomer (2R, 4S)-2-(tert-butyl)-4-methyltetrahydro-2H-pyran 12a smelled dry, 
woody-spicy, agrestic, slightly chocolate (order threshold: 250 ng/L air) 
  
(2R, 4S)-2-(tert-Butyl)-4-methyltetrahydro-2H-pyran 
1H NMR (500 MHz, CD2Cl2): δ 3.94 (cis isomer, qd, J = 11.3, 1.4 Hz, 0.88H), 3.72 
(trans isomer, ddq, J = 11.6 Hz, 5.3 Hz, 0.7 Hz, 0.11H), 3.64–3.59 (trans isomer, m, 
0.11H), 3.34 (cis isomer, dt, J = 11.5 Hz, 2.2 Hz, 0.90H), 3.09 (trans isomer, dd, J = 11.9 
Hz, 2.0 Hz, 0.11H), 2.83 (cis isomer, dd, J = 11.2 Hz, 1.6 Hz, 0.87H), 2.14–2.08 (trans 
isomer, m, 0.11H), 1.82–1.74 (trans isomer, m, 0.13H), 1.60–1.46 (m, cis isomer 2.5H 
and trans isomer 0.1H), 1.32 (trans isomer, qd, J = 13.1 Hz, 2.1 Hz, 0.12H), 1.22 (trans 
isomer, pd, J = 13.4 Hz, 1.9 Hz, 0.15H), 1.15–1.06 (cis isomer, m, 0.9H; δ at 1.08 trans 
isomer, d, J = 7.3 Hz, 0.39H), 0.93 (cis isomer, d, J = 6.4 Hz, 2.7H), 0.91–0.83 (cis 
isomer, m 0.94H; δ at 0.86 cis isomer, s, 8.2 H; δ at 0.84 trans isomer, s, 1.0H) (spectra 
complicated due to the presence of two diastereo isomers). 
13C NMR (126 MHz, CD2Cl2): δ 85.8 (cis isomer), 79.7 (trans isomer), 68.7 (cis isomer), 
63.7 (trans isomer), 35.4 (cis isomer), 35.0 (cis isomer), 34.2 (cis isomer), 34.15 (trans 
isomer), 32.1 (trans isomer), 31.8 (trans isomer), 31.1 (cis isomer), 26.3 (cis isomer), 
26.2 (trans isomer), 25.7 (trans isomer), 22.8 (cis isomer), 17.8 (trans isomer). 
HRMS (EI) (m/z): calculated for C10H21O1 [M]: 157.1592; found: 157.1591.  
GC The enantiomeric ratio was measured by GC analysis on Hydrodex-gamma-TBDAc-
CD column tR (cis) = 11.08 min (major) and tR (cis) = 11.95 min (minor), er = 97.5:2.5; tR 
(trans) = 14.31 min (major) and tR (trans) = 15.21 min (minor), er = 95.5:4.5. 
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7.3.1.2 X-Ray Data  
X-Ray Structural Analysis Parameter for 11o: 
 
Crystal data and structure refinement: 
Identification code  9749 
Empirical formula  C12 H13 Br1 O1 
Color  colorless 
Formula weight  253.13  g · mol-1  
Temperature  100 K 
Wavelength  0.71073 Å 
Crystal system  MONOCLINIC 
Space group  P21,  (no. 4)  
Unit cell dimensions a = 4.3752(18) Å α= 90°. 
 b = 9.783(4) Å β= 98.083(6)°. 
 c = 12.561(5) Å γ = 90°. 
Volume 532.3(4) Å3 
Z 2 
Density (calculated) 1.579  Mg · m-3 
C6
C2
C3
C9
C8
C4
Br1
C10
C7
C1
C11
C12
O1
C5
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Absorption coefficient 3.825 mm-1 
F(000) 256 e 
Crystal size 0.275 x 0.220 x 0.040 mm3 
θ range for data collection 1.638 to 30.841°. 
Index ranges -6 ≤ h ≤ 6, -13≤ k ≤ 14, -17 ≤ l ≤ 18 
Reflections collected 10215 
Independent reflections 3321 [Rint = 0.0316] 
Reflections with I>2σ(I) 3036 
Completeness to θ = 27.500° 100.0 %  
Absorption correction Gaussian 
Max. and min. transmission 0.86 and 0.48 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3321 / 1 / 127 
Goodness-of-fit on F2 1.174 
Final R indices [I>2σ(I)] R1 = 0.0263 wR
2 = 0.0744 
R indices (all data) R1 = 0.0319 wR
2 = 0.0863 
Absolute structure parameter 0.003(7) 
Largest diff. peak and hole 0.6 and -0.6 e · Å-3 
 
Bond lengths [Å] and angles [°] 
_____________________________________________________________________  
Br(1)-C(10) 1.898(3)  O(1)-C(1) 1.420(4) 
O(1)-C(5) 1.435(5)  C(1)-C(2) 1.533(5) 
C(1)-C(7) 1.516(5)  C(2)-C(3) 1.504(6) 
C(3)-C(4) 1.496(6)  C(3)-C(6) 1.324(5) 
C(4)-C(5) 1.519(6)  C(7)-C(8) 1.390(5) 
C(7)-C(12) 1.392(5)  C(8)-C(9) 1.391(5) 
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C(9)-C(10) 1.399(6)  C(10)-C(11) 1.369(6) 
C(11)-C(12) 1.396(5)  
C(1)-O(1)-C(5) 111.3(3)  O(1)-C(1)-C(2) 110.2(3) 
O(1)-C(1)-C(7) 108.5(3)  C(7)-C(1)-C(2) 113.2(3) 
C(3)-C(2)-C(1) 110.0(3)  C(4)-C(3)-C(2) 113.4(3) 
C(6)-C(3)-C(2) 122.9(4)  C(6)-C(3)-C(4) 123.7(4) 
C(3)-C(4)-C(5) 110.3(3)  O(1)-C(5)-C(4) 110.8(3) 
C(8)-C(7)-C(1) 119.7(3)  C(8)-C(7)-C(12) 118.9(3) 
C(12)-C(7)-C(1) 121.3(3)  C(7)-C(8)-C(9) 121.6(3) 
C(8)-C(9)-C(10) 117.7(3)  C(9)-C(10)-Br(1) 118.4(3) 
C(11)-C(10)-Br(1) 119.4(3)  C(11)-C(10)-C(9) 122.2(3) 
C(10)-C(11)-C(12) 119.0(3)  C(7)-C(12)-C(11) 120.6(3)  
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7.3.2 Oxa-Pictet−Spengler Reaction  
7.3.2.1 Products 
 
A 2 mL GC vial was charged with starting material (0.1 mmol), catalyst (14.0 mg, 0.01 
equiv., 10 mol%), molecular sieves 5 Å (50 mg) and a magnetic stirring bar at room 
temperature. Then 500 µL (0.2 M) of MTBE was added followed by aldehyde (2.5 
equiv., 0.25 mmol). The vial was filled with argon and sealed. It was then introduced to 
the desired temperature for the reaction. The progress of the reaction was monitored by 
TLC. For aromatic aldehydes, the reactions were quenched with trimethylamine. 
Purification was performed by column chromatography or preparative thin layer 
chromatography on silica gel using EtOAc/hexanes as eluents. 
 
 
(S)-1-isobutylisochroman-6-ol  
Prepared according to the general procedure. 18.0 mg yellow oil, 87%. 
1H NMR (500 MHz, CDCl3): δ6.92 (d, J = 8.5 Hz, 1H), 6.65 (dd, J = 8.4, 2.7 Hz, 1H), 
6.57 (d, J = 2.7 Hz, 1H), 4.72 (d, J = 10.1 Hz, 1H), 4.09 (ddd, J = 11.5, 5.5, 1.8 Hz, 1H), 
3.75 (ddd, J = 12.9, 8.8, 4.0 Hz, 1H), 2.90 (ddd, J = 16.3, 8.8, 5.3 Hz, 1H), 2.66 (td, J = 
16.4, 4.2 Hz, 1H), 2.08–1.86 (m, 1H), 1.75 (ddd, J = 11.9, 10.2, 3.8 Hz, 1H), 1.59–1.51 
(m, 1H), 1.01 (d, J = 6.6 Hz, 3H), 0.95 (d, J = 6.6 Hz, 3H). 
13C NMR (126 MHz, CDCl3): δ153.76, 135.45, 131.61, 126.21, 115.14, 113.48, 73.96, 
62.74, 45.52, 29.37, 24.59, 24.12, 21.68.  
HRMS (ESI+) (m/z): calculated for C13H18O2.H [M+H]
+: 207.138070; found: 
207.137955. 
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HPLC The enantiomeric ratio was measured by HPLC analysis using ChiralpakOJ-3, 
heptane/ iPrOH = 85:15, flow rate = 1.0 mL/min, λ = 279 nm, tR = 5.7 min (major) and 
tR= 8.9 min (minor). er = 96.8:3.2. 
[α]D
25= –70.0 (c 0.50, CHCl3). 
 
 
(S)-1-butylisochroman-6-ol  
Prepared according to the general procedure. 17.0 mg colorless oil, 82%. 
1H NMR (500 MHz, CDCl3): δ6.95 (d, J = 6.4 Hz, 1H), 6.67 (dd, J = 8.4, 2.6 Hz, 1H), 
6.57 (d, J = 2.6 Hz, 1H), 4.68 (dd, J = 7.9, 1.7 Hz, 1H), 4.1 (td, J = 5.6, 3.7 Hz, 1H), 3.74 
(ddd, J = 12.6, 8.8, 3.7Hz, 1H), 2.93 (ddd, J = 16.3, 9.5, 4.9 Hz, 1H), 2.62 (td, J = 16.3, 
3.6 Hz, 1H), 1.94–1.82 (m, 1H), 1.81–1.70 (m, 1H), 1.51–1.30 (m, 4H), 0.91 (t, J = 7.3 
Hz, 3H). 
13C NMR (126 MHz, CDCl3): δ153.85, 135.61, 130.97, 126.22, 115.12, 113.58, 75.92, 
63.14, 35.88, 29.41, 27.50, 22.95, 14.23. 
HRMS (ESI+) (m/z): calculated for C13H18O2H [M+H]
+:207.138000; found: 207.137955. 
HPLC The enantiomeric ratio was measured by HPLC analysis using ChiralpakOD-3, 
heptane/ iPrOH = 95:5, flow rate = 0.5mL/min,λ = 279 nm,tR = 12.7 min (major) and 
tR= 14.4 min (minor).er = 97.3:2.7. 
[α]D
25= –81.6 (c 0.50, CHCl3). 
 
 
(S)-1-phenethylisochroman-6-ol  
Prepared according to the general procedure. 20.5 mg yellow oil, 80.6%. 
1H NMR (500 MHz, CDCl3): δ. 7.28 (t, J = 7.7 Hz, 2H), 7.23 (d, J = 7.5 Hz, 2H), 7.18 (t, 
J = 7.4 Hz, 1H), 6.93 (d, J = 8.4 Hz, 1H), 6.65 (dd, J = 8.4, 2.6 Hz, 1H), 6.59 (d, J = 2.6 
Hz, 1H), 4.78–4.63 (m, 1H), 4.23–4.09 (m, 1H), 3.85–3.71 (m, 1H), 2.97 (ddd, J = 16.4, 
9.5, 5.4 Hz, 1H), 2.77 (t, J = 8.9 Hz, 2H), 2.65 (td, J = 16.4, 3.6 Hz, 1H), 2.63–2.13 (m, 
1H), 2.13–1.97 (m, 1H), 1.62 (br s, 1H). 
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 13C NMR (126 MHz, CDCl3): δ 153.88, 142.54, 135.74, 123.62, 128.66, 128.48, 126.13, 
125.86, 11.20, 113.63, 75.11, 63.23, 37.90, 31.50, 29.41.  
HRMS (ESI+) (m/z): calculated for C17H18O2Na [M+Na]
+: 277.120080; found: 
277.119899. 
HPLC The enantiomeric ratio was measured by HPLC analysis using ChiralpakAD-3, 
heptane/ iPrOH = 90:10, flow rate = 1.0 mL/min, λ = 279 nm, tR = 7.6 min (major) and 
tR= 8.7 min (minor). er = 97.4:2.6.  
[α]D
25 = –27.6 (c 0.55, CHCl3). 
 
 
(S)-1-phenylisochroman-6-ol 
Prepared according to the general procedure. 20.6 mg white solid, 91%.  
1H NMR (500 MHz, CD2Cl2): δ 7.42–7.22 (m,5H), 6.61 (d, J = 2.5 Hz, 1H), 6.58 (d, J = 
8.4 Hz, 1H), 6.55 (dd, J = 8.4, 2.5 Hz, 1H), 5.65 (s, 1H), 5.12 (br s, 1H), 4.13 (ddd, J = 
11.3, 5.6, 3.7 Hz, 1H), 3.87 (ddd, J = 13.6, 9.6, 4.0 Hz, 1H), 3.06 (ddd, J = 16.4, 9.5, 5.5 
Hz, 1H), 2.73 (dd, J = 16.5,3.8 Hz, 1H). 
13C NMR (126 MHz, CD2Cl2): δ154.82, 143.26, 136.13, 123.32, 129, 30, 128.83, 128.63, 
128.50, 79.87, 64.15, 29.48. 
HRMS (ESI–) (m/z): calculated for C15H13O2 [M–H]
–: 225.092080; found: 225.092105. 
HPLC The enantiomeric ratio was measured by HPLC analysis using ChiralpakOD-3, 
heptane/ iPrOH = 90:10, flow rate = 1.0 mL/min, λ = 279 nm, tR = 7.1 min (major) and 
tR= 12.7 min (minor). er = 96.7:3.3. 
 [α]D
25 = –14.8 (c 0.50, CHCl3). 
 
 
(S)-1-(3-bromophenyl)isochroman-6-ol  
Prepared according to the general procedure. 22.8 mg yellow solid, 75%.  
7 EXPERIMENTAL PART 
 
152 
   
1H NMR (500 MHz, CDCl3): δ 7.49–7.41 (m, 2H), 7.26–7.17 (m, 2H), 6.65–6.52 (m, 
3H), 5.64 (s, 1H), 4.99 (br s, 1H), 4.15 (ddd, J = 11.4, 5.6, 3.8 Hz, 1H), 3.89 (ddd, J = 
13.5, 9.6, 4.1 Hz, 1H), 3.07 (ddd, J = 16.5, 9.5, 5.7 Hz, 1H), 2.74 (dd, J = 16.4, 3.9 Hz, 
1H).  
13C NMR (126 MHz, CDCl3): δ154.41, 144.67, 135.49, 131.92, 131.37, 130.11, 128.90, 
128.27, 12.61, 122.69, 115.07, 113.73, 78.86, 63.84, 28.90. 
HRMS (ESI+) (m/z): calculated for C15H13Br1O2.Na [M+Na]
+: 326.999270; found: 
326.999124. 
HPLC The enantiomeric ratio was measured by HPLC analysis using Chiralpak AS-3, 
heptane/ iPrOH = 90:10, flow rate = 1.0 mL/min, λ = 279 nm, tR = 5.2 min (major) and 
tR= 5.9 min (minor). er = 99.2:0.8. 
 [α]D
25 = –5.6 (c 0.50, CHCl3). 
 
 
(S)-1-(3-methoxyphenyl)isochroman-6-ol 
Prepared according to the general procedure. 23.8 mg yellow oil, 93%. 
1H NMR (500 MHz, CDCl3): δ 7.34–7.17 (m, 1H), 6.90 (d, J = 7.6 Hz, 1H), 6.88–6.80 
(m, 2H), 6.63 (d, J = 8.4 Hz, 1H), 6.59 (d, J = 2.6 Hz, 1H), 6.54 (dd, J = 8.4, 2.6 Hz, 1H), 
5.65 (s, 1H), 5.08 (br s, 1H), 4.16 (ddd, J = 11.4, 5.5, 3.9 Hz, 1H), 3.90 (ddd, J = 13.6, 
9.5, 4.1 Hz, 1H), 3.78 (s, 3H), 3.06 (ddd, J = 16.4, 9.4, 5.6 Hz), 2.74 (dd, J = 16.4, 4.0, 
1H).  
13C NMR (126 MHz, CDCl3): δ 159.76, 154.31, 143.87, 135.41, 129.52, 129.48, 128.32, 
121.41, 114.91, 114.38, 113.84, 113.57, 79.48, 63.78, 55.37, 29.00.  
HRMS (ESI+) (m/z): calculated for C16H16O3Na [M+Na]
+: 279.099350; found: 
279.099164. 
HPLC The enantiomeric ratio was measured by HPLC analysis using Chiralpak AD-3, 
heptane/ iPrOH = 94:6, flow rate = 1.0 mL/min, λ = 279 nm, tR = 19.4 min (minor) and 
tR= 20.6 min (major). er = 98.1:1.9.  
[α]D
25 = –14.4 (c 0.50, CHCl3). 
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(S)-1-(4-bromophenyl)isochroman-6-ol 
Prepared according to the general procedure. 26.4 mg yellow solid, 87%.  
1H NMR (500 MHz, CDCl3): δ 7.46 (d, J = 8.4 Hz, 2H), 7.18 (d, J = 8.4 Hz, 2H), 6.89–
6.31 (m, 3H), 5.64 (s, 1H), 5.13 (br s, 1H), 4.14 (ddd, J = 11.4, 5.4, 3.9 Hz, 1H), 3.90 
(ddd, J = 13.5, 9.6, 4.0 Hz, 1H), 3.06 (ddd, J = 16.5, 9.6, 5.5 Hz, 1H), 2.73 (td, J = 16.5, 
4.0 Hz, 1H). 
13C NMR (126 MHz, CDCl3): δ 154.42, 141.36, 135.45, 131.69, 130.66, 129.05, 128.23, 
122.29, 115.02, 113.67, 78.88, 63.82, 28.95.  
HRMS (ESI+) m/z calculated for C15H13Br1O2Na [M+Na]
+: 326.999310; found: 
326.999124. 
HPLC The enantiomeric ratio was measured by HPLC analysis using Chiralpak AD-3, 
heptane/ iPrOH = 90:10, flow rate = 1.0 mL/min, λ = 279 nm, tR = 4.9 min (major) and 
tR= 5.3 min (minor). er = 98.2:1.8.  
[α]D
25 = +4.0 (c 0.50, CHCl3). 
 
 
(S)-1-(napthalen-1yl)isochroman-6-ol 
Prepared according to the general procedure. 20.1 mg yellow solid, 73%.  
1H NMR (500 MHz, CDCl3): δ 7.90–7.79 (m, 3H), 7.76 (s, 1H), 7.55–7.44 (m, 2H), 7.40 
(dd, J = 8.6, 1.7 Hz, 1H), 6.64 (d, J = 2.5 Hz, 1H), 6.62 (d, J = 3.50 Hz, 1H), 6.53 (dd, J 
= 8.50, 2.6 Hz, 1H), 5.84 (s, 1H), 4.20 (ddd, J = 11.4, 5.6, 3.8 Hz, 1H), 3.95 (ddd, J = 
13.6, 9.6, 4.40 Hz, 1H), 3.12 (ddd, J = 16.5, 9.5, 5.5 Hz, 1H), 2.76 (dd, J = 16.5, 3.8, 
1H).  
13C NMR (126 MHz, CDCl3): δ154.29, 139.72, 135.59, 133.37, 133.20, 129.67, 128.56, 
128.50, 128.21, 128.16, 127.82, 126.53, 126.23, 114.98, 113.60, 79.74, 63.89, 29.07. 
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HRMS (ESI+) m/z calculated for C19H16O2Na [M+Na]
+: 299.104430; found: 
299.104249. 
HPLC The enantiomeric ratio was measured by HPLC analysis using Chiralpak AD-3, 
heptane/ iPrOH= 94:6, flow rate = 1.0 mL/min, λ = 279 nm, tR = 12.3 min (major) and 
tR= 13.5 min (minor). er = 95.4:4.6.  
[α]D
25 = +25.4 (c 0.27, CHCl3). 
 
 
(S)-1-isobutyl-7-methoxyisochroman-6-ol  
Prepared according to the general procedure. 21.7 mg white solid, 92%.  
1H NMR (500 MHz, CD2Cl2): δ 6.61 (s, 1H), 6.53 (s, 1H), 5.53 (br s, 1H), 4.67 (dd, J = 
10.4, 2.0 Hz, 1 H), 4.07–3.99 (m, 1H), 3.84 (s, 3H), 3.69 (ddd, J = 12.8, 8.7, 4.1 Hz, 1H), 
2.79 (tddd, J = 16.2, 8.7, 5.3, 1.0 Hz, 1H), 2.58 (dd, J = 16.1, 4.4Hz, 1H), 2.01–1.87 (m, 
1H), 1.71 (ddd, J = 14.4, 10.4, 3.9 Hz, 1H), 1.54 (ddd, J = 14.2, 9.9, 2.9 Hz, 1H), 1.01 (d, 
J = 6.7 Hz, 3H), 0.95 (d, J = 6.7 Hz, 3H). 
13C NMR (126 MHz, CDCl3): δ145.64, 144.47, 131.27, 127.16, 124.68, 107.84, 74.14, 
63.12, 56.63, 45.83, 28.99, 25.05, 24.30, 21.80.  
HRMS (ESI–) m/z calculated for C14H19O3 [M–H]
–: 235.133940; found: 235.133970. 
HPLC The enantiomeric ratio was measured by HPLC analysis using OD-3, heptane/ 
iPrOH = 95:5, flow rate = 1 mL/min,λ = 279 nm tR = 5.8 min (major) and tR= 7.0 min 
(minor). er = 99.6:0.4. 
[α]D
25 = –116.4 (c 0.50, CHCl3). 
 
 
(S)-7-methoxy-1-phenylisochroman-6-ol  
Prepared according to the general procedure. 25.0 mg yellow solid, 98%.  
1H NMR (500 MHz, CDCl3): δ 7.43–7.28 (m, 5H), 6.73 (s, 1H), 6.21 (s, 1H), 5.67 (s, 
1H), 5.56 (br s, 1H), 4.13 (ddd, J = 11.3, 5.3, 4.3 Hz, 1H), 3.88 (ddd, J = 13.3, 9.1, 4.1 
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Hz, 1H), 3.36 (s, 3H), 3.01 (ddd, J = 16.20, 9.1, 5.4 Hz, 1H), 2.71 (dd, J = 16.1, 4.2 Hz, 
1H). 
 13C NMR (126 MHz, CDCl3): δ 159.76, 154.31, 143.87, 135.41, 129.52, 129.48, 128.32, 
121.41, 114.91, 114.38, 113.84, 113.57, 79.48, 63.78, 55.37, 29.00. 
HRMS (ESI+) (m/z): calculated for C16H16O3Na [M+Na]
+: 279.099230; found: 
279.099164. 
HPLC The enantiomeric ratio was measured by HPLC analysis using ChiralpakAD-3, 
heptane/ iPrOH = 95:5, flow rate = 1.0 mL/min, λ = 279 nm, tR = 11.8 min (major) and 
tR= 16.2 min (minor). er = 98.8:1.2. 
 [α]D
25 = –60.3 (c 0.60, CHCl3). 
 
7.3.2.2 Catalysts synthesis 
 
(1S,3'S)-6,6'-Dinitro-3,3'-bis(2,4,6-triethylphenyl)-[1,1'-binaphthalene]-2,2'-diol  
A solution of HNO3 (94 µL, 2 mmol) in CHCl3 (1.3 mL) was added dropwise to the 
solution of corresponding BINOL (570mg, 0.94 mmol) in CHCl3 (5.6 ml) at –40 °C 
under argon. After 20 min at 0 °C, the solution was warmed up to room temperature for 
further 20 min. The reaction was cooled to 0 °C, and then water (45 mL) was carefully 
added, and the mixture was extracted with CH2Cl2 (45×3 mL). The organic layer was 
collected, dried (MgSO4), filtered, and the solvent was removed under reduced pressure. 
The residue was purified by column chromatography on silica gel using 50% 
CH2Cl2/hexane as the eluent yielding the title compound as a yellow solid (504mg, 77%).  
1H NMR (500 MHz, CD2Cl2): δ 8.87 (d, J = 1.5 Hz, 2H), 8.09 (dd, J = 9.2 Hz, 1.7 Hz, 
2H), 8.02 (br s, 2H), 7.34 (d, J = 9.2 Hz, 2H), 7.14 (d, J = 7.8 Hz, 4H), 5.43 (br s, 2H), 
2.71 (q, J = 7.5 Hz, 4H), 2.54–2,31 (m, 8H), 1.30 (t, J = 7.5 Hz, 6H), 1.11 (t, J = 7.4 Hz, 
6H), 1.02 (t, J = 7.4 Hz, 6H).  
13C NMR (126 MHz, CD2Cl2): δ 154.1, 146.2, 144.4, 144.1, 144.0, 136.9, 133.3, 131.8, 
129.7, 127.9, 126.8, 126.7, 126.0, 125.6, 120.5, 114.5, 29.2, 27.4, 27.3, 15.7, 15.6. 
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HRMS (ESI–) (m/z): calculated for C44H43N2O6 [M–H]
–: 695.312662; found: 
695.312750. 
O
O
O2N
O2N
P Cl
Et Et
Et
Et
Et O
Et17a  
(2S,4R,11bS)-4-chloro-9,14-dinitro-2,6-bis(2,4,6-triethylphenyl)dinaphtho[2,1-d:1',2'-
f][1,3,2]dioxaphosph-epine 4-oxide  
To a solution of 15a (350 mg, 0.50 mmol) in pyridine (1.6 mL) under argon was added 
POCl3 (466 µL, 5.0 mmol) at room temperature. The mixture was stirred at room 
temperature for 5 h and then concentrated to dryness under vacuum. The residue was 
passed through a short silica gel column using 40% CH2Cl2/hexane as the eluent yielding 
the title compound as a colorless solid (350 mg, 90%). 
 1H NMR (600 MHz, CDCl3): δ 8.94 (dd, J = 6.1 Hz, 2.3 Hz, 2H), 8.20 (d, J = 17.4 Hz, 
2H), 8.15 (dq, J = 9.4 Hz, 0.9 Hz, 2H), 7.36 (dd, J = 9.3 Hz, 6.8 Hz, 2H), 7.13 (d, J = 
28.4 Hz, 2H), 7.02 (d, J = 7.9 Hz, 2H), 2.74–2.69(m, 4H), 2.56–2.24(m, 8H), 1.36–1.31 
(m, 6H), 1.27 (t, J = 7.5 Hz, 3H), 1.21 (t, J = 7.6 Hz, 3H), 7.36 (dt, J = 7.6 Hz, 4.0 Hz, 
6H).  
13C NMR (151 MHz, CDCl3): δ 148.0, 147.9, 147.8, 145.9, 145.2, 144.9, 143.0, 142.5, 
142.0, 141.7, 135.6, 135.5, 135.3, 135.1, 134.7, 134.6,  134.4, 134.3, 130.7, 130.4, 130.0, 
129.8, 128.3, 128.2, 125.64, 125.62, 125.3, 125.1, 125.0, 124.7, 122.0, 121.9, 121.84, 
121.82, 120.7, 120.6, 28.81, 28.80, 27.5, 27.0, 26.8, 16.1, 15.3, 15.2, 15.18, 14.7, 14.5. 
31PNMR (202 MHz, CDCl3): δ 6.52 (s).  
HRMS (ESI+) (m/z): calculated for C44H42N2O7P1Na1 [M+Na]
+: 799.231039; found: 
799.230700. 
 
  
7 EXPERIMENTAL PART 
 
157 
   
O
O
P
OH
N
O
O
P
O
Et
Et
Et
Et
Et
Et
Et
Et
Et
Et
Et
Et
O2N
O2N
18a  
4-((4-hydroxy-9,14-dinitro-2,6-bis(2,4,6-triethylphenyl)-4l5-dinaphtho[2,1-d:1',2'-
][1,3,2]dioxaphosphepin-4-ylidene)amino)-2,6-bis(2,4,6-triethylphenyl)dinaphtho[2,1-
d:1',2'-f][1,3,2]dioxaphosphepine 4-oxide  
Sodium hydride (60% dispersion in mineral oil, 48 mg, 1.2 mmol) was added to a 
solution of 16a (250 mg, 0.32 mmol) and 17a (203 mg, 0.30 mmol) in DMF (3 ml) under 
argon at room temperature. After 2.5 h at room temperature, 10% aqueous HCl solution 
(1 mL) was added. The organic layer was separated and the solvent was removed under 
reduced pressure. The residue was purified by column chromatography on silica gel using 
5–15% ethyl acetate/hexane as the eluents giving a colorless solid. The solid was 
dissolved in CH2Cl2 (5 mL) and stirred with 6N aqueous HCl (5 mL) for 1 h. The organic 
layer was separated, washed with 6N aqueous HCl (5 mL) and concentrated under 
reduced pressure to give the title compound as a pale yellow solid (206 mg, 48%).  
1H NMR (500 MHz, CD2Cl2): δ 8.87 (d, J = 2.3 Hz, 1H), 8.84 (d, J = 2.3 Hz, 1H), 8.15 
(dd, J = 9.3 Hz, 2.4 Hz, 1H), 8.05 (br s, 1H), 7.97 (dd, J = 9.4 Hz, 2.4 Hz, 1H), 7.90 (t, J 
= 8.4 Hz, 2H), 7.84 (d, J = 14.5 Hz, 2H), 7.61 (br s, 1H), 7.56–7.53(m, 1H), 7.48–
7.42(m, 4H), 7.25–7.21(m, 1H), 7.06 (t, J = 9.8 Hz, 2H), 6.98 (d, J = 4.9 Hz, 2H), 6.87–
6.86(m, 4H), 6.44 (br s, 1H), 6.33 (br s, 1H), 2.63–2.49(m, 8H), 2.29–2.09(m, 10H), 
2.05–1.90(m, 3H), 1.78–1.71 (m, 1H), 1.22–1.15(m, 12H), 1.09 (q, J = 7.7 Hz, 6H), 
0.98–0.92(m, 7H), 0.86–0.79(m, 7H), 0.08–0.01(m, 6H). 
13C NMR (126 MHz, CD2Cl2): δ150.4, 150.3, 149.5, 149.4, 146.1, 146.0, 145.8, 145.7, 
145.67, 145.59, 145.0, 144.7, 144.6, 144.3, 144.1, 144.0, 143.71, 143.70, 143.4, 143.0, 
142.9, 142.3, 136.3, 136.27, 135.8, 135.77, 135.7, 135.3, 135.2, 134.5, 133.3, 133.28, 
133.0, 132.9, 132.7, 132.6, 132.0, 131.9, 131.88, 131.7, 130.6, 130.0, 128.9, 128.3, 
127.8, 127.3, 127.0, 126.9, 126.4, 126.2, 126.0, 125.8, 125.7, 125.6, 125.4, 125.2, 125.1, 
125.08, 124.9, 122.8, 122.7, 122.5, 122.2, 120.5, 120.3, 30.2, 29.2, 29.19, 29.18, 29.1, 
7 EXPERIMENTAL PART 
 
158 
   
27.5, 27.45, 27.4, 27.22, 27.2, 27.1, 24.1, 17.8, 17.77, 16.3, 16.0, 15.9, 15.8, 15.6, 15.5, 
15.4, 15.3, 15.1. 
31PNMR (202 MHz, CD2Cl2): δ 5.90 (d, J = 86.0, 1P), 3.54 (d, J = 85.5, 1P). 
HRMS (ESI–) (m/z): calculated for C88H86N3O10P2 [M–H]
–: 1406.579400; 
found:1406.579070. 
 
(S)-3,3'-bis(2-cyclohexyl-5-methylphenyl)-6,6'-dinitro-[1,1'-binaphthalene]-2,2'-diol  
A solution of HNO3 (63 µL, 1.4 mmol) in CHCl3 (1 mL) was added dropwise to a 
solution of corresponding BINOL (441mg, 0.70 mmol) in CHCl3 (4.2 mL) at –40 °C 
under argon. Then the solution was warmed up to room temperature for further 30 min. 
The reaction was cooled to 0 °C, and water (35 mL) was carefully added, and the mixture 
was extracted with CH2Cl2 (3×35 mL). The organic layer was collected, dried over 
MgSO4, filtered, and the solvent was removed under reduced pressure. The residue was 
purified by column chromatography on silica gel using 50% CH2Cl2/hexane as the eluent 
yielding the title compound as a yellow solid (434 mg, 86%). 
1H NMR (300 MHz, CDCl3, major): δ 8.87–8.85 (m, 2H), 8.12–8.00 (m, 4H), 7.40–7.28 
(m, 6H), 7.22 (br s, 1H), 7.16–7.15 (m, 1H), 5.37–5.29 (m, 2H), 2.50–2.37 (m, 8H), 
1.82–1.54 (m, 11H), 1.45–0.87 (m, 9H). 
13C NMR (75 MHz, CDCl3, major): δ 153.4, 153.3, 153.2, 144.43, 144.4, 144.36, 144.3, 
144.29, 144.2, 144.1, 136.6, 136.5, 136.45, 136.4, 136.36, 133.2, 133.0, 132.97, 132.93, 
132.89, 132.6, 132.3, 131.2, 130.8, 130.7, 127.7, 127.5, 127.47, 127.2, 127.1, 127.07, 
125.9, 125.6, 125.4, 120.6, 120.5, 114.1, 114.06, 113.9, 41.4, 41.3, 41.04, 41.0, 35.3, 
35.1, 35.0, 34.96, 34.0, 27.3, 27.0, 26.9, 26.1, 21.1, 21.0. 
HRMS (ESI–) (m/z): calculated for C46H43 N2O6 [M–H]
−: 719.3126; found: 719.3127.  
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(4R,11bS)-4-chloro-2,6-bis(2-cyclohexyl-5-methylphenyl)-9,14-dinitrodinaphtho[2,1-
d:1',2'-f][1,3,2]dioxa-phosphepine 4-oxide  
POCl3 (96 µL, 0.77 mmol) was added to a solution of 15b (184 mg, 0.256 mmol) in 
pyridine (0.8 mL) under argon at room temperature. The mixture was stirred at room 
temperature for 5 h and then concentrated to dryness under vacuum. The residue was 
filtered over a short silica gel column using 40% CH2Cl2/hexane as the eluent yielding 
the title compound as a pale yellow solid (170 mg, 83%). 
1H NMR (300 MHz, CDCl3): δ 9.05–8.91 (m, 2H), 8.25–8.12 (m, 4H), 7.48–7.27 (m, 
6.5H), 7.22–7.05 (m, 1.4H), 2.39–2.19 (m, 8H), 2.01–1.56 (m, 9H), 1.51–0.77 (m, 11H) 
(spectra complicated due to presence of rotamers).  
13C NMR (126 MHz, CDCl3): δ 147.54, 147.5, 147.44, 147,41, 147.3, 146.2, 146.1, 
146.03, 146.01, 143.9, 143.87, 143.5, 143.4, 142.8, 142.7, 136.9, 136.86, 136.7, 136.67, 
136.6, 135.5, 135.3, 135.1, 135.0, 135.0, 134.96, 134.8, 134.7, 134.5, 134.4, 134.3, 
134.2, 134.1, 133.2, 133.0, 132.9, 132.5, 132.4, 132.0, 131.9, 131.7, 131.6, 131.5, 131.4, 
130.93, 130.90, 130.86, 130.4, 130.3, 130.2, 130.1, 130.0, 128.5, 128.4, 128.2, 128.0, 
127.8, 127.7, 127.6, 127.5, 126.3, 125.9, 125.4, 125.3, 125.2, 125.1, 125.0, 122.8, 122.5, 
121.7, 121.5, 121.47, 121.4, 121.36, 120.92, 120,87, 120.67, 120.6, 41.7, 41.6, 41.5, 
41.47, 40.9, 40.8, 40.7, 37.7, 37.6, 36.7, 36.6, 35.5, 35.46, 35.0, 34.9, 34.0, 33.9, 33.5, 
33.3, 33.27, 33.24, 32.6, 27.3, 27.2, 27.08, 27.06, 26.9, 26.7, 26.68, 26.6, 26.5, 26.1, 
26.07, 25.95, 25.93, 24.3, 20.89, 20.86, 19.7 (spectra complicated due to presence of 
rotamers and unassigned C−P-coupling). 
31P NMR (202 MHz, CDCl3): δ 6.75, 6.58 (major), 6.38, 6.23 (spectra complicated due 
to the presence of rotamers). 
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HRMS (ESI+) (m/z): calculated for C46H42N2O7P1Na1 [M+Na]
+: 823.2310; found: 
823.2308.  
 
4-((2,6-bis(2-cyclohexyl-5-methylphenyl)-4-hydroxy-9,14-dinitro-4l5-dinaphtho[2,1-
d:1',2'-f][1,3,2]dioxaphosphepin-4-ylidene)amino)-2,6-bis(2-cyclohexyl-5-
methylphenyl)dinaphtho[2,1-d:1',2'-f][1,3,2]dioxaphosphepine 4-oxide  
Sodium hydride (60% dispersion of in mineral oil, 12 mg, 0.32 mmol) was added to a 
solution of 16b (70 mg, 0.088 mmol) and 17b (55 mg, 0.08 mmol) in DMF (0.8 mL) 
under argon at room temperature. After 2.5 h at room temperature, 10% aqueous HCl 
solution (0.1 mL) was added. The solvent was removed under reduced pressure. The 
residue was purified by column chromatography on silica gel using 10−20% ethyl 
acetate/hexane as the eluents giving a pale yellow solid. The solid was dissolved in 
CH2Cl2 (2 mL) and stirred with 6N aqueous HCl (2 mL) for 30 min. The organic layer 
was separated, washed with 6N aqueous HCl (2 mL) and concentrated under reduced 
pressure to give the title compound as a pale yellow solid (60 mg, 52%). 
 1H NMR (500 MHz, CD2Cl2): δ 9.01–8.83(m, 2H), 8.26–5.69(m, 28H), 2.91–2.38(m, 
2H), 2.34–2.21(m, 3H), 2.18–1.68(m, 17H), 1.63–0.33(m, 34H) (spectra complicated due 
to presence of rotamers). 
13C NMR (126 MHz, CD2Cl2): δ 148.8, 148.6, 147.3, 146.2, 146.18, 146.0, 145.7, 144.4, 
144.1, 144.0, 143.9, 143.7, 143.6, 143.1, 143.0, 137.1, 136.7, 136.5, 136.1, 135.8, 135.6, 
135.4, 135.3, 135.1, 135.0, 134.8, 134.7, 134.66, 134.5, 134.4, 134.1, 134.09, 133.7, 
133.3, 133.2, 133.1, 132.9, 132.7, 132.4, 132.3, 132.2, 132.0, 131.9, 131.8, 131.7, 131.6, 
131.5, 131.4, 131.2, 131.1, 130.8, 130.4, 130.3, 130.1, 130.0, 129.9, 129.7, 129.5, 129.2, 
129.1, 128.8, 128.7, 128.6, 128.5, 128.3, 128.2, 128.0, 127.9, 127.8, 127.5, 127.4, 127.3, 
127.2, 127.1, 126.9, 125.7, 125.5, 125.4, 125.3, 125.0, 123.7, 123.4, 123.3, 122.4, 122.2, 
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121.8, 121.7, 120.5, 120.3, 120.1, 119.9, 119.8, 41.7, 41.6, 41.5, 41.3, 41.2, 41.1, 40.7, 
40.4, 40.3, 40.2, 40.1, 39.9, 39.2, 37.8, 37.4, 36.9, 36.5, 36.3, 35.9, 35.8, 35.6, 35.2, 34.9, 
34.5, 34.1, 34.0, 33.8, 33.3, 33.1, 32.5, 32.3, 31.4, 30.5, 29.9, 29.85, 29.7, 27.6, 27.5, 
27.4, 27.37, 27.2, 27.15, 27.1, 27.0, 26.9, 26.5, 26.4, 26.2, 23.1, 21.4, 21.2, 21.14, 21.1, 
21.0, 20.7, 20.65, 20.5, 20.3 (spectra complicated due to presence of rotamers and 
unassigned C−P-coupling). 
31P NMR (202 MHz, CD2Cl2): δ 3.84–0.58 (m, 1P), −1.17–−2.30 (m, 1P). 
HRMS (ESI−) m/z calculated for C92H86N3O10P2 [M−H]
−: 1454.5794; found: 1454.5790.  
 
(S)-3,3'-Bis(2-isopropyl-5-methylphenyl)-6,6'-dinitro-[1,1'-binaphthalene]-2,2'-diol  
A solution of HNO3 (90 µL, 2.0 mmol) in CHCl3 (1.35 mL) was added dropwise to a 
solution of corresponding BINOL (525 mg, 0.953 mmol) in CHCl3 (6.6 mL) at –40 °C 
under argon. Then the solution was warmed up to room temperature for further 30 min. 
The reaction was cooled to 0 °C, water (45 mL) was carefully added, and the mixture was 
extracted with CH2Cl2 (45×3 mL). The organic layer was collected, dried over MgSO4, 
filtered, and the solvent was removed under reduced pressure. The residue was purified 
by column chromatography on silica gel using 50% CH2Cl2/hexane as the eluent yielding 
the title compound as a yellow solid (340 mg, 56%). 
1H NMR (500 MHz, CDCl3): δ 8.86–8.85 (m, 2H), 8.10–8.07 (m, 4H), 7.34–7.27 (m, 
8H), 7.22 (br s, 1H), 5.55–5.54 (m, 2H), 2.98–2.97 (m, 2H), 2.26–2.18 (m, 6H), 1.31–
01.30 (m, 12H) (spectra complicated due to presence of rotamers). 
13C NMR (126 MHz, CDCl3): δ 153.2, 151.7, 147.6, 144.2, 136.4, 134.4, 134.3, 133.3, 
132.7, 130.9, 128.5, 127.6, 126.0, 125.6, 125.4, 120.6, 113.9, 33.8, 24.1, 19.5 (spectra 
complicated due to presence of rotamers). 
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HRMS (ESI+) (m/z): calculated for C40H36 N2O6Na1 [M+Na]
+: 663.2465; found: 
663.2467.  
 
(4R,11bS)-4-chloro-2,6-bis(2-isopropyl-5-methylphenyl)-9,14-dinitrodinaphtho[2,1-
d:1',2'-f][1,3,2]dioxaphosphepine 4-oxide  
POCl3 (92 µL, 0.99 mmol) was added to a solution of 15c (210 mg, 0.328 mmol) in 
pyridine (1.0 mL) under argon at room temperature. The mixture was stirred at room 
temperature for 5 h and then concentrated to dryness under vacuum. The residue was 
passed through a short silica gel column using 40% CH2Cl2/hexane as the eluent yielding 
the title compound as a pale yellow solid (193 mg, 82%). 
1H NMR (300 MHz, CD2Cl2): δ 9.00–8.99 (m, 2H), 8.30–8.21 (m, 2H), 8.16–8.12 (m, 
2H), 7.52–7.28 (m, 6H), 7.22–7.10 (m, 2H), 3.69–2.68 (m, 2H), 2.39–2.32 (m, 6H), 1.49–
0.99 (m, 12H) (spectra complicated due to presence of rotamers). 
13C NMR (126 MHz, CD2Cl2): δ 147.7, 147.65, 146.4, 145.0, 144.5, 137.1, 136.9, 135.7, 
135.5, 135.4, 135.0, 134.8, 133.6, 133.5, 132.3, 132.27, 132.1, 132.0, 131.5, 131.3, 
130.7, 130.5, 130.4, 129.0, 128.8, 127.1, 126.8, 125.8, 125.7, 125.6, 125.5, 125.4, 122.1, 
121.9, 120.9, 120.88, 31.1, 30.9, 30.4, 30.0, 27.0, 25.9, 25.4, 25.1, 23.8, 23.5, 23.3, 22.9, 
21.0, 20.96 (spectra complicated due to presence of rotamers and unassigned C−P-
coupling). 
31P NMR (202 MHz, CD2Cl2): δ 6.79 (major), 6.62, 6.42(spectra complicated due to the 
presence of rotamers). 
HRMS (ESI+) (m/z): calculated for C40H34 N2O7Cl1P1Na1 [M+Na]
+: 743.1684; found: 
743.1687.  
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4-((4-hydroxy-2,6-bis(2-isopropyl-5-methylphenyl)-9,14-dinitro-4l5-dinaphtho[2,1-
d:1',2'-f][1,3,2]dioxaphosphepin-4-ylidene)amino)-2,6-bis(2-isopropyl-5-
methylphenyl)dinaphtho[2,1-d:1',2'-f][1,3,2]dioxaphosphepine 4-oxide  
Sodium hydride (60% dispersion of in mineral oil, 24 mg, 0.60 mmol) was added to a 
solution of 16c (120.0 mg, 0.166 mmol) and 17c (92.5 mg, 0.151 mmol) in DMF (1.5 
mL) under argon at room temperature. After 3 h at room temperature, 10% aqueous HCl 
solution (0.1 mL) was added. The solvent was removed under reduced pressure. The 
residue was purified by column chromatography on silica gel using 10–20% ethyl 
acetate/hexane as the eluents giving a pale yellow solid. The solid was dissolved in 
CH2Cl2 (2 mL) and stirred with 6N aqueous HCl (2 mL) for 30 min. The organic layer 
was separated, washed with 6N aqueous HCl (2 mL) and concentrated under reduced 
pressure to give the title compound as a pale yellow solid (62 mg, 32%).  
1H NMR (500 MHz, CD2Cl2, major): δ 9.08–8.23 (m, 2H), 8.45–5.74 (m, 28H), 2.91–
2.02 (m, 10H), 1.93–1.26 (m, 6H), 1.20–0.15 (m, 24H). 
13C NMR (126 MHz, CD2Cl2, major): δ 145.7, 144.5, 135.5, 135.3, 135.1, 135.0, 134.8, 
134.7, 134.1, 133.0, 132.8, 132.7, 132.6, 132.2, 131.5, 131.0, 130.6, 130.2, 130.1, 130.0, 
129.6, 129.3, 129.1, 129.0, 128.9, 128.8, 128.7, 128.2, 127.4, 127.3, 127.2, 127.1, 
127.07, 127.0, 126.8, 126.79, 126.64, 126.6, 126.4, 126.3, 126.26, 125.8, 125.7, 125.5, 
125.44, 125.42, 125.4, 125.3, 125.1, 120.3, 30.8, 30.78, 30.7, 30.6, 30.5, 30.2, 30.0, 25.4, 
25.3, 25.1, 25.0, 24.9, 24.89, 24.83, 24.8, 24.67, 24.65, 24.2, 24.0, 23.7, 23.6, 23.56, 
23.2, 23.16, 23.1, 23.0, 22.8, 21.2, 21.1, 21.06, 21.04, 21.0, 20.8, 20.7, 20.6, 20.54, 
20.53, 1.18. 
31P NMR (202 MHz, CD2Cl2): δ 12.30–9.45 (m, 2P). 
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HRMS (ESI−) (m/z): calculated for C80H70N3O10P2  [M−H]
−: 1294.4531; found: 
1294.4550.  
7.3.2.2 X-Ray Data  
 
A 2 mL GC vial was charged with starting material 14g (0.08 mmol), followed by 
triethylamine (1.2 equiv, 0.10 mmol), 4-bromobenzoylchloride (1.2 equiv, 0.10 mmol) 
and a magnetic stirring bar at room temperature. The vial was filled with argon and 
sealed. It was then stirred at room temperature for half an hour. The progress of the 
reaction was monitored by TLC. Purification of 19a was performed by column 
chromatography or preparative thin layer chromatography on silica gel using 
EtOAc/hexanes as the eluents. 
(S)-1-isobutyl-7-methoxyisochroman-6-yl 4-bromobenzoate 19a 
1H NMR (500 MHz, CD2Cl2): δ 8.04 (dd, J = 8.7, 2.0 Hz, 2H), 7.68 (dd, J = 8.8, 2.0 Hz, 
2H), 6.88 (s, 1H), 6.69 (s, 1H), 4.76 (dd, J = 10.4, 2.0 Hz, 1H), 4.13–4.03 (m, 1H), 3.77 
(s, 3H), 3.76–3.69 (m, 1H), 2.93–2.79 (m, 1H), 2.66 (dd, J = 16.0, 4.4 Hz, 1H), 2.06–1.92 
(m, 1H), 1.80 (ddd, J = 14.2, 10.5, 3.9 Hz, 1H), 1.60 (ddd, J = 12.0, 9.9, 2.9 Hz, 1H), 
1.04 (d, J = 6.7 Hz, 3H), 0.98 (d, J = 6.7 Hz, 3H).  
13C NMR (126 MHz, CD2Cl2): δ 164.51, 149.77, 138.46, 138.41, 132.34, 132.04, 128.96, 
128.89, 126.83, 123.12, 109.44, 74.09, 62.78, 56.42, 45.52, 28.59, 24.94, 24.11, 21.59.  
HRMS (ESI+) (m/z): calculated for C21H23O4Br1Na1 [M+Na]
+: 441.067410; found 
441.067204. The enantiomeric ratio was measured by HPLC analysis using Chiralpak 
AD-3, heptane/ iPrOH = 70:30, flow rate = 1.0 mL/min, λ = 279 nm, tR = 4.0 min (minor) 
and tR= 5.2 min (major). er = 99.1:0.9. 
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X-Ray structural analysis parameter for 19a: 
Crystal data and structure refinement 
Identification code  9920 
Empirical formula  C21 H23 BrO4 
Color  colorless 
Formula weight  419.30  g · mol-1 
Temperature  100.15 K 
Wavelength  0.71073 Å 
Crystal system  Orthorhombic 
Space group  P212121,  (no. 19) 
Unit cell dimensions a = 5.4738(5) Å α= 90°. 
 b = 7.8392(11) Å β= 90°. 
 c = 45.290(3) Å γ = 90°. 
Volume 1943.4(4) Å3 
Z 4 
Density (calculated) 1.433  Mg · m-3 
Absorption coefficient 2.138 mm-1 
F(000) 864 e 
Crystal size 0.18 x 0.12 x 0.06 mm3 
θ range for data collection 2.637 to 31.097°. 
Index ranges -7 ≤ h ≤ 7, -11≤ k ≤ 11, -65≤ l ≤ 65 
Reflections collected 31126 
Independent reflections 6225 [Rint = 0.0748] 
Reflections with I>2σ(I) 4759 
Completeness to θ = 25.242° 99.8 %  
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Absorption correction Gaussian 
Max. and min. transmission 0.89 and 0.75 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 6225 / 0 / 238 
Goodness-of-fit on F2 1.112 
Final R indices [I>2σ(I)] R1 = 0.0478 wR
2 = 0.1213 
R indices (all data) R1 = 0.0759 wR
2 = 0.1534 
Absolute structure parameter -0.031(7) 
Largest diff. peak and hole 0.7 and -1.2 e · Å-3 
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Bond lengths [Å] and angles [°]. 
______________________________________________________________________  
Br(1)-C(19) 1.903(4)  O(1)-C(5) 1.433(6) 
O(1)-C(6) 1.432(6)  O(2)-C(2) 1.350(6) 
O(2)-C(10) 1.428(6)  O(3)-C(1) 1.402(5) 
O(3)-C(15) 1.364(6)  O(4)-C(15) 1.196(6) 
C(1)-C(2) 1.401(7)  C(1)-C(9) 1.376(7) 
C(2)-C(3) 1.380(6)  C(3)-C(4) 1.405(7) 
C(4)-C(5) 1.527(6)  C(4)-C(8) 1.390(7) 
C(5)-C(11) 1.524(7)  C(6)-C(7) 1.517(7) 
C(7)-C(8) 1.511(7)  C(8)-C(9) 1.403(6) 
C(11)-C(12) 1.537(7)  C(12)-C(13) 1.521(8) 
C(12)-C(14) 1.548(8)  C(15)-C(16) 1.485(6) 
C(16)-C(17) 1.396(6)  C(16)-C(21) 1.385(6) 
C(17)-C(18) 1.388(6)  C(18)-C(19) 1.383(7) 
C(19)-C(20) 1.376(7)  C(20)-C(21) 1.383(6)  
C(6)-O(1)-C(5) 111.5(4)  C(2)-O(2)-C(10) 117.2(4) 
C(15)-O(3)-C(1) 114.3(3)  C(2)-C(1)-O(3) 118.5(4) 
C(9)-C(1)-O(3) 119.6(4)  C(9)-C(1)-C(2) 121.9(4) 
O(2)-C(2)-C(1) 115.9(4)  O(2)-C(2)-C(3) 126.2(4) 
C(3)-C(2)-C(1) 117.9(4)  C(2)-C(3)-C(4) 121.2(4) 
C(3)-C(4)-C(5) 120.3(4)  C(8)-C(4)-C(3) 119.9(4) 
C(8)-C(4)-C(5) 119.7(4)  O(1)-C(5)-C(4) 111.2(4) 
O(1)-C(5)-C(11) 105.5(4)  C(11)-C(5)-C(4) 113.8(4) 
O(1)-C(6)-C(7) 109.9(4)  C(8)-C(7)-C(6) 111.3(4) 
C(4)-C(8)-C(7) 121.4(4)  C(4)-C(8)-C(9) 119.1(4) 
C(9)-C(8)-C(7) 119.5(4)  C(1)-C(9)-C(8) 119.8(4) 
C(5)-C(11)-C(12) 114.4(4)  C(11)-C(12)-C(14) 112.5(5) 
C(13)-C(12)-C(11) 110.1(5)  C(13)-C(12)-C(14) 112.6(6) 
O(3)-C(15)-C(16) 112.9(4)  O(4)-C(15)-O(3) 122.5(4) 
O(4)-C(15)-C(16) 124.6(4)  C(17)-C(16)-C(15) 123.1(4) 
C(21)-C(16)-C(15) 117.1(4)  C(21)-C(16)-C(17) 119.8(4) 
C(18)-C(17)-C(16) 120.0(4)  C(19)-C(18)-C(17) 118.6(4) 
C(18)-C(19)-Br(1) 119.8(4)  C(20)-C(19)-Br(1) 118.0(3) 
C(20)-C(19)-C(18) 122.2(4)  C(19)-C(20)-C(21) 118.7(4) 
C(20)-C(21)-C(16) 120.6(4)  
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7.4 Catalytic Asymmtric [4+2]-Cycloaddition Reaction of Dienes with Aldehydes 
7.4.1 Products 
  
Unless specified otherwise, aldehyde (0.1 mmol) and diene (0.12−1.0 mmol) were added 
to a mixture of catalyst 22 (0.2−3 mol%) and 70 mg/mL 5Å molecular sieves in 
anhydrous MeCy (0.01−1.0 M). Purification was performed by column chromatography 
or preparative thin layer chromatography on silica gel using 2−6% diethyl ether/pentane 
as the eluent.  
 
(R)-4,5-dimethyl-2-phenyl-3,6-dihydro-2H-pyran 
Aldehyde (0.1 mmol) and diene (0.2 mmol) were added to a mixture of catalyst 22c (1 
mol%) and 5 Å molecular sieves (21 mg) in anhydrous MeCy (0.3 mL) at –78 °C, then 
the reaction mixture was stirred at –20 °C for 24 h. 21a was obtained as a colorless oil 
(18.2 mg, 0.097 mmol, 97%).  
1H NMR (600 MHz, CD2Cl2): δ 7.39–7.34 (m, 4H), 7.28 (tt, J = 7.1, 1.6 Hz, 1H), 4.54 
(dd, J = 10.6, 3.5 Hz, 1H), 4.21 (pd, J = 15.5, 1.0 Hz, 1H), 4.09 (d, J = 15.5 Hz, 1H), 
2.30–2.24 (m, 1H), 2.10 (dd, J = 16.7, 0.6 Hz, 1H), 1.72 (br s, 3H), 1.62–1.616 (m, 3H). 
13C NMR (151 MHz, CD2Cl2): δ 143.5, 128.6, 127.6, 126.2, 125.0, 124.2, 76.5, 70.6, 
39.0, 18.5, 14.0. 
HRMS (ESI+) (m/z): calculated for C13H16O1Na1 [M+Na]
+: 211.1093; found: 211.1092.  
[]
: +224 (c = 0.50, CHCl3). 
GC: The enantiomeric ratio was measured by GC analysis on a chiral column (Hydrodex-
gamma-TBDAc column: 25.0 m; i.D. 0.25mm); FID; Temperature: 220 °C (injector), 350 
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°C (detector), 100 °C (108 min, iso); Gas: H2 (0.50 bar); tR = 88.43 min (major) and tR= 
92.67 min (minor), er = 98:2. 
 
(R)-2-(2-fluorophenyl)-4,5-dimethyl-3,6-dihydro-2H-pyran 
Aldehyde (0.1 mmol) and diene (0.2 mmol) were added to a mixture of catalyst 22c (1 
mol%) and 5 Å molecular sieves (21 mg) in anhydrous MeCy (0.3 mL) at –78 °C, then 
the reaction mixture was stirred at –10 °C for 72 h. 21b was obtained as a colorless oil 
(16.6 mg, 0.081 mmol, 81%).  
1H NMR (500 MHz, CDCl3): δ 7.51 (dt, J = 7.5, 1.6 Hz, 1H), 7.25–7.22 (m, 1H), 7.15 
(dt, J = 7.6, 0.8 Hz, 1H), 7.01 (ddd, J = 10.2, 8.2, 0.8 Hz, 1H), 4.86 (dd, J = 10.6, 3.6 Hz, 
1H), 4.24 (d, J = 15.5 Hz, 1H), 4.12 (d, J = 15.5 Hz, 1H), 2.28–2.22 (m, 1H), 2.14 (d, J = 
16.6 Hz, 1H), 1.69 (br s, 3 H), 1.60 (br s, 3 H). 
13C NMR (126 MHz, CDCl3): δ 160.7, 158.7, 130.0, 129.9, 129.6, 128.8, 128.7, 128.4, 
127.24, 127.20, 126.4, 124.48, 124.45, 124.0, 115.3, 115.1, 70.4, 70.35, 70.33, 37.7, 
18.4, 14.0. 
HRMS (ESI+) (m/z): calculated for C13H15O1F1Na1 [M+Na]
+: 229.09991; found: 
229.09996. 
 []
: +178.4 (c = 0.50, CHCl3). 
HPLC: The enantiomeric ratio was measured by HPLC analysis using Chiralpak IA-3, 
i.D. 4.6 mm. Heptane/ iPrOH = 99.5:0.5, flow rate = 1.0 mL/min, λ = 254 nm, tR = 4.1 
min (major) and tR= 4.5 min (minor), er = 92:8.  
 
 
(R)-2-(3-fluorophenyl)-4,5-dimethyl-3,6-dihydro-2H-pyran 
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Aldehyde (0.1 mmol) and diene (0.2 mmol) were added to a mixture of catalyst 22c (1 
mol%) and 5 Å molecular sieves (21 mg) in anhydrous MeCy (0.3 mL) at –78 °C, then 
the reaction mixture was stirred at –20 °C for 24 h. 21c was obtained as a colorless oil 
(19.5 mg, 0.0945 mmol, 94.5%).  
1H NMR (500 MHz, CDCl3): δ 7.30 (dt, J = 7.9, 2.0 Hz, 1H), 7.14–7.09 (m, 2H), 6.95 
(ddt, J = 8.9, 2.5, 0.5 Hz, 1H), 4.54 (dd, J = 10.6, 3.8 Hz, 1H), 4.20 (td, J = 15.6, 1.1 Hz, 
1H), 4.10 (d, J = 15.5 Hz, 1H), 2.29–2.22 (m, 1H), 2.09 (d, J = 16.6 Hz, 1H), 1.69 (br s, 
3H), 1.59 (br s, 3H). 
13C NMR (126 MHz, CDCl3): δ 164.0, 162.1, 145.54, 145.49, 129.96, 129.90, 124.7, 
123.7, 121.46, 121.45, 114.4, 114.2, 113.0, 112.8, 75.71, 75.70, 70.4, 38.6, 18.5, 14.0. 
HRMS (ESI+) (m/z): calculated for C13H15O1F1Na1 [M+Na]
+: 229.0999; found: 
229.1001.  
[]
: +184 (c = 0.50, CHCl3). 
HPLC: The enantiomeric ratio was measured by HPLC analysis using Chiralpak IA-3, 
i.D. 4.6 mm. Heptane/ iPrOH = 99.5:0.5, flow rate = 1.0 mL/min, λ = 220 nm, tR = 4.5 
min (major) and tR= 4.9 min (minor), er = 98:2. 
 
 
(R)-2-(4-fluorophenyl)-4,5-dimethyl-3,6-dihydro-2H-pyran 
Aldehyde (0.1 mmol) and diene (0.2 mmol) were added to a mixture of catalyst 22c (1 
mol%) and 5 Å molecular sieves (21 mg) in anhydrous MeCy (0.3 mL) at –78 °C, then 
the reaction mixture was stirred at –20 °C for 24 h. 21d was obtained as a colorless oil 
(16 mg, 0.089 mmol, 89%).  
1H NMR (500 MHz, CDCl3): δ 7.34 (dt, J = 5.6, 2.0 Hz, 2H), 7.02 (tt, J = 6.8, 2.9 Hz, 
2H), 4.52 (dd, J = 10.6, 3.5 Hz, 1H), 4.20 (td, J = 15.5, 1.1 Hz, 1H), 4.10 (d, J = 15.5 Hz, 
1H), 2.30–2.24 (m, 1H), 2.07 (d, J = 16.7 Hz, 1H), 1.69 (br s, 3H), 1.59 (br s, 3H). 
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13C NMR (126 MHz, CDCl3): δ 163.2, 161.3, 138.63, 138.60, 127.7, 127.6, 124.7, 123.8, 
115.4, 115.2, 75.8, 70.4, 38.7, 18.5, 14.0. 
HRMS (ESI+) (m/z): calculated for C13H15O1F1Na1 [M+Na]
+: 229.0999; found: 
229.1001. 
[]
: +164 (c = 0.50, CHCl3). 
HPLC: The enantiomeric ratio was measured by HPLC analysis using Chiralpak IA-3, 
i.D. 4.6 mm. Heptane/ iPrOH = 99.5:0.5, flow rate = 1.0 mL/min, λ = 220 nm, tR = 5.0 
min (major) and tR= 5.5 min (minor), er = 97:3. 
  
(R)-2-(4-bromophenyl)-4,5-dimethyl-3,6-dihydro-2H-pyran 
Aldehyde (0.1 mmol) and diene (1.0 mmol) were added to a mixture of catalyst 22c (3 
mol%) and 5 Å molecular sieves (21 mg) in anhydrous MeCy (0.3 mL) at –78 °C, then 
the reaction mixture was stirred at –60 °C for 6 days. 21e was obtained as a colorless oil 
(9.6 mg, 0.036 mmol, 36%). 
1H NMR (500 MHz, CDCl3): δ 7.47 (dt, J = 8.5, 2.4 Hz, 2H), 7.25 (dt, J = 8.4, 1.5 Hz, 
2H), 4.50 (dd, J = 10.6, 3.5 Hz, 1H), 4.19 (td, J = 15.6, 1.1 Hz, 1H), 4.09 (d, J = 15.6 Hz, 
1H), 2.26–2.20 (m, 1H), 2.07 (d, J = 16.7 Hz, 1H), 1.68 (br s, 3H), 1.59 (br s, 3H). 
13C NMR (126 MHz, CDCl3): δ 141.9, 131.6, 127.7, 124.7, 123.7, 121.2, 75.7, 70.4, 
38.6, 18.5, 14.0. 
HRMS (ESI+) (m/z): calculated for C13H16O1Br1 [M+H]
+: 267.0379; found: 267.0380.  
[]
: +154 (c = 0.50, CHCl3). 
HPLC: The enantiomeric ratio was measured by HPLC analysis using Chiralpak IA-3, 
i.D. 4.6 mm. Heptane/ iPrOH = 99.5:0.5, flow rate = 1.0 mL/min, λ = 254 nm, tR = 5.6 
min (major) and tR= 6.2 min (minor), er = 95:5. 
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(R)-4,5-dimethyl-2-(p-tolyl)-3,6-dihydro-2H-pyran 
Aldehyde (0.1 mmol) and diene (0.5 mmol) were added to a mixture of catalyst 22c (3 
mol%) and 5 Å molecular sieves (21 mg) in anhydrous MeCy (0.3 mL) at –78 °C, then 
the reaction mixture was stirred at –60 °C for 6 days. 21f was obtained as a colorless oil 
(18.9 mg, 0.093 mmol, 93%).  
1H NMR (500 MHz, CD2Cl2): δ 7.23 (d, J = 8.0 Hz, 2H), 7.15 (d, J = 8.0 Hz, 2H), 4.48 
(dd, J = 10.6, 3.5 Hz, 1H), 4.17 (d, J = 15.5 Hz, 1H), 4.05 (d, J = 15.5 Hz, 1H), 2.33 (s, 
3H), 2.26–2.21 (m, 1H), 2.06 (d, J = 16.7 Hz, 1H), 1.69 (br s, 3H), 1.59 (br s, 3H). 
13C NMR (126 MHz, CD2Cl2): δ 140.4, 137.3, 129.2, 126.1, 124.9, 124.2, 76.4, 70.6, 
38.9, 21.2, 18.5, 13.9. 
HRMS (ESI+) (m/z): calculated for C14H18O1Na1 [M+Na]
+: 225.1250; found: 225.1250.  
[]
: +184 (c = 0.50, CHCl3). 
HPLC: The enantiomeric ratio was measured by HPLC analysis using Chiralpak IA-3, 
i.D. 4.6 mm. Heptane/ iPrOH = 99.5:0.5, flow rate = 1.0 mL/min, λ = 254 nm, tR = 5.4 
min (major) and tR= 6.2 min (minor), er = 95:5.  
  
(R)-4,5-dimethyl-2-(thiophen-2-yl)-3,6-dihydro-2H-pyran 
Aldehyde (0.1 mmol) and diene (0.2 mmol) were added to a mixture of catalyst 4c (1 
mol%) and 5 Å molecular sieves (21 mg) in anhydrous MeCy (0.3 mL) at –78 °C, then 
the reaction mixture was stirred at –10 °C for 72 h. 3g was obtained as a colorless oil (9.3 
mg, 0.048 mmol, 48%).  
1H NMR (500 MHz, CD2Cl2): δ 7.25 (dd, J = 4.5, 1. Hz, 1H), 6.98–6.96 (m, 2H), 4.49 
(dd, J = 10.0, 3.7 Hz, 1H), 4.17 (d, J = 15.6 Hz, 1H), 4.02 (d, J = 15.5 Hz, 1H), 2.42–
2.36 (m, 1H), 2.21 (d, J = 16.6 Hz, 1H), 1.70 (br s, 3H), 1.57 (br s, 3H). 
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13C NMR (126 MHz, CD2Cl2): δ 146.6, 126.8, 124.9, 124.8, 124.0, 123.6, 72.4, 70.2, 
38.6, 18.4, 13.9. 
HRMS (ESI+) (m/z): calculated for C11H14O1S1Na1 [M+Na]
+: 217.0658; found: 
217.0659. 
[]
: +64 (c = 0.50, CHCl3). 
HPLC: The enantiomeric ratio was measured by HPLC analysis using Chiralpak IA-3, 
i.D. 4.6 mm. Heptane/ iPrOH = 99.5:0.5, flow rate = 1.0 mL/min, λ = 220 nm, tR = 5.6 
min (major) and tR= 6.0 min (minor), er = 99.7:0.3. 
  
(S)-2-isobutyl-4,5-dimethyl-3,6-dihydro-2H-pyran 
Aldehyde (0.30 mmol) and diene (3.0 mmol) were added to a mixture of catalyst 22b (1 
mol%) and 5 Å molecular sieves (70 mg) in anhydrous MeCy (1.0 mL) at –78 °C, then the 
reaction mixture was stirred at –20 °C for 70 h. 21i was obtained as a colorless oil (46 mg, 
0.27 mmol, 91%). 
1H NMR (500 MHz, CD2Cl2): δ 3.91–3.75 (m, 2H), 3.42 (dddd, J = 10.1, 8.2, 4.8, 3.6 Hz, 
1H), 1.84–1.76 (m, 1H), 1.73–1.66 (m, 2H), 1.54 (s, 3H), 1.44 (s, 3H), 1.37 (ddd, J = 14.1, 8.2, 
6.2 Hz, 1H), 1.14 (ddd, J = 13.7, 7.9, 4.8 Hz, 1H), 0.82 (dd, J = 6.7, 2.0 Hz, 6H).  
13C NMR (126 MHz, CD2Cl2): δ 124.6, 123.7, 72.5, 69.7, 45.2, 37.3, 24.6, 23.1, 22.4, 
18.2, 13.7. 
HRMS (EI) (m/z): calculated for C11H20O1 [M]: 168.1509; found 168.1510.  
[]
: +64.4 (c = 0.30, CH2Cl2). 
GC: The enantiomeric ratio was measured by GC analysis on a chiral column 
(Cyclodextrin-H column: 25.0 m; i.D. 0.25mm); FID; Temperature: 220 °C (injector), 
350 °C (detector), 75 °C (iso); Gas: H2 (0.40 bar); tR = 20.68 min (minor) and tR = 21.55 
min (major), er = 94:6. 
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(S)-2-butyl-4,5-dimethyl-3,6-dihydro-2H-pyran 
Aldehyde (0.30 mmol) and diene (3.0 mmol) were added to a mixture of catalyst 22b (1 
mol%) and 5 Å molecular sieves (70 mg) in anhydrous MeCy (1.0 mL) at –78 °C, then 
the reaction mixture was stirred at –20 °C for 48 h. 21j was obtained as a colorless oil 
(44 mg, 0.26 mmol, 87%). 
1H NMR (500 MHz, CD2Cl2): δ 3.91–3.76 (m, 2H), 3.33 (dddd, J = 10.4, 7.4, 5.0, 3.6 
Hz, 1H), 1.86–1.76 (m, 1H), 1.71 (d, J = 16.5 Hz, 1H), 1.54 (s, 3H), 1.44 (s, 3H), 1.38–
1.17 (m, 6H), 0.82 (t, J = 7.1 Hz, 3H). 
13C NMR (126 MHz, CD2Cl2): δ 124.4, 123.4, 74.2, 69.6, 36.7, 35.6, 27.7, 22.8, 18.0, 
13.8, 13.5. 
HRMS (EI) (m/z): calculated for C11H20O1 [M]: 168.1509; found 168.1508. 
[]
: +66.1 (c = 0.36, CH2Cl2). 
GC: The enantiomeric ratio was measured by GC analysis on a chiral column 
(Cyclodextrin-H column: 25.0 m; i.D. 0.25mm); FID; Temperature: 230 °C (injector), 
350 °C (detector), 115 °C (10 min, iso) to 170 °C (8 °C/min, 3 min iso); Gas: H2 (0.50 
bar); tR = 4.21 min (minor) and tR = 4.35 min (major), er = 97:3. 
 
(S)-2-ethyl-4,5-dimethyl-3,6-dihydro-2H-pyran 
Aldehyde (0.30 mmol) and diene (3.0 mmol) were added to a mixture of catalyst 22b (1 
mol%) and 5 Å molecular sieves (70 mg) in anhydrous MeCy (1.0 mL) at –78 °C, then the 
reaction mixture was stirred at –20 °C for 48 h. 21k was obtained as a colorless oil (67 mg, 
0.28 mmol, 94%). 
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1H NMR (500 MHz, CD2Cl2): δ 3.91–3.75 (m, 2H), 3.33 (dddd, J = 10.4, 7.2, 4.9, 3.4 
Hz, 1H), 1.86–1.76 (m, 1H), 1.71 (d, J = 16.5 Hz, 1H), 1.54 (s, 3H), 1.45–1.39 (m, 4H), 
1.36–1.29 (m, 2H), 1.24–1.16 (m, 13H), 0.80 (t, J = 6.9 Hz, 3H). 
13C NMR (126 MHz, CD2Cl2): δ 126.3, 125.4, 76.1, 71.5, 38.6, 37.8, 33.8, 31.63, 31.55, 
31.5, 31.2, 27.4, 24.6, 20.0, 15.8, 15.4. 
HRMS (EI) (m/z): calculated for C16H30O1 [M]: 238.2291; found 238.2288.  
[]
: +118.0 (c = 0.36, CH2Cl2). 
GC: The enantiomeric ratio was measured by GC analysis on a chiral column 
(Cyclodextrin-H column: 25.0 m; i.D. 0.25mm); FID; Temperature: 220 °C (injector), 
350 °C (detector), 130 °C (40 min, iso); Gas: H2 (0.50 bar); tR = 34.49 min (minor) and tR 
= 35.43 min (major), er = 97:3. 
 
(R)-2-isopropyl-4,5-dimethyl-3,6-dihydro-2H-pyran 
Aldehyde (0.30 mmol) and diene 2a (3.0 mmol) were added to a mixture of catalyst 22b (1 
mol%) and 5 Å molecular sieves (70 mg) in anhydrous MeCy (1.0 mL) at –78 °C, then the 
reaction mixture was stirred at –10 °C for 70 h. 21l was obtained as a colorless oil (38 mg, 
0.25 mmol, 83%). 
1H NMR (500 MHz, CD2Cl2): δ 3.92–3.77 (m, 2H), 3.03 (ddd, J = 10.4, 6.8, 3.4 Hz, 1H), 
1.90–1.82 (m, 1H), 1.69 (d, J = 16.5 Hz, 1H), 1.61–1.52 (m, 4H), 1.44 (dt, J = 2.3, 1.2 
Hz, 3H), 0.83 (dd, J = 26.5, 6.8 Hz, 6H). 
13C NMR (126 MHz, CD2Cl2): δ 124.4, 123.5, 79.3, 70.0, 33.7, 32.9, 18.4, 18.1, 17.9, 13.5. 
HRMS (ESI+) (m/z): calculated for C10H19O1 [M+H]
+: 155.1430; found 155.1432.  
[]
: +163.2 (c = 0.32, CH2Cl2). 
GC: The enantiomeric ratio was measured by GC analysis on a chiral column (Hydrodex-
gamma-TBDAc column: 25.0 m; i.D. 0.25mm); FID; Temperature: 220 °C (injector), 350 °C 
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(detector), 65 °C (25 min, iso) to 220 °C (8 °C/min, 5 min iso); Gas: H2 (0.50 bar); tR = 21.81 
min (minor) and tR = 23.46 min (major), er = 97:3. 
  
(S)-4,5-dimethyl-2-phenethyl-3,6-dihydro-2H-pyran 
Aldehyde (0.30 mmol) and diene (3.0 mmol) were added to a mixture of catalyst 22b (1 
mol%) and 5 Å molecular sieves (70 mg) in anhydrous MeCy (1.0 mL) at –78 °C, then the 
reaction mixture was stirred at –10 °C for 48 h. 21m was obtained as a colorless oil (47 mg, 
0.22 mmol, 73%). 
1H NMR (500 MHz, CD2Cl2): δ 7.23–7.03 (m, 5H), 3.94–3.77 (m, 2H), 3.34 (dddd, J = 
10.3, 8.0, 4.6, 3.5 Hz, 1H), 2.68 (ddd, J = 13.7, 9.8, 5.5 Hz, 1H), 2.58 (ddd, J = 13.7, 9.6, 
6.9 Hz, 1H), 1.91–1.83 (m, 1H), 1.77–1.61 (m, 3H), 1.54 (s, 3H), 1.44 (s, 3H). 
13C NMR (126 MHz, CD2Cl2): δ 142.5, 128.4, 128.2, 125.6, 124.4, 123.4, 73.2, 69.6, 
37.5, 36.6, 31.7, 18.0, 13.5. 
HRMS (EI) (m/z): calculated for C15H20O1 [M]: 216.1509; found 216.1511. 
[]
: +80.2 (c = 0.34, CH2Cl2). 
GC: The enantiomeric ratio was measured by GC analysis on a chiral column (Cyclodextrin-
H column: 25.0 m; i.D. 0.25mm); FID; Temperature: 230 °C (injector), 350 °C (detector), 
125 °C (45 min, iso) to 170 °C (8 °C/min, 3 min iso); Gas: H2 (0.60 bar); tR = 37.79 min 
(minor) and tR = 38.98 min (major), er = 96:4. 
 
(R)-4-methyl-2-phenyl-3,6-dihydro-2H-pyran 
Aldehyde (0.1 mmol) and diene (0.2 mmol) were added to a mixture of catalyst 22b (1 
mol%) and 5 Å molecular sieves (21 mg) in anhydrous MeCy (0.3 mL) at –78 °C, then 
the reaction mixture was stirred at –20 °C for 24 h. 21n was obtained as a colorless oil 
(17 mg, 0.097 mmol, 97%). 
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1H NMR (500 MHz, CD2Cl2): δ 7.38–7.33 (m, 4H), 7.27 (tt, J = 8.6, 1.8 Hz, 1H), 5.51 
(br s, 1H), 4.51 (dd, J = 10.4, 3.5 Hz, 1H), 4.29–4.28 (m, 2H), 2.28–2.22 (m, 1H), 2.10 
(d, J = 16.8 Hz, 1H), 1.75 (br s, 3H). 
13C NMR (126 MHz, CD2Cl2): δ 143.4, 132.5, 128.6, 127.7, 126.2, 120.2, 76.1, 66.8, 
38.1, 23.0.  
HRMS (ESI+) (m/z): calculated for C12H14O1Na1 [M+Na]
+: 197.09368; found: 
197.09366.  
[]
: +161 (c = 0.50, CHCl3). 
GC: The enantiomeric ratio was measured by GC analysis on a chiral column (Hydrodex-
gamma-TBDAc column: 25.0 m; i.D. 0.25mm); FID; Temperature: 220 °C (injector), 350 
°C (detector), 115 °C (35 min, iso); Gas: H2 (0.53 bar); tR = 18.86 min (major) and tR= 
19.87 min (minor), er = 98:2. 
 
(2R,6S)-6-methyl-2-phenyl-3,6-dihydro-2H-pyran 
Aldehyde (0.2 mmol) and diene (2.0 mmol) were added to a mixture of catalyst 22b (2 
mol%) and 5 Å molecular sieves (42 mg) in anhydrous MeCy (0.6 mL) at –78 °C, then 
the reaction mixture was stirred at –20 °C for 72 h. 21o was obtained as a colorless oil 
(7.0 mg, 0.04 mmol, 20%).    
1H NMR (500 MHz, CD2Cl2): δ 7.38–7.32 (m, 4H), 7.26 (tt, J = 7.2, 1.5 Hz, 1H), 5.93–
5.88 (m, 1H), 5.78 (qd, J = 12.2, 2.0 Hz, 1H), 4.72 (t, J = 6.5 Hz, 1H), 4.46–4.41 (m, 
1H), 2.26–2.23 (m, 2H), 1.30 (d, J = 6.8 Hz, 3H). 
13C NMR (126 MHz, CD2Cl2): δ 143.4, 131.6, 128.6, 127.6, 126.6, 124.1, 69.9, 69.7, 
32.6, 20.2.  
HRMS (EI) (m/z): calculated for C12H14O1 [M]: 174.1045; found: 174.1042.  
[]
: +124 (c = 0.15, CHCl3). 
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GC: The enantiomeric ratio was measured by GC analysis on a chiral column (Hydrodex-
gamma-TBDAc column: 25.0 m; i.D. 0.25mm); FID; Temperature: 220 °C (injector), 350 
°C (detector), 110 °C (30 min, iso); 230 °C (8 min); Gas: H2 (0.50 bar); tR = 22.14 min 
(minor) and tR= 23.39 min (major), er = 99:1.  
 
(R)-4,6,6-trimethyl-2-phenyl-3,6-dihydro-2H-pyran 
Aldehyde (0.1 mmol) and diene (0.5 mmol) were added to a mixture of catalyst 22b (2 
mol%) and 5 Å molecular sieves (700 mg) in anhydrous MeCy (10.0 mL) at –78 °C, then 
the reaction mixture was stirred at –45 °C for 48 h. 21p was obtained as a colorless oil 
(16.5 mg, 0.082 mmol, 82%). 
1H NMR (500 MHz, CD2Cl2): δ 7.40–7.38 (m, 2H), 7.33 (dt, J = 7.4, 2.0 Hz, 2H), 7.26 
(tt, J = 6.6, 1.4 Hz, 1H), 5.42 (t, J = 1.0 Hz, 1H), 4.69 (dd, J = 10.7, 3.3 Hz, 1H), 2.18–
2.11 (m, 1H), 2.01 (dd, J = 16.7, 3.3 Hz, 1H), 1.72 (br s, 3H), 1.29 (d, J = 1.6 Hz, 6H). 
13C NMR (126 MHz, CD2Cl2): δ 143.9, 130.6, 129.1, 128.6, 127.5, 126.5, 73.7, 71.1, 
37.8, 30.1, 26.2, 23.1.   
HRMS (ESI+) (m/z): calculated for C14H18O1Na1 [M+Na]
+: 225.1250; found: 225.1248. 
[]
: +80 (c = 0.50, CHCl3). 
GC: The enantiomeric ratio was measured by GC analysis on a chiral column 
(Cyclodextrin-H column: 25.0 m; i.D. 0.25mm); FID; Temperature: 220 °C (injector), 
350 °C (detector), 90 °C (60 min, iso); Gas: H2 (0.50 bar); tR = 42.0 min (minor) and tR = 
45.2 min (major), er = 96:4. 
 
(2R,6R)-4,6-dimethyl-2-phenyl-3,6-dihydro-2H-pyran 
7 EXPERIMENTAL PART 
 
179 
   
Aldehyde (0.1 mmol) and diene (0.5 mmol) were added to a mixture of catalyst 22b (1 
mol%) and 21 mg 5Å molecular sieves in anhydrous MeCy (0.1 M) at –78 °C, then the 
reaction mixture was stirred at –40 °C for 20 h. 21q was obtained as a colorless oil in 
81% yield.  
1H NMR (300 MHz, CD2Cl2): δ 7.41–7.23 (m, 5H), 5.41 (tt, J = 2.5, 1.4 Hz, 1H), 4.56 
(dd, J = 10.5, 3.7 Hz, 1H), 4.39–4.20 (m, 1H), 2.26–2.14 (m, 1H), 2.10–2.02 (m, 1H), 
1.74–1.73 (m, 3H), 1.25 (d, J = 6.6 Hz, 3H). 
13C NMR (75 MHz, CD2Cl2): δ 143.6, 132.5, 128.6, 127.6, 126.3, 125.6, 76.3, 72.0, 
38.1, 22.9, 21.8.   
HRMS (EI) m/z calculated for C13H16O1 [M]: 188.11957; found: 188.11951. 
The enantiomeric ratio was measured by GC analysis on Hydrodex-BTBDAC-G681 
column: tR = 38.2 min (minor) and tR= 39.6 min (major), er = 96:4. 
 
(R)-4,6,6-trimethyl-2-phenyl-3,6-dihydro-2H-pyran 
Aldehyde (0.1 mmol) and diene (0.3 mmol) were added to a mixture of catalyst 22b (2 
mol%) and 5 Å molecular sieves (21 mg) in anhydrous MeCy (0.3 mL) at –78 °C, then 
the reaction mixture was stirred at –40 °C for 4 days. 21r was obtained as a colorless oil 
(8.7 mg, 0.036 mmol, 36%).  
1H NMR (500 MHz, CD2Cl2): δ 7.38–7.32 (m, 4H), 7.27 (tt, J = 6.2, 1.8 Hz, 1H), 5.51 
(q, J = 1.2 Hz, 1H), 5.13 (ddt, J = 8.2, 2.8, 1.4 Hz, 1H), 4.50 (dd, J = 10.4, 3.5 Hz, 1H), 
4.31 (p, J = 1.7 Hz, 2H), 2.28–2.22 (m, 1H), 2.15–2.11 (m, 3H), 2.07–2.04 (m, 2H), 1.69 
(d, J = 0.9 Hz, 3H), 1.62 (br s, 3H). 
13C NMR (126 MHz, CD2Cl2): δ 143.5, 136.2, 132.1, 128.7, 128.6, 127.6, 126.2, 124.3, 
119.9, 76.1, 66.8, 37.3, 36.7, 26.4, 25.8, 17.8.  
HRMS (ESI+) (m/z): calculated for C17H22O1Na1 [M+Na]
+: 265.1563; found: 265.1562. 
[]
: +36 (c = 0.45, CHCl3). 
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GC: The enantiomeric ratio was measured by GC analysis on a chiral column (Hydrodex-
gamma-TBDAc column: 25.0 m; i.D. 0.25mm); FID; Temperature: 220 °C (injector), 350 
°C (detector), 130 °C (140 min, iso); Gas: H2 (0.50 bar); tR = 114.5 min (major) and tR= 
117.4 min (minor), er = 96:4. 
 
(3S,5S,8R,9S,10S,13R,14S,17R)-10,13-dimethyl-17-((R)-5-methylhexan-2-
yl)hexadecahydro-1H-cyclopenta[a]phenanthren-3-yl 9-((S)-4,5-dimethyl-3,6-dihydro-
2H-pyran-2-yl)nonanoate 
Aldehyde (0.1 mmol) and diene (1.0 mmol) were added to a mixture of catalyst 22b (1 
mol%) and 5 Å molecular sieves (21 mg) in anhydrous MeCy (0.3 mL) at –78 °C, then 
the reaction mixture was stirred at –10 °C for 72 h. 21s was obtained as a colorless solid 
(52 mg, 0.081 mmol, 81%). 
1H NMR (500 MHz, CD2Cl2): δ 4.66 (hept, J = 5.0 Hz, 1H), 3.96 (td, J = 15.4, 0.9 Hz, 
1H), 3.87 (d, J = 15.4 Hz, 1H   3.43–3.38 (m, 1H), 2.23 (t, J = 7.4 Hz, 2H), 1.97 (td, J = 
12.6, 3.3 Hz, 1H), 1.92–1.60 (m, 10H), 1.60–1.46 (m, 10.8H), 1.44–0.96 (m, 30.9H), 0.91 
(d, J = 6.5 Hz, 3H), 0.86 (dd, J = 6.6, 2.0 Hz, 6H), 0.83 (s, 3H), 0.69–0.61 (m, 4H). 
13C NMR (126 MHz, CD2Cl2): δ 173.5, 124.8, 123.9, 74.6, 73.7, 70.1, 56.9, 56.8, 54.7, 
45.1, 43.0, 40.5, 39.9, 37.21, 37.19, 36.6, 36.32, 36.26, 35.93, 35.88, 35.1, 34.5, 32.5, 
30.1, 29.9, 29.7, 29.5, 29.1, 28.6, 28.5, 28.0, 25.9, 25.5, 24.6, 24.3, 23.0, 22.7, 21.6, 18.9, 
18.5, 14.0, 12.4, 12.3.  
[]
: +32 (c = 0.50, CHCl3). 
HPLC: The diastereomeric ratio was measured by Heart-Cut-HPLC analysis using 
Chiralpak OD-3, i.D. 4.6 mm. Heptane/ iPrOH = 99:1, flow rate = 1.0 mL/min, λ = 204 
nm, tR = 4.0 min (major) and tR= 4.7 min (minor), dr = 19:1. 
  
Dihydrocholesterol-derivatized aldehyde 27 
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To a round-bottom flask were added dihydrocholesterol (1.2 g, 3.0 mmol, 1.0 equiv), 4-
(dimethylamino)-pyridine (DMAP, 18.3 mg, 0.15 mmol, 0.05 equiv), benzene (18.0 mL), 
trimethylamine (TEA, 0.46 mL, 3.3 mmol, 1.1 equiv), and followed by the addition of 
10-undecenoyl chloride (1.0 mL, 4.5 mmol, 1.5 equiv). The reaction mixture was stirred 
at room temperature overnight.  The solvent was removed under reduced pressure and the 
residue was purified by column chromatography on silica gel using 5–10% ethyl 
acetate/hexanes as the eluent giving a colorless solid (0.98 g, 1.8 mmol, 59%). To a 
round bottom flask were added the obtained colorless solid (0.55 g, 1.0 mmol, 1.0 equiv), 
triphenylphosphine (Ph3P, 0.80 g, 3.0 mmol, 3.0 equiv), and CH2Cl2 (10 mL), followed 
by the bubbling of the ozone at –40 °C until the starting material was fully consumed. 
The solvent was removed under reduced pressure and the residue was purified by column 
chromatography on silica gel using 5–10% ethyl acetate/hexanes as eluents giving a 
colorless solid 27 (0.38 g, 0.69 mmol, 69%).   
1H NMR (500 MHz, CD2Cl2): δ 9.72 (s, 1H), 4.66 (hept, J = 4.6 Hz, 1H), 2.39 (dt, J = 
7.4, 1.6 Hz, 2H), 2.23 (t, J = 7.5 Hz, 2H), 1.97 (td, J = 12.6, 3.2 Hz, 1H), 1.85–1.71 (m, 
3H), 1.67–1.43 (m, 10.6H), 1.38–0.95 (m, 28H), 0.91 (d, J = 6.5 Hz, 3H), 0.86 (dd, J = 
6.6, 1.9 Hz, 6H), 0.82 (s, 3H), 0.69–0.63 (m, 4H). 
13C NMR (126 MHz, CD2Cl2): δ 203.1, 173.5, 73.7, 56.9, 56.7, 54.7, 45.1, 44.3, 43.0, 
40.5, 39.9, 37.2, 36.6, 36.3, 35.92, 35.87, 35.0, 34.5, 32.5, 29.6, 29.50, 29.48, 29.4, 29.1, 
28.6, 28.4, 28.0, 25.4, 24.6, 24.2, 23.0, 22.7, 22.5, 21.6, 18.9, 12.4, 12.2. 
HRMS (ESI+) (m/z): calculated for C37H64O3Na1 [M+Na]
+: 579.4748; found: 579.4756. 
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Gram-Scale Reaction 
 
To a flame-dried schlenk, 700 mg 5 Å molecular sieves, catalyst 22c (45 mg/0.02 mmol) 
and 10 mL anhydrous methylcyclohexane were added. The mixture was stirred for 5 min 
at room temperature. Then benzaldehyde (1.06 g/10.0 mmol) was added to the reaction 
mixture at −78 °C. Subsequently, 2,3-dimethyl-1,3-butadiene (985.8 mg/12.0 mmol)   
was dropped in slowly within 10 mins at −78 °C. The reaction was stirred at −20 °C for 1 
day. Purification of product 21a was performed by column chromatography on silica gel 
using pentane/diethyl ether = 100/2 as the eluent (1.825 g/9.7 mmol, 97% and 98:2 er). 
The catalyst 22c could be recycled by column chromatography on silica gel using 
hexane/ethyl acetate = 50/50 as the eluent affording a white solid. The solid was 
dissolved in CH2Cl2 (10 mL) and stirred with 6 N aqueous HCl (10 mL) for 30 min. The 
organic layer was separated, washed with 6 N aqueous HCl (10 mL) and concentrated 
under reduced pressure to furnish the recycled catalyst 22c (43.7 mg, 97%).  
 
To a flame-dried schlenk, 700 mg 5 Å molecular sieves, catalyst 22c (45 mg/0.02 mmol) 
and 10 mL anhydrous methylcyclohexane were added. The mixture was stirred for 5 min 
at room temperature. Then benzaldehyde (1.06 g/10.0 mmol) was added to the reaction 
mixture at −78 °C. Subsequently, isoprene 20c (817.4 mg/12.0 mmol)   was dropped in 
slowly within 10 mins at −78 °C. The reaction was stirred at −20 °C for 2 days. 
Purification of product 21n was performed by column chromatography on silica gel using 
pentane/diethyl ether = 100/2 as the eluent (1.51 g/8.7 mmol, 87% and 98:2 er). The 
catalyst 22c was recycled by column chromatography.  
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To a flame-dried schlenk, 1.05 g 5 Å molecular sieves, catalyst 22b (104.8 mg/0.405 
mmol), 15 ml anhydrous methylcyclohexane were added in sequence at room 
temperature. Then 2,3-dimethyl-1,3-butadiene (3.7 g/45.0 mmol) and decyl aldehyde 
(703.2 mg/4.5 mmol) was were added to the reaction mixture in sequence in the reaction 
mixture at −20 °C. The reaction was performed for 2 days at −20 °C. Purification of 
product 21k was performed by column chromatography on silica gel using 
pentane/diethyl ether = 100/2 as the eluent (0.95 g/3.99 mmol, 89% and 96.5:3.5 er).  
 
Derivatization 
 
21n (31.5 mg, 0.18 mmol) was dissolved in anhydrous and degassed ethanol (1.0 mL) at 
room temperature, followed by the addition of palladium (10%) on charcoal (10.4 mg). 
An atmosphere of hydrogen was introduced and the resulting suspension was stirred at −
20 °C for 2 h. The reaction mixture was warmed up to room temperature and performed 
overnight. The reaction mixture was filtered over Celite and the residue was purified by 
column chromatography on silica gel using 5% diethyl ether/pentane as the eluent 
affording Doremox 26 as a clear oil. (31 mg, 0.176 mmol, 98%, cis:trans = 8.5:1, 98:2 
ercis, 94.5:5.5 ertrans).  
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(2R,4S)-4-methyl-2-phenyltetrahydro-2H-pyran  
1H NMR (600 MHz, CD2Cl2): δ 7.34–7.30 (m, 4H), 7.25–7.22 (m, 1H), 4.64 (trans 
isomer, dd, J = 9.9, 3.0 Hz, 0. 12H), 4.29 (cis isomer, dd, J = 11.3, 2.2 Hz, 0.95H), 4.10 
(cis isomer, ddd, J = 11.5, 4.7, 1.6 Hz, 0.97H), 3.81–3.79 (trans isomer, m, 0.24H), 3.57 
(cis isomer, ddd, J = 12.4, 11.4, 2.2 Hz, 0.99H), 2.12–2.07 (trans isomer, m, 0.12H), 
1.92–1.73 (m, 2.22H), 1.63-1.58 (m, 1.13H), 1.35–1.26 (m, 1.22H), 1.20–1.14 (m, 
1.37H), 0.97 (d, J = 6.5 Hz, 3.0H), (spectra were complicated due to the presence of two 
diastereomers). 
13C NMR (151 MHz, CD2Cl2): δ 144.1 (cis isomer), 143.8 (trans isomer), 128.54 (trans 
isomer), 128.52 (cis isomer), 127.5 (cis isomer), 127.3 (trans isomer), 126.4 (trans 
isomer), 126.2 (cis isomer), 80.0 (cis isomer), 74.2 (trans isomer), 68.8 (cis isomer), 63.3 
(trans isomer), 43.3 (cis isomer), 39.6 (trans isomer), 34.9 (cis isomer), 32.4 (trans 
isomer), 31.2 (cis isomer), 25.9 (trans isomer), 22.5 (cis isomer), 18.5 (trans isomer), 
(spectra were complicated due to the presence of two diastereomers). 
HRMS (ESI+) (m/z) calculated for C12H16O1Na1 [M+Na]
+: 199.1093; found: 199.1094.  
GC: The enantiomeric ratio was measured by GC analysis on a chiral column (Hydrodex-
gamma-TBDAc column: 25.0 m; i.D. 0.25mm); FID; Temperature: 220 °C (injector), 350 
°C (detector), 120 °C (30 min, iso); Gas: H2 (0.50 bar); tR (cis) = 17.04 min (minor) and 
tR (cis) = 17.76 min (major), e.r. = 98:2; tR (trans) = 19.45 min (major) and tR (trans) = 
21.17 min (minor), er = 94.5:5.5.   
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7.4.2 Catalyst Synthesis 
 
(S)-3,3'-bis(3,5-bis(pentafluoro-λ6-sulfanyl)phenyl)-[1,1'-binaphthalene]-2,2'-diol  
To a three-necked round bottom flask with a condenser were added barium hydroxide 
octahydrate (2.3 g, 7.2 mmol, 4.5 equiv), a 1,4-dioxane/H2O solution (3:1, 30 mL), (S)-
2,2'-(2,2'-bis(methoxymethoxy)-[1,1'-binaphthyl]-3,3'-diyl)bis(4,4,-5,5-tetramethyl-1,3,2-
dioxaborolane) (1.0 g, 1.6 mmol, 1.0 equiv), and 2,4-
bis(pentafluorosulfanyl)bromobenzene (2.17 g, 5.3 mmol, 3.3 equiv). After degassing the 
reaction mixture with argon for 20 min, tetrakis(triphenylphosphine)palladium (0.14 g, 
0.12 mmol, 0.075 equiv) was added. The mixture was refluxed for 24 h, then cooled to 
room temperature, and quenched with HCl (10 mL, 1.0 M, aq.). After extraction with 
CH2Cl2 (3×30 mL), the combined organic layers were successively washed with HCl (60 
mL, 1.0 M, aq.), NaHCO3 (60 mL, sat., aq.), and brine (60 mL). The organic layers were 
dried over Na2SO4, and concentrated under reduced pressure. 1,4-dioxane (90 mL) and 
HCl (30 mL, conc. aq.) were added to the residue and the reaction mixture was stirred at 
70 °C for 5 h in a round bottom flask equipped with a condenser. After cooling to room 
temperature, the reaction solution was extracted with CH2Cl2 (3×100 mL). The organic 
layers were combined, dried over Na2SO4, and the solvent was removed under reduced 
pressure. The residue was purified by column chromatography on silica gel using 5–10% 
ethyl acetate/hexanes affording the title compound 23a as a colorless solid (1.0 g, 1.06 
mmol, 66%).  
1H NMR (500 MHz, CDCl3): δ 8.33 (d, J = 1.9 Hz, 4H), 8.17 (t, J = 1.9 Hz, 2H), 8.10 (s, 
2H), 8.02 (d, J = 7.9 Hz, 2H), 7.50 (ddd, J = 8.0, 6.9, 1.0 Hz, 2H), 7.44 (ddd, J = 8.3, 6.9, 
1.3 Hz, 2H), 7.22 (d, J = 8.3 Hz, 2H), 5.39 (s, 2H). 
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13C NMR (126 MHz, CDCl3): δ 153.9, 153.7, 153.6, 153.4, 153.3, 149.8, 139.6, 133.5, 132.7, 
130.4, 129.6, 129.1, 127.1, 125.6, 124.1, 123.1, 111.9; δ 153.6 (p, J = 18.8 Hz). 
19F NMR (470 MHz, CDCl3): δ 81.94 (p, J = 150.5 Hz), 63.09 (d, J = 150.5 Hz). 
HRMS (ESI–) (m/z): calculated for C32H17O2F20S4 [M–H]
–: 940.9798; found 940.9803. 
 
 
N-((11cS)-2-(3,5-bis(pentafluoro-λ6-sulfanyl)phenyl)-4-(((11cS)-2-(3,5-bis(pentafluoro-
λ
6-sulfanyl)phenyl)-6-(3-(pentafluoro-λ6-sulfanyl)-5-((tetrafluoro-λ5-sulfanyl)-l2-
fluoranyl)phenyl)-4-(((trifluoromethyl)sulfonyl)imino)-4λ5-dinaphtho[2,1-d:1',2'-
f][1,3,2]dioxaphosphepin-4-yl)imino)-6-(3-(pentafluoro-λ6-sulfanyl)-5-((tetrafluoro-λ5-
sulfanyl)- λ2-fluoranyl)phenyl)-4l5-dinaphtho[2,1-d:1',2'-f][1,3,2]dioxaphosphepin-4-yl)-
1,1,1-trifluoromethanesulfonamide 
In a flame-dried flask under argon, diol 23a (0.1 g, 0.1 mmol, 2.1 equiv) was dissolved in 
toluene (1.4 mL). Subsequently, N,N-diisopropylethylamine (DIPEA, 0.14 mL, 0.80 
mmol, 16.0 equiv), followed by trifluoromethylsulfonyl trichlorophosphazene (P(NTf)Cl3, 
30.4 mg, 0.1 mmol, 2.1 equiv) were added and the solution was stirred at room 
temperature for 5 min. 1,1,1,3,3,3-hexamethyldisilazane (HMDS, 10.4 mg, 0.05 mmol, 
1.0 equiv) was added to the reaction mixture, which was stirred at stirred at 120 °C for 12 
h. The reaction mixture was cooled to room temperature and the solvent was removed 
under reduced pressure. The residue was purified by column chromatography on silica 
gel using 20–40% ethyl acetate/hexanes as the eluent affording a colorless solid. The 
solid was dissolved in CH2Cl2 (25 mL) and stirred with HCl (6.0 M, aq., 25 mL) for 30 
min. The organic layer was separated, washed with HCl (6.0 M, aq., 25 mL), and 
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concentrated under reduced pressure to provide compound 22c as a colorless solid (90 
mg, 0.04 mmol, 80%). 
 1H NMR (500 MHz, CD2Cl2): δ 8.20 (br s, 2H), 8.18 (t, J = 1.75 Hz, 2H), 8.16–8.15 (m, 
2H), 8.13 (br s, 2H), 7.97–7.94 (m, 2H), 7.92–7.91 (m, 2H), 7.87 (d, J = 1.60 Hz, 4H), 
7.80–7.75 (m, 4H), 7.66 (t, J = 7.30 Hz, 2H), 7.48 (br s, 4H), 7.40–7.37 (m, 2H), 7.36 (s, 
2H), 7.07 (d, J = 8.60 Hz, 2H), 6.58 (s, 2H), 4.93 (br s, 2H). 
13C NMR (126 MHz, CD2Cl2): δ 154.0, 153.9, 153.8, 153.6, 144.0, 141.4, 138.6, 138.2, 
134.0, 133.0, 132.6, 132.4, 132.3, 131.5, 130.84, 130.78, 130.1, 129.9, 129.61, 129,56, 
128.7, 128.6, 127.9, 127.8, 127.14, 127.11, 124.5, 124.1, 123.9, 121.7, 120.3, 117.7. 
19F NMR (470 MHz, CD2Cl2): δ 80.8 (sext, J = 152.0 Hz, 8F), 63.1 (d, J = 150.6 Hz, 
16F), 62.3 (d, J = 150.0 Hz, 16F), –79.5 (s, 6F). 
31P NMR (202 MHz, CD2Cl2): δ –15.3. 
HRMS (ESI−) (m/z): calculated for C66H32N3O8F46P2S10 [M−H]
–: 2249.8143; found: 
2249.8128. 
 
(S)-3,3'-bis(3,5-dinitrophenyl)-[1,1'-binaphthalene]-2,2'-diol 
To a two-necked round flask with a condenser were added barium hydroxide octahydrate 
(1.76 mmol), a 1,4-dioxane/H2O solution (3/1, 10 mL), (2,2'-dimethoxy-[1,1'-
binaphthalene]-3,3'-diyl)diboronic acid (0.6 mmol) and 1-brom-3,5-dinitrobenzene (1.91 
mmol), the mixture was degass by Ar2 for 20min, then add 
tetrakis(triphenylphosphine)palladium (0.063 mmol), The mixture was refluxed at 70 °C 
for 48 h , then cooled to room temperature. The dioxane was removed, and the resulting 
residue was redissolved in CH2Cl2, washed with 1 N HCl solution and brine, dried over 
Na2SO4. The crude product as afforded as red oil which was purified by column 
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chromatography with a eluent: hexane:ethylacetate 95:5−85:15. Remove the solvent 
under reduced pressure to give the methoxyl-protected title compound as a pale solid 
(0.362 mmol, 60.3%). 
Under argon, add the protected compound 160 mg/0.25 mmol and dry CH2Cl2 15 mL to a 
flamed schlenk. Then cool the reaction mixture to 0 °C. A solution of BBr3 in CH2Cl2 
(2.0 mL, 1.0 M, 8eq) was then added dropwise over 10 mins. The reaction mixture was 
stirred at room temperature for another 6 hours with a full conversion. Quench the 
reaction by slowly adding water. The reaction mixture was diluted with CH2Cl2, washed 
with water then brine. The combined organic layers were dried over Na2SO4, filtered and 
concentrated. The crude product was purified by silica flash column chromatography 
(4:1−3:1 CH2Cl2:hexane) affording the literature reported product 23b (21.6 mmol, 
86.3%). 
 
N,N'-((11bS,11b'S)-azanediylbis(2,6-bis(3,5-dinitrophenyl)-4λ5-dinaphtho[2,1-d:1',2'-
f][1,3,2]dioxaphosphepine-4-yl-4-ylidene))bis(1,1,1-trifluoromethanesulfonamide)  
To a mixture of the 3, 3’-disubstituted BINOL 23b (2.0 equiv.) and 
trifluoromethylsulfonyl trichlorophosphazene (P(NTf)Cl3, 2.0 equiv.) in tetrahzdrofuran 
(0.2 M) was added Et3N (12 equiv.) at room temperature under argon atmosphere. After 
being stirred for 10 min, NH3 in dioxane (1.0 equiv., 0.5 M), DMAP (0.4 equiv.) was 
added. After an additional stirring for 10 min at room temperature, the reaction mixture 
was heated to 70 °C for 45 hours. The solvent was removed by reduced pressure and the 
residue was purified by column chromatography on silica gel using 3% ethyl 
acetate/DCM as the eluents giving a pale yellow solid. The solid was dissolved in CH2Cl2 
and stirred with 6 N aqueous HCl for 30 mins. The organic layer was separated, washed 
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with 6 N aqueous HCl and concentrated under reduced pressure to give the title 
compound 22d as a white solid (74%).  
1H NMR (600 MHz, CD2Cl2): δ 8.99 (t, J = 4.2 Hz, 2H), 8.69 (d, J = 2.4 Hz, 5H), 8.67 
(t, J = 4.2 Hz, 2H), 8.20 (s, 2H), 8.13 (d, J = 8.4 Hz, 2H), 7.95 (d, J = 1.8 Hz, 5H), 7.93–
7.90 (m, 2H), 7.88–7.85 (m, 5H), 7.80–7.77 (m, 2H), 7.66 (ddd, J = 7.8, 6.6, 1.2 Hz, 2H), 
7.43 (ddd, J = 8.4, 7.2, 1.2 Hz, 2H), 7.31 (d, J = 7.8 Hz, 2H), 6.87 (s, 2H). 
13C NMR (151 MHz, CD2Cl2): δ 148.69, 148.39, 143.91, 143.88, 143.85, 143.19, 143.15, 
143.11, 139.76, 139.27, 133.06, 132.89, 132.42, 131.94, 131.48, 131.30, 130.93, 130.21, 
129.63, 129.52, 129.22, 129.21, 129.20, 129.19, 129.18, 129.16, 129.15, 128.50, 127.75, 
127.59, 127.50, 127.36, 123.74, 123.73, 123.72, 122.83, 122.47, 122.46, 122.45, 120.71, 
118.58, 118.30, 118.05, 116.47. 
31P NMR (202 MHz, CD2Cl2): δ–5.37 (S). 
19F NMR (470 MHz, CD2Cl2): δ –79.9 (S). 
HRMS (ESI−) (m/z): calculated for C66H32N11O24F6P2S2 [M−H]
−: 1602.0448; found: 
1602.0449. 
 
(S)-3,3'-bis(4-methyl-3,5-dinitrophenyl)-[1,1'-binaphthalene]-2,2'-diol 
To a two-necked round flask with a condenser were added barium hydroxide octahydrate 
(1.76 mmol), a 1,4-dioxane/H2O solution (3/1, 10 mL), (2,2'-dimethoxy-[1,1'-
binaphthalene]-3,3'-diyl)diboronic acid (0.6 mmol) and 1-brom-3,5-dinitrotoluene (1.91 
mmol), the mixture was degass by Ar2 for 20min, then add 
tetrakis(triphenylphosphine)palladium (0.063 mmol), The mixture was refluxed at 70 °C 
for 48 h , then cooled to room temperature. The dioxane was removed, and the resulting 
residue was redissolved in CH2Cl2, washed with 1 N HCl solution and brine, dried over 
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Na2SO4. The crude product as afforded as red oil which was purified by column 
chromatography with an eluent of 3−10% hexane:ethylacetate. Remove the solvent under 
reduced pressure to give the methoxyl-protected title compound as a pale solid (0.31 
mmol, 52%). 
Under argon, add the protected compound 138 mg/0.25 mmol and dry CH2Cl2 12 ml to a 
flamed schlenk. Then cool the reaction mixture to 0 °C. A solution of BBr3 in CH2Cl2 1.6 
mL, 1.0 M, 8eq) was then added dropwise over 10 mins. The reaction mixture was stirred 
at room temperature for another 6 hours with a full conversion. Quench the reaction by 
slowly adding water. The reaction mixture was diluted with CH2Cl2, washed with water 
then brine. The combined organic layers were dried over Na2SO4, filtered and 
concentrated. The crude product was purified by silica flash column chromatography 
with an elent of 25−40% CH2Cl2:hexane, affording the literature reported product 23c 
(0.155 mmol, 77.3%). 
 
N,N'-((11bS,11b'S)-azanediylbis(2,6-bis(4-methyl-3,5-dinitrophenyl)-4λ5-dinaphtho[2,1-
d:1',2'-f][1,3,2]dioxaphosphepine-4-yl-4-ylidene))bis(1,1,1-trifluoromethanesulfonamide) 
To a mixture of the 3, 3’-disubstituted BINOL 23c (2.0 equiv.) and 
trifluoromethylsulfonyl trichlorophosphazene (P(NTf)Cl3, 2.0 equiv.) in tetrahzdrofuran 
(0.2 M) was added Et3N (12 equiv.) at room temperature under argon atmosphere. After 
being stirred for 10 min, NH3 in dioxane (0.5 M, 1.0 equiv.), DMAP (0.4 equiv.) was 
added. After an additional stirring for 10 min at room temperature, the reaction mixture 
was heated to 70 °C for 45 hours. The solvent was removed by reduced pressure and the 
residue was purified by column chromatography on silica gel using 1−25% ethyl 
acetate/DCM as the eluents giving a pale yellow solid. The solid was dissolved in CH2Cl2 
and stirred with 6N aqueous HCl for 30 mins. The organic layer was separated, washed 
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with 6 N aqueous HCl and concentrated under reduced pressure to give the title 22e 
compound as a white solid (75%).  
1H NMR (600 MHz, CD2Cl2): δ 8.36 (br s, 2H), 8.21 (s, 1H), 8.11 (d, J = 8.4 Hz, 1H), 
8.03 (d, J = 8.4 Hz, 1H), 7.88 (ddd, J = 8.4, 6.6, 1.2 Hz,  1H), 7.67 (ddd, J = 8.4, 6.6, 1.2 
Hz,  1H), 7.62 (ddd, J = 8.4, 6.6, 1.2 Hz, 1H), 7.42 (d, J = 9.0 Hz, 1H), 7.37 (ddd, J = 
8.4, 7.2, 1.2 Hz, 1H), 7.24 (br s, 2H), 7.20 (d, J = 2.4 Hz, 1H), 6.90 (s, 1H), 2.62 (s, 3H), 
2.29 (s, 3H). 
13C NMR (151 MHz, CD2Cl2): δ 151.61, 151.54, 144.34, 144.30, 144.27, 143.25, 143.21, 
143.17, 136.86, 135.83, 133.04, 132.73, 132.42, 131.89, 131.32, 131.11, 130.01, 129.59, 
129.53, 129.52, 129.51, 129.50, 129.41, 129.08, 129.07, 129.06, 128.28, 127.61, 127.35, 
127.22, 127.15, 127.12, 127.09, 126.75, 125.30, 123.86, 123.85, 123.84, 122.84, 122.15, 
122.14, 122.13, 120.72, 118.59, 116.48, 15.23, 14.42. 
31P NMR (202 MHz, CD2Cl2): δ –6.28 (S). 
19F NMR (470 MHz, CD2Cl2): δ –79.86 (S). 
HRMS (ESI) (m/z): calculated for C70H40N11O24F6P2S2 [M−H]: 1658.1074; found: 
1658.1087. 
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7.4.3 X-Ray Data 
X-ray structural analysis parameter for 21e: 
 
Crystal data and structure refinement 
Crystal data and structure refinement 
Identification code  10450 
Empirical formula  C13 H15 Br1 O1 
Color  colourless 
Formula weight  267.16  g·mol-1 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  orthorhombic 
Space group  P 21 21 21,  (no. 19)  
Unit cell dimensions a = 6.836(2) Å α= 90°. 
 b = 11.5511(9) Å β= 90°. 
 c = 15.3107(9) Å γ = 90°. 
Volume 1208.9(4) Å3 
Z 4 
Density (calculated) 1.468  Mg·m-3 
Absorption coefficient 3.372 mm-1 
F(000) 544 e 
Crystal size 0.23 x 0.15 x 0.09 mm3 
θ range for data collection 3.528 to 33.119°. 
Index ranges -10 ≤ h ≤ 10, -17≤ k ≤ 17, -23≤ l ≤ 23 
Reflections collected 65284 
Independent reflections 4595 [Rint = 0.0406] 
Reflections with I>2σ(I) 4427 
Completeness to θ = 25.242° 99.1 %  
Absorption correction Gaussian 
Max. and min. transmission 0.75447 and 0.51719 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4595 / 0 / 138 
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Goodness-of-fit on F2 1.109 
Final R indices [I>2σ(I)] R1 = 0.0203 wR
2= 0.0521 
R indices (all data) R1 = 0.0220 wR
2 = 0.0530 
Absolute structure parameter -0.006(3) 
Extinction coefficient 0 
Largest diff. peak and hole 0.463 and -0.355 e·Å-3 
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Atomic coordinates and equivalent isotropic displacement parameters (Å2). 
 Ueq is defined as one third of the trace of the orthogonalized Uij tensor. 
____________________________________________________________________ 
 x y z Ueq 
____________________________________________________________________ 
C(1) 0.2649(2) 0.3189(2) 0.5884(1) 0.018(1) 
C(2) 0.0983(2) 0.3329(2) 0.6540(1) 0.020(1) 
C(3) 0.0412(2) 0.4578(2) 0.6672(1) 0.021(1) 
C(4) 0.1547(2) 0.5432(2) 0.6371(1) 0.021(1) 
C(5) 0.3487(2) 0.5167(2) 0.5945(1) 0.023(1) 
C(6) -0.1475(3) 0.4750(2) 0.7163(2) 0.032(1) 
C(7) 0.1107(3) 0.6705(2) 0.6422(1) 0.028(1) 
C(8) 0.3544(2) 0.1997(1) 0.5929(1) 0.017(1) 
C(9) 0.5089(2) 0.1772(2) 0.6500(1) 0.020(1) 
C(10) 0.5871(2) 0.0659(2) 0.6570(1) 0.022(1) 
C(11) 0.5082(2) -0.0221(1) 0.6060(1) 0.020(1) 
C(12) 0.3551(3) -0.0018(1) 0.5486(1) 0.022(1) 
C(13) 0.2789(2) 0.1097(2) 0.5422(1) 0.021(1) 
Br(1) 0.6150(1) -0.1736(1) 0.6157(1) 0.029(1) 
O(1) 0.4148(2) 0.4013(1) 0.6078(1) 0.021(1) 
____________________________________________________________________ 
Bond lengths [Å] and angles [°]. 
______________________________________________________________________ 
C(1)-O(1) 1.430(2) C(1)-C(8) 1.508(2)
C(1)-C(2) 1.528(2) C(2)-C(3) 1.507(2)
C(3)-C(4) 1.337(3) C(3)-C(6) 1.506(2)
C(4)-C(7) 1.502(2) C(4)-C(5) 1.509(2)
C(5)-O(1) 1.422(2) C(8)-C(9) 1.396(2)
C(8)-C(13) 1.397(2) C(9)-C(10) 1.397(2)
C(10)-C(11) 1.390(2) C(11)-C(12) 1.387(2)
C(11)-Br(1) 1.9020(16) C(12)-C(13) 1.393(2) 
O(1)-C(1)-C(8) 107.89(12) O(1)-C(1)-C(2)            109.09(13)
C(8)-C(1)-C(2) 111.72(13) C(3)-C(2)-C(1)            112.47(14)
C(4)-C(3)-C(6) 124.83(17) C(4)-C(3)-C(2)            120.68(14)
C(6)-C(3)-C(2) 114.48(16) C(3)-C(4)-C(7)            126.01(15)
C(3)-C(4)-C(5) 120.57(15) C(7)-C(4)-C(5)            113.41(15)
O(1)-C(5)-C(4) 114.07(14) C(9)-C(8)-C(13)          119.29(15)
C(9)-C(8)-C(1) 120.38(14) C(13)-C(8)-C(1)          120.29(14)
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C(8)-C(9)-C(10) 120.58(15) C(11)-C(10)-C(9)        118.82(14)
C(12)-C(11)-C(10) 121.68(15) C(12)-C(11)-Br(1)       119.63(13)
C(10)-C(11)-Br(1) 118.70(12) C(11)-C(12)-C(13)      118.89(15)
C(12)-C(13)-C(8) 120.74(15) C(5)-O(1)-C(1)            111.52(12)  
______________________________________________________________________ 
 
Anisotropic displacement parameters (Å2).  
The anisotropic displacement factor exponent takes the form:  
 -2π2[ h2a*2U11 + ... + 2 h k a* b* U12 ]. 
___________________________________________________________________ 
 U11 U22 U33 U23 U13 U12 
___________________________________________________________________ 
C(1) 0.016(1)  0.021(1) 0.016(1)  0.000(1) 0.000(1)  0.003(1) 
C(2) 0.015(1)  0.024(1) 0.021(1)  -0.002(1) 0.003(1)  0.001(1) 
C(3) 0.015(1)  0.027(1) 0.019(1)  -0.005(1) 0.000(1)  0.002(1) 
C(4) 0.019(1)  0.024(1) 0.019(1)  -0.004(1) -0.002(1)  0.005(1) 
C(5) 0.023(1)  0.020(1) 0.027(1)  0.004(1) 0.006(1)  0.004(1) 
C(6) 0.019(1)  0.036(1) 0.041(1)  -0.011(1) 0.008(1)  0.003(1) 
C(7) 0.029(1)  0.025(1) 0.030(1)  -0.003(1) -0.001(1)  0.008(1) 
C(8) 0.016(1)  0.021(1) 0.015(1)  0.000(1) 0.001(1)  0.002(1) 
C(9) 0.020(1)  0.022(1) 0.017(1)  -0.002(1) -0.004(1)  0.002(1) 
C(10) 0.022(1)  0.024(1) 0.019(1)  0.001(1) -0.004(1)  0.004(1) 
C(11) 0.022(1)  0.020(1) 0.018(1)  0.002(1) 0.001(1)  0.003(1) 
C(12) 0.023(1)  0.022(1) 0.021(1)  -0.002(1) -0.002(1)  0.000(1) 
C(13) 0.019(1)  0.024(1) 0.019(1)  -0.001(1) -0.003(1)  0.002(1) 
Br(1) 0.037(1)  0.021(1) 0.029(1)  0.004(1) -0.001(1)  0.007(1) 
O(1) 0.015(1)  0.020(1) 0.027(1)  0.002(1) 0.003(1)  0.002(1) 
___________________________________________________________________
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 Hydrogen coordinates and isotropic displacement parameters (Å2).  
_________________________________________________________________ 
 x  y  z  Ueq 
_________________________________________________________________ 
 
H(1) 0.2141 0.3330 0.5281 0.021 
H(2A) -0.0170 0.2890 0.6333 0.024 
H(2B) 0.1388 0.2996 0.7108 0.024 
H(5A) 0.3372 0.5309 0.5309 0.028 
H(5B) 0.4484 0.5707 0.6177 0.028 
H(6A) -0.1378 0.4383 0.7738 0.048 
H(6B) -0.2553 0.4399 0.6834 0.048 
H(6C) -0.1722 0.5580 0.7235 0.048 
H(7A) -0.0276 0.6816 0.6568 0.042 
H(7B) 0.1386 0.7068 0.5857 0.042 
H(7C) 0.1924 0.7061 0.6874 0.042 
H(9) 0.5614 0.2382 0.6845 0.024 
H(10) 0.6922 0.0506 0.6959 0.026 
H(12) 0.3031 -0.0630 0.5142 0.026 
H(13) 0.1743 0.1246 0.5029 0.025 
_________________________________________________________________ 
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X-ray structural analysis parameter for 22c: 
 
Identification code  10698  
Empirical formula  C83.20 H33 Cl3.80 F44.80 N3 O7.20 P2 S10 
Color  colourless 
Formula weight  2558.17  g·mol-1  
Temperature  100(2) K 
Wavelength  1.54178 Å 
Crystal system  orthorhombic 
Space group  P 21 21 2,  (no. 18)  
Unit cell dimensions a = 18.7656(13) Å α= 90°. 
 b = 41.726(3) Å β= 90°. 
 c = 14.4668(10) Å γ = 90°. 
Volume 11327.8(14) Å3 
Z 4 
Density (calculated) 1.500  Mg·m-3 
Absorption coefficient 4.015 mm-1 
F(000) 5074 e 
Crystal size 0.300 x 0.189 x 0.030 mm3 
θ range for data collection 4.831 to 63.596°. 
Index ranges -21 ≤ h ≤ 21, -47≤ k ≤ 48, -14≤ l ≤ 16 
Reflections collected 165258 
Independent reflections 18356 [Rint = 0.0717] 
Reflections with I>2σ(I) 16034 
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Completeness to θ = 63.596° 99.1 %  
Absorption correction Gaussian 
Max. and min. transmission 0.90830 and 0.51138 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 18356 / 46 / 1405 
Goodness-of-fit on F2 1.513 
Final R indices [I>2σ(I)] R1 = 0.0674 wR2 = 0.1847 
R indices (all data) R1 = 0.0785 wR2 = 0.1920 
Absolute structure parameter 0.031(4) 
Extinction coefficient 0 
Largest diff. peak and hole 0.905 and -0.805 e·Å-3 
 
The structure of the asymmetric unit in the crystal of 22c was obtained with crystal 
solvent (hexane and dichloromethane). The structure of 22c was solved by direct methods 
and refined by full-matrix least-squares against F2 to R1 = 0.0674 [I > 2σ(I)], wR2 = 
0.1920, 1405 parameters. The trifluoromethyl-sulfonyl-amino group is disordered over 
the two positions. In addition, the trifluoromethyl-sulfonyl-amino and trifluoromethyl-
sulfonyl-phosphazene groups are slightly disordered. The major components (80% 
occupation) could be located and refined. Only the S atoms of the minor triflate 
components could be located and refined. All non-H atoms of one of the two 
trifluoromethyl-sulfonyl-amino/phosphazene groups were refined with anisotropic atomic 
displacement parameters. The atomic displacement parameters of the F, C and O atoms 
of the second trifluoromethyl-sulfonyl-amino/phosphazene group were restrained to be 
isotropic with an effective standard deviation of 0.005, whereby the atomic displacement 
parameters of the three F atoms were constrained to be equal. For this tri-fluoromethyl-
sulfonyl-amino/phosphazene group the respective S...F, C−F and F...F distances were 
restrained to be equal with an effective standard deviation of 0.02, as were the S−C 
distances of both trifluoromethyl-sulfonyl-amino/phosphazene groups (total 46 
restraints). The solvate (dichloromethane/hexane) region of the crystal was modeled by C 
and Cl atoms of various occupancies and refined isotropic atomic displacement 
parameters. A void of 43.95 \%A, close to symmetry elements, remained (0.4 % of the 
unit cell volume, probe radius 1.2 \%A, grid spacing 0.7 \%A). The H atom attached to 
the trifluoromethyl-sulfonyl-amino group could not be located and was refined using a 
riding model, as were the other H atoms in the imidodiphosphorimidate (IDPI). The 
riding model used C-H distances of 0.95 Å and UH = 1.2 × UC (CHaromatic) and 0.88 Å and 
UH = 1.5 × UN (NH). S = 1.522, residual electron density 0.90 (0.82 Å from F6)/ -0.80 
(0.95 from F29) e Å-3. The Flack parameter (Parsons' method: Parsons, Flack and 
Wagner, Acta Cryst. B69 (2013) 249-259) is 0.031(4) [6454 quotients].  
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Atomic coordinates and equivalent isotropic displacement parameters (Å2). 
 Ueq is defined as one third of the trace of the orthogonalized Uij tensor. 
____________________________________________________________________ 
 x y z Ueq 
____________________________________________________________________ 
C(1) -0.0927(7) 0.3431(4) 0.5747(8) 0.068(4) 
C(2) 0.1322(13) 0.4636(6) 0.3201(18) 0.203(16) 
C(3) -0.1190(4) 0.3272(2) 0.2149(5) 0.027(2) 
C(4) -0.1132(4) 0.2951(2) 0.1997(4) 0.025(1) 
C(5) -0.1765(3) 0.2761(2) 0.1881(5) 0.026(2) 
C(6) -0.1755(4) 0.2426(2) 0.1802(5) 0.031(2) 
C(7) -0.2386(4) 0.2255(2) 0.1698(5) 0.033(2) 
C(8) -0.3053(4) 0.2416(2) 0.1692(5) 0.037(2) 
C(9) -0.3075(4) 0.2742(2) 0.1772(5) 0.030(2) 
C(10) -0.2437(3) 0.2927(2) 0.1873(5) 0.027(2) 
C(11) -0.2458(3) 0.3257(2) 0.1999(5) 0.028(2) 
C(12) -0.1853(4) 0.3440(2) 0.2145(5) 0.030(2) 
C(13) -0.1913(4) 0.3790(2) 0.2275(5) 0.031(2) 
C(14) -0.2424(4) 0.3916(2) 0.2894(6) 0.039(2) 
C(15) -0.2506(4) 0.4242(2) 0.2958(6) 0.043(2) 
C(16) -0.2105(5) 0.4456(2) 0.2446(7) 0.052(2) 
C(17) -0.1597(5) 0.4330(2) 0.1841(7) 0.048(2) 
C(18) -0.1497(4) 0.4002(2) 0.1766(6) 0.041(2) 
C(19) -0.0018(3) 0.2821(2) 0.2825(4) 0.024(1) 
C(20) -0.0423(3) 0.2793(2) 0.2040(5) 0.026(2) 
C(21) -0.0156(4) 0.2594(2) 0.1311(5) 0.027(2) 
C(22) -0.0490(4) 0.2573(2) 0.0444(5) 0.030(2) 
C(23) -0.0231(4) 0.2377(2) -0.0240(5) 0.037(2) 
C(24) 0.0378(4) 0.2190(2) -0.0065(5) 0.037(2) 
C(25) 0.0720(4) 0.2203(2) 0.0755(5) 0.032(2) 
C(26) 0.0476(4) 0.2411(2) 0.1460(5) 0.028(2) 
C(27) 0.0834(4) 0.2433(2) 0.2328(5) 0.028(2) 
C(28) 0.0595(3) 0.2632(2) 0.3005(4) 0.025(1) 
C(29) 0.0913(4) 0.2616(2) 0.3962(5) 0.029(2) 
C(30) 0.1641(4) 0.2630(2) 0.4099(5) 0.029(2) 
C(31) 0.1922(4) 0.2579(2) 0.4975(5) 0.029(2) 
C(32) 0.1477(4) 0.2506(2) 0.5721(5) 0.033(2) 
C(33) 0.0748(4) 0.2482(2) 0.5559(5) 0.031(2) 
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C(34) 0.0474(4) 0.2539(2) 0.4701(5) 0.028(2) 
C(35) 0.2607(4) 0.3532(2) 0.3578(5) 0.030(2) 
C(36) 0.2917(4) 0.3416(2) 0.2776(5) 0.030(2) 
C(37) 0.3657(4) 0.3473(2) 0.2622(5) 0.036(2) 
C(38) 0.3991(4) 0.3406(2) 0.1758(5) 0.036(2) 
C(39) 0.4693(4) 0.3488(2) 0.1631(6) 0.043(2) 
C(40) 0.5094(5) 0.3617(2) 0.2346(7) 0.050(2) 
C(41) 0.4793(4) 0.3686(2) 0.3167(6) 0.043(2) 
C(42) 0.4060(4) 0.3623(2) 0.3334(6) 0.036(2) 
C(43) 0.3726(4) 0.3715(2) 0.4160(6) 0.039(2) 
C(44) 0.2996(4) 0.3677(2) 0.4293(5) 0.034(2) 
C(45) 0.2668(4) 0.3808(2) 0.5138(5) 0.036(2) 
C(46) 0.2838(6) 0.4109(3) 0.5440(7) 0.063(3) 
C(47) 0.2534(6) 0.4231(3) 0.6257(7) 0.068(3) 
C(48) 0.2061(6) 0.4044(2) 0.6782(7) 0.061(3) 
C(49) 0.1888(4) 0.3742(2) 0.6464(5) 0.038(2) 
C(50) 0.2180(4) 0.3615(2) 0.5661(5) 0.034(2) 
C(51) 0.1884(4) 0.3429(2) 0.1702(5) 0.029(2) 
C(52) 0.2461(4) 0.3263(2) 0.2059(5) 0.029(2) 
C(53) 0.2586(3) 0.2949(2) 0.1730(5) 0.029(2) 
C(54) 0.3097(4) 0.2745(2) 0.2155(5) 0.033(2) 
C(55) 0.3197(4) 0.2431(2) 0.1826(5) 0.039(2) 
C(56) 0.2816(4) 0.2325(2) 0.1048(5) 0.036(2) 
C(57) 0.2323(4) 0.2515(2) 0.0623(5) 0.031(2) 
C(58) 0.2180(4) 0.2830(2) 0.0962(5) 0.029(2) 
C(59) 0.1651(4) 0.3033(2) 0.0572(5) 0.032(2) 
C(60) 0.1499(4) 0.3326(2) 0.0912(5) 0.026(2) 
C(61) 0.0998(4) 0.3548(2) 0.0421(5) 0.028(2) 
C(62) 0.1227(4) 0.3859(2) 0.0221(5) 0.031(2) 
C(63) 0.0815(4) 0.4055(2) -0.0332(5) 0.028(2) 
C(64) 0.0164(4) 0.3957(2) -0.0689(5) 0.035(2) 
C(65) -0.0058(4) 0.3648(2) -0.0458(5) 0.031(2) 
C(66) 0.0349(4) 0.3439(2) 0.0092(5) 0.032(2) 
C(67) -0.026(4) 0.5337(17) 0.623(5) 0.14(2) 
C(68) 0.036(2) 0.5669(11) 0.660(3) 0.083(12) 
C(69) 0.444(2) 0.3890(11) 0.913(3) 0.051(11) 
C(70) 0.3138(9) 0.3638(4) 0.9426(12) 0.107(5) 
C(71) 0.3838(17) 0.3577(7) 0.902(2) 0.178(11) 
C(72) 0.3852(12) 0.3514(5) 0.8029(16) 0.144(7) 
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C(73) 0.4503(14) 0.3365(6) 0.7647(19) 0.117(7) 
C(74) 0.6996(17) 0.3420(8) 0.559(2) 0.123(9) 
C(75) 0.529(5) 0.447(2) 0.782(7) 0.31(4) 
C(76) 0.534(5) 0.434(2) 0.662(6) 0.30(4) 
C(77) 0.352(3) 0.6380(12) 0.000(3) 0.077(12) 
C(78) 0.4494(12) 0.3193(5) 0.6588(16) 0.142(7) 
C(79) 0.437(2) 0.4626(10) 0.398(3) 0.262(17) 
C(80) 0.591(3) 0.3843(12) 0.596(4) 0.188(17) 
C(81) 0.6619(17) 0.3586(8) 0.602(2) 0.121(9) 
C(82) 0.3048(18) 0.4290(8) 0.151(2) 0.211(12) 
C(83) 0.348(5) 0.4560(17) 0.217(5) 0.33(3) 
C(84) 0.400(3) 0.4567(13) 0.322(5) 0.20(2) 
C(85) 0.380(3) 0.4419(14) 0.161(4) 0.108(16) 
C(86) 0.600(5) 0.389(3) 0.507(8) 0.13(3) 
C(87) 0.566(8) 0.419(4) 0.691(10) 0.25(6) 
C(88) 0.404(3) 0.4524(11) 0.234(4) 0.160(15) 
C(89) 0.281(5) 0.4597(18) 0.243(6) 0.28(3) 
C(90) 0.361(4) 0.4683(16) 0.056(5) 0.26(3) 
C(91) 0.326(5) 0.541(2) -0.091(7) 0.19(3) 
C(92) 0.320(3) 0.5505(16) 0.019(4) 0.118(18) 
C(93) 0.413(5) 0.549(2) 0.080(6) 0.18(3) 
C(94) 0.324(3) 0.5206(16) -0.022(5) 0.121(18) 
C(95) 0.342(2) 0.5822(11) -0.025(3) 0.079(11) 
C(96) 0.399(3) 0.3417(14) 0.669(4) 0.21(2) 
C(97) 0.308(5) 0.588(2) -0.102(7) 0.18(3) 
C(98) 0.359(7) 0.580(3) 0.044(9) 0.22(4) 
C(99) 0.701(5) 0.306(3) 0.537(7) 0.13(3) 
N(1) 0.0636(3) 0.3502(2) 0.3053(4) 0.036(2) 
N(2A) -0.0478(4) 0.3613(2) 0.4081(5) 0.048(2) 
N(2B) -0.0478(4) 0.3613(2) 0.4081(5) 0.048(2) 
N(3A) 0.1359(5) 0.4043(2) 0.3498(6) 0.066(2) 
N(3B) 0.1359(5) 0.4043(2) 0.3498(6) 0.066(2) 
O(1) -0.0571(2) 0.3453(1) 0.2326(4) 0.032(1) 
O(2) -0.0232(2) 0.3040(1) 0.3516(3) 0.028(1) 
O(3) 0.1863(2) 0.3488(1) 0.3700(3) 0.035(1) 
O(4) 0.1696(3) 0.3722(1) 0.2120(3) 0.031(1) 
O(5) -0.1466(5) 0.3905(2) 0.4826(6) 0.063(2) 
O(6) -0.1675(4) 0.3358(2) 0.4240(5) 0.048(2) 
O(7) 0.0153(8) 0.4304(3) 0.3361(9) 0.119(4) 
7 EXPERIMENTAL PART 
 
202 
   
O(8) 0.1010(12) 0.4386(5) 0.4791(13) 0.186(7) 
F(1) -0.1516(5) 0.3389(3) 0.6237(5) 0.107(4) 
F(2) -0.0569(5) 0.3175(2) 0.5644(6) 0.090(3) 
F(3) -0.0526(4) 0.3662(2) 0.6167(5) 0.083(3) 
F(4) 0.1332(19) 0.4545(8) 0.2377(19) 0.364(11) 
F(5) 0.0871(19) 0.4855(6) 0.332(2) 0.364(11) 
F(6) 0.1901(16) 0.4691(8) 0.353(2) 0.364(11) 
F(7) -0.3746(4) 0.4542(2) 0.4431(5) 0.084(2) 
F(8) -0.3467(3) 0.4643(1) 0.2980(5) 0.074(2) 
F(9) -0.2647(4) 0.4668(2) 0.4098(5) 0.080(2) 
F(10) -0.2924(4) 0.4173(2) 0.4545(4) 0.079(2) 
F(11) -0.3743(3) 0.4148(1) 0.3427(5) 0.069(2) 
F(12) -0.0636(5) 0.4838(2) 0.0563(7) 0.141(4) 
F(13) -0.0395(4) 0.4385(2) 0.1259(7) 0.112(3) 
F(14) -0.1259(6) 0.4420(2) 0.0260(5) 0.122(4) 
F(15) -0.1731(4) 0.4836(1) 0.1025(5) 0.093(2) 
F(16) -0.0849(4) 0.4798(2) 0.2040(6) 0.104(3) 
F(17) 0.3697(2) 0.2610(1) 0.5347(3) 0.045(1) 
F(18) 0.3022(2) 0.2373(1) 0.4315(3) 0.044(1) 
F(19) 0.2957(2) 0.2900(1) 0.4535(3) 0.040(1) 
F(20) 0.2773(2) 0.2823(1) 0.6041(3) 0.043(1) 
F(21) 0.2848(2) 0.2296(1) 0.5828(3) 0.046(1) 
F(22) -0.0297(2) 0.2222(2) 0.7298(3) 0.058(2) 
F(23) -0.0408(2) 0.2600(1) 0.6255(3) 0.047(1) 
F(24) -0.0201(2) 0.2088(1) 0.5841(3) 0.047(1) 
F(25) 0.0747(2) 0.2079(1) 0.6785(3) 0.041(1) 
F(26) 0.0535(2) 0.2588(1) 0.7194(3) 0.045(1) 
F(27) 0.2966(9) 0.4976(3) 0.6963(8) 0.234(9) 
F(28) 0.1908(6) 0.4710(2) 0.6838(7) 0.133(4) 
F(29) 0.2658(7) 0.4768(2) 0.5627(7) 0.144(5) 
F(30) 0.3572(7) 0.4570(3) 0.6434(7) 0.170(6) 
F(31) 0.2857(8) 0.4506(3) 0.7654(7) 0.193(7) 
F(32) 0.0732(3) 0.3289(1) 0.7669(4) 0.059(1) 
F(33) 0.0735(3) 0.3790(1) 0.7210(4) 0.050(1) 
F(34) 0.1630(3) 0.3595(2) 0.8062(3) 0.064(2) 
F(35) 0.1766(3) 0.3195(1) 0.7041(4) 0.058(1) 
F(36) 0.0881(2) 0.3390(1) 0.6195(3) 0.047(1) 
F(37) 0.1457(3) 0.4783(1) -0.0944(4) 0.056(1) 
F(38) 0.0959(3) 0.4390(1) -0.1701(3) 0.047(1) 
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F(39) 0.1926(2) 0.4305(1) -0.0841(4) 0.049(1) 
F(40) 0.1370(3) 0.4524(1) 0.0370(3) 0.047(1) 
F(41) 0.0406(3) 0.4607(1) -0.0502(4) 0.047(1) 
F(42) -0.1634(2) 0.3399(1) -0.1351(3) 0.049(1) 
F(43) -0.0573(2) 0.3176(1) -0.1228(3) 0.043(1) 
F(44) -0.0710(3) 0.3654(1) -0.1918(3) 0.049(1) 
F(45) -0.1280(2) 0.3835(1) -0.0675(3) 0.047(1) 
F(46) -0.1138(2) 0.3362(1) 0.0016(3) 0.041(1) 
P(1) -0.0144(1) 0.3413(1) 0.3268(1) 0.029(1) 
P(2) 0.1328(1) 0.3696(1) 0.3114(1) 0.032(1) 
S(1A) -0.1190(1) 0.3589(1) 0.4613(2) 0.036(1) 
S(1B) -0.0649(7) 0.3753(4) 0.4756(10) 0.069(4) 
S(3) -0.3172(1) 0.4402(1) 0.3746(2) 0.058(1) 
S(2A) 0.0916(2) 0.4294(1) 0.3878(3) 0.068(1) 
S(2B) 0.1563(11) 0.4310(4) 0.3799(12) 0.082(5) 
S(4) -0.1079(2) 0.4601(1) 0.1158(3) 0.087(1) 
S(5) 0.2868(1) 0.2595(1) 0.5178(1) 0.033(1) 
S(6) 0.0186(1) 0.2345(1) 0.6485(1) 0.039(1) 
S(7) 0.2751(3) 0.4630(1) 0.6628(3) 0.145(2) 
S(8) 0.1270(1) 0.3501(1) 0.7103(1) 0.040(1) 
S(9) 0.1155(1) 0.4446(1) -0.0650(1) 0.040(1) 
S(10) -0.0899(1) 0.3512(1) -0.0941(1) 0.037(1) 
Cl(1) 0.3225(15) 0.6421(7) -0.026(2) 0.180(10) 
Cl(2) 0.336(3) 0.6082(14) 0.027(3) 0.304(19) 
Cl(3) 0.1011(8) 0.5567(4) 0.4146(11) 0.122(4) 
Cl(4) 0.0986(12) 0.5123(5) 0.5210(15) 0.113(6) 
Cl(5) 0.6299(6) 0.3380(3) 0.4771(8) 0.095(3) 
Cl(6) 0.6318(11) 0.3333(5) 0.5244(15) 0.175(7) 
Cl(7) 0.6658(7) 0.3332(3) 0.6724(9) 0.113(4) 
Cl(8) 0.6984(12) 0.3277(5) 0.6874(14) 0.137(6) 
Cl(9) 0.2268(11) 0.5852(5) 0.7243(15) 0.152(6) 
Cl(10) 0.0796(9) 0.5422(4) 0.7731(12) 0.117(4) 
Cl(11) 0.1244(9) 0.5479(4) 0.7886(11) 0.111(4) 
Cl(12)        0.1749(16)      0.5665(7)      0.680(2)     0.202(10)     
_________________________________________________________________ 
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Bond lengths [Å] and angles [°]. 
___________________________________________________________________ 
C(1)-F(2) 1.273(17) C(1)-F(1)                 1.325(15)
C(1)-F(3) 1.365(17) C(1)-S(1A)             1.836(13)
C(1)-S(1B) 2.03(2) C(2)-F(6) 1.21(3)
C(2)-F(4) 1.25(3) C(2)-F(5) 1.26(3)
C(2)-S(2B) 1.68(3) C(2)-S(2A) 1.89(3)
C(3)-C(4) 1.359(10) C(3)-O(1) 1.410(8)
C(3)-C(12) 1.430(10) C(4)-C(5)                  1.439(10)
C(4)-C(20) 1.488(10) C(5)-C(6)                1.405(10)
C(5)-C(10) 1.437(10) C(6)-C(7)              1.389(10)
C(7)-C(8) 1.422(11) C(8)-C(9)                1.365(11)
C(9)-C(10) 1.433(10) C(10)-C(11)      1.388(10)
C(11)-C(12) 1.386(10) C(12)-C(13)      1.474(10)
C(13)-C(18) 1.390(11) C(13)-C(14)      1.415(11)
C(14)-C(15) 1.370(12) C(15)-C(16)      1.382(12)
C(15)-S(3) 1.817(8) C(16)-C(17)       1.396(13)
C(17)-C(18) 1.387(12) C(17)-S(4) 1.788(9)
C(19)-C(20) 1.372(9) C(19)-O(2) 1.413(8)
C(19)-C(28) 1.418(9) C(20)-C(21)      1.432(10)
C(21)-C(22) 1.405(10) C(21)-C(26)      1.427(10)
C(22)-C(23) 1.372(10) C(23)-C(24)       1.410(11)
C(24)-C(25) 1.350(11) C(25)-C(26)      1.414(10)
C(26)-C(27) 1.427(10) C(27)-C(28)        1.361(10)
C(28)-C(29) 1.509(9) C(29)-C(30)      1.383(10)
C(29)-C(34) 1.388(10) C(30)-C(31)      1.389(10)
C(31)-C(32) 1.397(10) C(31)-S(5) 1.801(7)
C(32)-C(33) 1.390(10) C(33)-C(34)      1.365(10)
C(33)-S(6) 1.798(7) C(35)-C(36)      1.385(10)
C(35)-C(44) 1.403(10) C(35)-O(3) 1.420(8)
C(36)-C(37) 1.425(10) C(36)-C(52)      1.488(10)
C(37)-C(42) 1.424(11) C(37)-C(38)      1.425(11)
C(38)-C(39) 1.375(11) C(39)-C(40)      1.388(12)
C(40)-C(41) 1.348(12) C(41)-C(42)      1.420(11)
C(42)-C(43) 1.404(12) C(43)-C(44)      1.392(11)
C(44)-C(45) 1.473(11) C(45)-C(46)      1.368(12)
C(45)-C(50) 1.432(11) C(46)-C(47)      1.409(13)
C(47)-C(48) 1.406(14) C(47)-S(7)        1.795(10)
C(48)-C(49) 1.377(12) C(49)-C(50)      1.390(11)
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C(49)-S(8) 1.793(8) C(51)-C(52)      1.385(10)
C(51)-O(4) 1.408(9) C(51)-C(60)      1.420(10)
C(52)-C(53) 1.414(11) C(53)-C(54)      1.425(10)
C(53)-C(58) 1.435(10) C(54)-C(55)      1.406(12)
C(55)-C(56) 1.404(11) C(56)-C(57)      1.363(11)
C(57)-C(58) 1.431(10) C(58)-C(59)      1.420(10)
C(59)-C(60) 1.350(10) C(60)-C(61)       1.500(10)
C(61)-C(66) 1.385(10) C(61)-C(62)      1.394(10)
C(62)-C(63) 1.381(10) C(63)-C(64)      1.386(11)
C(63)-S(9) 1.813(7) C(64)-C(65)       1.398(10)
C(65)-C(66) 1.406(10) C(65)-S(10) 1.817(7)
C(67)-C(68) 1.89(8) C(68)-Cl(10) 2.10(5)
C(69)-C(71) 1.74(5) C(70)-C(71) 1.46(3)
C(71)-C(72) 1.46(3) C(72)-C(73) 1.48(3)
C(72)-C(96) 2.00(6) C(73)-C(78) 1.69(3)
C(73)-C(96) 1.70(6) C(74)-C(81) 1.17(4)
C(74)-Cl(6) 1.42(3) C(74)-C(99) 1.54(11)
C(74)-Cl(5) 1.78(3) C(74)-Cl(7) 1.79(4)
C(74)-Cl(8) 1.95(4) C(75)-C(76) 1.82(12)
C(75)-C(87) 1.89(16) C(76)-C(87) 0.96(16)
C(77)-Cl(1) 0.68(5) C(77)-Cl(2) 1.34(6)
C(78)-C(96) 1.34(5) C(79)-C(84) 1.32(6)
C(80)-C(86) 1.32(10) C(80)-C(81) 1.72(5)
C(81)-Cl(7) 1.47(3) C(81)-Cl(6) 1.64(4)
C(81)-Cl(8) 1.91(4) C(81)-Cl(5) 2.09(3)
C(82)-C(85) 1.52(7) C(82)-C(83) 1.68(7)
C(82)-C(89) 1.90(9) C(83)-C(88) 1.09(8)
C(83)-C(85) 1.17(9) C(83)-C(89) 1.32(9)
C(83)-C(84) 1.81(9) C(84)-C(88) 1.29(6)
C(85)-C(88) 1.23(7) C(85)-C(90) 1.91(9)
C(86)-Cl(5) 2.26(10) C(91)-C(94) 1.32(10)
C(91)-C(92) 1.64(11) C(91)-C(97) 1.97(13)
C(91)-C(95) 1.97(11) C(92)-C(94) 1.38(8)
C(92)-C(98) 1.47(13) C(92)-C(95) 1.52(8)
C(92)-C(93) 1.95(11) C(93)-C(98) 1.70(14)
C(95)-C(98) 1.06(12) C(95)-C(97) 1.30(9)
C(95)-Cl(2) 1.33(6) C(97)-Cl(2) 2.12(10)
C(98)-Cl(2) 1.28(13) C(99)-Cl(6) 1.74(10)
C(99)-Cl(5) 2.08(10) N(1)-P(2) 1.531(6)
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N(1)-P(1) 1.543(6) N(2A)-S(1A) 1.545(7)
N(2A)-P(1) 1.573(6) N(2B)-S(1B)     1.183(15)
N(2B)-P(1) 1.573(6) N(3A)-S(2A) 1.445(9)
N(3A)-P(2) 1.553(8) N(3B)-S(2B)      1.256(17)
N(3B)-P(2) 1.553(8) O(1)-P(1) 1.589(5)
O(2)-P(1) 1.604(5) O(3)-P(2) 1.575(5)
O(4)-P(2) 1.600(5) O(5)-S(1A) 1.447(8)
O(6)-S(1A) 1.434(7) O(7)-S(2A)             1.615(16)
O(8)-S(2A) 1.386(18) F(7)-S(3) 1.576(6)
F(8)-S(3) 1.596(7) F(9)-S(3) 1.570(7)
F(10)-S(3) 1.568(7) F(11)-S(3) 1.577(6)
F(12)-S(4) 1.553(7) F(13)-S(4) 1.575(8)
F(14)-S(4) 1.539(10) F(15)-S(4) 1.580(7)
F(16)-S(4) 1.578(9) F(17)-S(5) 1.577(4)
F(18)-S(5) 1.583(5) F(19)-S(5) 1.584(5)
F(20)-S(5) 1.579(5) F(21)-S(5) 1.564(5)
F(22)-S(6) 1.570(5) F(23)-S(6) 1.576(5)
F(24)-S(6) 1.596(5) F(25)-S(6) 1.590(5)
F(26)-S(6) 1.583(5) F(27)-S(7) 1.578(8)
F(28)-S(7) 1.645(12) F(29)-S(7)         1.570(12)
F(30)-S(7) 1.587(14) F(31)-S(7)         1.583(14)
F(32)-S(8) 1.571(5) F(33)-S(8) 1.577(5)
F(34)-S(8) 1.592(5) F(35)-S(8) 1.583(5)
F(36)-S(8) 1.573(5) F(37)-S(9) 1.575(5)
F(38)-S(9) 1.581(5) F(39)-S(9) 1.587(5)
F(40)-S(9) 1.565(5) F(41)-S(9) 1.573(5)
F(42)-S(10) 1.574(5) F(43)-S(10) 1.583(5)
F(44)-S(10) 1.573(5) F(45)-S(10) 1.576(5)
F(46)-S(10) 1.584(5) Cl(1)-Cl(2) 1.63(6)
Cl(3)-Cl(4) 2.41(3) Cl(5)-Cl(6) 0.71(2)
Cl(6)-Cl(7) 2.24(3) Cl(7)-Cl(8) 0.69(2)
Cl(9)-Cl(12) 1.41(3) Cl(10)-Cl(11)    0.901(18)
Cl(10)-Cl(12) 2.46(3) Cl(11)-Cl(12) 2.00(3) 
 
F(2)-C(1)-F(1) 113.0(14) F(2)-C(1)-F(3)       110.8(12)
F(1)-C(1)-F(3) 108.4(11) F(2)-C(1)-S(1A) 109.9(9)
F(1)-C(1)-S(1A) 107.5(9) F(3)-C(1)-S(1A)    107.0(10)
F(6)-C(2)-F(4) 115(2) F(6)-C(2)-F(5) 114(2)
F(4)-C(2)-F(5) 111(2) F(6)-C(2)-S(2A) 107(2)
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F(4)-C(2)-S(2A) 106(2) F(5)-C(2)-S(2A) 102(2)
C(4)-C(3)-O(1) 119.5(6) C(4)-C(3)-C(12) 123.6(7)
O(1)-C(3)-C(12) 117.0(6) C(3)-C(4)-C(5) 119.7(6)
C(3)-C(4)-C(20) 120.2(6) C(5)-C(4)-C(20) 119.9(6)
C(6)-C(5)-C(10) 119.4(6) C(6)-C(5)-C(4) 123.2(6)
C(10)-C(5)-C(4) 117.3(6) C(7)-C(6)-C(5) 120.6(7)
C(6)-C(7)-C(8) 120.6(7) C(9)-C(8)-C(7) 119.8(7)
C(8)-C(9)-C(10) 121.4(7) C(11)-C(10)-C(9) 121.6(6)
C(11)-C(10)-C(5) 120.1(6) C(9)-C(10)-C(5) 118.2(6)
C(12)-C(11)-C(10) 123.0(6) C(11)-C(12)-C(3) 116.2(7)
C(11)-C(12)-C(13) 120.3(7) C(3)-C(12)-C(13) 123.5(6)
C(18)-C(13)-C(14) 118.5(7) C(18)-C(13)-C(12) 121.3(7)
C(14)-C(13)-C(12) 120.1(7) C(15)-C(14)-C(13) 119.3(8)
C(14)-C(15)-C(16) 122.8(8) C(14)-C(15)-S(3) 118.9(7)
C(16)-C(15)-S(3) 118.3(6) C(15)-C(16)-C(17) 117.7(8)
C(18)-C(17)-C(16) 120.9(8) C(18)-C(17)-S(4) 120.4(7)
C(16)-C(17)-S(4) 118.7(7) C(17)-C(18)-C(13) 120.7(8)
C(20)-C(19)-O(2) 119.0(6) C(20)-C(19)-C(28) 123.6(6)
O(2)-C(19)-C(28) 117.4(5) C(19)-C(20)-C(21) 117.8(6)
C(19)-C(20)-C(4) 119.4(6) C(21)-C(20)-C(4) 122.7(6)
C(22)-C(21)-C(26) 118.2(6) C(22)-C(21)-C(20) 122.5(6)
C(26)-C(21)-C(20) 119.3(6) C(23)-C(22)-C(21) 121.5(7)
C(22)-C(23)-C(24) 119.3(7) C(25)-C(24)-C(23) 121.3(7)
C(24)-C(25)-C(26) 120.4(7) C(25)-C(26)-C(27) 121.5(6)
C(25)-C(26)-C(21) 119.2(6) C(27)-C(26)-C(21) 119.3(6)
C(28)-C(27)-C(26) 121.2(6) C(27)-C(28)-C(19) 118.3(6)
C(27)-C(28)-C(29) 120.2(6) C(19)-C(28)-C(29) 120.9(6)
C(30)-C(29)-C(34) 119.1(6) C(30)-C(29)-C(28) 121.4(6)
C(34)-C(29)-C(28) 118.9(6) C(29)-C(30)-C(31) 120.0(6)
C(30)-C(31)-C(32) 120.8(6) C(30)-C(31)-S(5) 121.1(5)
C(32)-C(31)-S(5) 118.1(5) C(33)-C(32)-C(31) 118.3(7)
C(34)-C(33)-C(32) 120.8(7) C(34)-C(33)-S(6) 120.7(5)
C(32)-C(33)-S(6) 118.4(6) C(33)-C(34)-C(29) 121.2(6)
C(36)-C(35)-C(44) 123.3(6) C(36)-C(35)-O(3) 118.2(6)
C(44)-C(35)-O(3) 118.4(6) C(35)-C(36)-C(37) 118.8(7)
C(35)-C(36)-C(52) 119.4(6) C(37)-C(36)-C(52) 121.5(7)
C(42)-C(37)-C(38) 119.1(7) C(42)-C(37)-C(36) 118.5(7)
C(38)-C(37)-C(36) 122.2(7) C(39)-C(38)-C(37) 119.3(8)
C(38)-C(39)-C(40) 121.2(8) C(41)-C(40)-C(39) 120.8(8)
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C(40)-C(41)-C(42) 121.1(8) C(43)-C(42)-C(41) 121.8(7)
C(43)-C(42)-C(37) 119.9(7) C(41)-C(42)-C(37) 118.3(7)
C(44)-C(43)-C(42) 121.8(7) C(43)-C(44)-C(35) 117.3(7)
C(43)-C(44)-C(45) 119.0(7) C(35)-C(44)-C(45) 123.6(7)
C(46)-C(45)-C(50) 119.7(8) C(46)-C(45)-C(44) 120.4(7)
C(50)-C(45)-C(44) 119.9(7) C(45)-C(46)-C(47) 120.4(9)
C(48)-C(47)-C(46) 120.5(9) C(48)-C(47)-S(7) 119.8(7)
C(46)-C(47)-S(7) 119.7(8) C(49)-C(48)-C(47) 118.4(8)
C(48)-C(49)-C(50) 122.3(8) C(48)-C(49)-S(8) 119.5(6)
C(50)-C(49)-S(8) 118.2(6) C(49)-C(50)-C(45) 118.7(7)
C(52)-C(51)-O(4) 118.0(6) C(52)-C(51)-C(60) 123.1(7)
O(4)-C(51)-C(60) 118.8(6) C(51)-C(52)-C(53) 117.9(6)
C(51)-C(52)-C(36) 119.7(7) C(53)-C(52)-C(36) 122.4(6)
C(52)-C(53)-C(54) 121.5(7) C(52)-C(53)-C(58) 119.5(6)
C(54)-C(53)-C(58) 118.9(7) C(55)-C(54)-C(53) 120.1(7)
C(56)-C(55)-C(54) 119.7(7) C(57)-C(56)-C(55) 121.6(7)
C(56)-C(57)-C(58) 120.5(7) C(59)-C(58)-C(57) 122.8(6)
C(59)-C(58)-C(53) 118.2(6) C(57)-C(58)-C(53) 119.0(7)
C(60)-C(59)-C(58) 122.9(7) C(59)-C(60)-C(51) 117.4(6)
C(59)-C(60)-C(61) 121.5(6) C(51)-C(60)-C(61) 120.8(6)
C(66)-C(61)-C(62) 120.3(7) C(66)-C(61)-C(60) 120.7(6)
C(62)-C(61)-C(60) 118.7(6) C(63)-C(62)-C(61) 119.9(6)
C(62)-C(63)-C(64) 122.3(6) C(62)-C(63)-S(9) 118.9(5)
C(64)-C(63)-S(9) 118.7(5) C(63)-C(64)-C(65) 116.5(7)
C(64)-C(65)-C(66) 123.0(7) C(64)-C(65)-S(10) 117.2(5)
C(66)-C(65)-S(10) 119.7(5) C(61)-C(66)-C(65) 117.9(7)
C(67)-C(68)-Cl(10) 96(3) C(70)-C(71)-C(72) 116(3)
C(70)-C(71)-C(69) 115(3) C(72)-C(71)-C(69) 102(3)
C(71)-C(72)-C(73) 117(2) C(71)-C(72)-C(96) 173(3)
C(73)-C(72)-C(96) 56(2) C(72)-C(73)-C(78) 121(2)
C(72)-C(73)-C(96) 78(2) C(78)-C(73)-C(96) 46(2)
C(81)-C(74)-Cl(6) 78(3) C(81)-C(74)-C(99) 135(5)
Cl(6)-C(74)-C(99) 72(4) C(81)-C(74)-Cl(5) 88(3)
C(99)-C(74)-Cl(5) 77(4) C(81)-C(74)-Cl(7) 55(2)
Cl(6)-C(74)-Cl(7) 87(2) C(99)-C(74)-Cl(7) 90(4)
Cl(5)-C(74)-Cl(7) 109.3(19) C(81)-C(74)-Cl(8) 71(2)
Cl(6)-C(74)-Cl(8) 105(2) C(99)-C(74)-Cl(8) 84(4)
Cl(5)-C(74)-Cl(8) 127(2) C(87)-C(76)-C(75) 79(10)
Cl(1)-C(77)-Cl(2) 102(6) C(96)-C(78)-C(73) 67(3)
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C(86)-C(80)-C(81) 93(6) C(74)-C(81)-Cl(7) 85(3)
C(74)-C(81)-Cl(6) 58(2) Cl(7)-C(81)-Cl(6) 91(2)
C(74)-C(81)-C(80) 145(4) Cl(7)-C(81)-C(80) 121(3)
Cl(6)-C(81)-C(80) 96(2) C(74)-C(81)-Cl(8) 74(2)
Cl(6)-C(81)-Cl(8) 97.5(19) C(80)-C(81)-Cl(8) 137(3)
C(74)-C(81)-Cl(5) 58(2) Cl(7)-C(81)-Cl(5)  108.4(19)
C(80)-C(81)-Cl(5) 90(2) Cl(8)-C(81)-Cl(5) 112.5(17)
C(85)-C(82)-C(89) 85(4) C(88)-C(83)-C(85) 66(7)
C(88)-C(83)-C(89) 150(10) C(85)-C(83)-C(89) 139(10)
C(88)-C(83)-C(82) 120(8) C(85)-C(83)-C(82) 62(5)
C(89)-C(83)-C(82) 78(6) C(88)-C(83)-C(84) 45(4)
C(85)-C(83)-C(84) 108(7) C(89)-C(83)-C(84) 105(7)
C(82)-C(83)-C(84) 138(5) C(88)-C(84)-C(79) 144(6)
C(79)-C(84)-C(83) 170(6) C(83)-C(85)-C(88) 54(5)
C(83)-C(85)-C(82) 76(6) C(88)-C(85)-C(82) 123(5)
C(83)-C(85)-C(90) 99(6) C(88)-C(85)-C(90) 123(5)
C(82)-C(85)-C(90) 87(4) C(80)-C(86)-Cl(5) 94(6)
C(76)-C(87)-C(75) 71(10) C(83)-C(88)-C(85) 60(5)
C(83)-C(88)-C(84) 99(7) C(85)-C(88)-C(84) 152(6)
C(83)-C(89)-C(82) 60(5) C(94)-C(91)-C(92) 54(5)
C(94)-C(91)-C(97) 135(8) C(92)-C(91)-C(97) 81(6)
C(94)-C(91)-C(95) 102(7) C(92)-C(91)-C(95) 49(4)
C(94)-C(92)-C(98) 146(8) C(94)-C(92)-C(95) 126(6)
C(94)-C(92)-C(91) 51(5) C(98)-C(92)-C(91) 114(7)
C(95)-C(92)-C(91) 77(5) C(94)-C(92)-C(93) 98(5)
C(98)-C(92)-C(93) 58(6) C(95)-C(92)-C(93) 89(4)
C(91)-C(92)-C(93) 113(6) C(98)-C(93)-C(92) 47(5)
C(91)-C(94)-C(92) 75(6) C(98)-C(95)-C(97) 167(10)
C(98)-C(95)-Cl(2) 64(8) C(97)-C(95)-Cl(2) 108(6)
C(98)-C(95)-C(92) 67(8) C(97)-C(95)-C(92) 113(6)
Cl(2)-C(95)-C(92) 117(5) C(98)-C(95)-C(91) 115(9)
C(97)-C(95)-C(91) 70(5) Cl(2)-C(95)-C(91) 165(5)
C(92)-C(95)-C(91) 54(4) C(78)-C(96)-C(73) 66(3)
C(78)-C(96)-C(72) 110(4) C(73)-C(96)-C(72) 46.1(17)
C(95)-C(97)-C(91) 71(6) C(91)-C(97)-Cl(2) 106(6)
C(95)-C(98)-Cl(2) 68(9) C(95)-C(98)-C(92) 72(8)
Cl(2)-C(98)-C(92) 123(10) C(95)-C(98)-C(93) 123(10)
Cl(2)-C(98)-C(93) 161(10) C(92)-C(98)-C(93) 75(8)
C(74)-C(99)-Cl(6) 51(3) C(74)-C(99)-Cl(5) 57(4)
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P(2)-N(1)-P(1) 157.1(5) S(1A)-N(2A)-P(1) 133.1(5)
S(1B)-N(2B)-P(1) 171.2(9) S(2A)-N(3A)-P(2) 142.2(7)
S(2B)-N(3B)-P(2) 164.4(12) C(3)-O(1)-P(1) 120.9(4)
C(19)-O(2)-P(1) 116.1(4) C(35)-O(3)-P(2) 119.2(5)
C(51)-O(4)-P(2) 115.8(4) N(1)-P(1)-N(2B) 113.6(4)
N(1)-P(1)-N(2A) 113.6(4) N(1)-P(1)-O(1) 106.3(3)
N(2B)-P(1)-O(1) 112.5(4) N(2A)-P(1)-O(1) 112.5(4)
N(1)-P(1)-O(2) 112.2(3) N(2B)-P(1)-O(2) 107.9(3)
N(2A)-P(1)-O(2) 107.9(3) O(1)-P(1)-O(2) 104.1(3)
N(1)-P(2)-N(3B) 123.0(4) N(1)-P(2)-N(3A) 123.0(4)
N(1)-P(2)-O(3) 106.3(3) N(3B)-P(2)-O(3) 107.3(4)
N(3A)-P(2)-O(3) 107.3(4) N(1)-P(2)-O(4) 110.6(3)
N(3B)-P(2)-O(4) 104.0(4) N(3A)-P(2)-O(4) 104.0(4)
O(3)-P(2)-O(4) 104.3(3) O(6)-S(1A)-O(5) 117.8(5)
O(6)-S(1A)-N(2A) 113.8(4) O(5)-S(1A)-N(2A) 110.9(5)
O(6)-S(1A)-C(1) 105.4(6) O(5)-S(1A)-C(1) 103.4(6)
N(2A)-S(1A)-C(1) 103.6(5) N(2B)-S(1B)-C(1) 109.1(12)
F(10)-S(3)-F(9) 90.3(4) F(10)-S(3)-F(7) 87.9(4)
F(9)-S(3)-F(7) 87.8(3) F(10)-S(3)-F(11) 90.5(4)
F(9)-S(3)-F(11) 175.9(3) F(7)-S(3)-F(11) 88.2(3)
F(10)-S(3)-F(8) 176.0(3) F(9)-S(3)-F(8) 89.8(4)
F(7)-S(3)-F(8) 88.0(4) F(11)-S(3)-F(8) 89.1(4)
F(10)-S(3)-C(15) 92.1(4) F(9)-S(3)-C(15) 91.9(4)
F(7)-S(3)-C(15) 179.7(4) F(11)-S(3)-C(15) 92.1(3)
F(8)-S(3)-C(15) 91.9(4) O(8)-S(2A)-N(3A) 119.4(9)
O(8)-S(2A)-O(7) 123.2(10) N(3A)-S(2A)-O(7) 110.7(6)
O(8)-S(2A)-C(2) 103.3(13) N(3A)-S(2A)-C(2) 96.7(8)
O(7)-S(2A)-C(2) 95.5(9) N(3B)-S(2B)-C(2) 117.3(16)
F(14)-S(4)-F(12) 87.7(5) F(14)-S(4)-F(13) 88.7(5)
F(12)-S(4)-F(13) 88.8(4) F(14)-S(4)-F(16) 175.8(5)
F(12)-S(4)-F(16) 88.3(5) F(13)-S(4)-F(16) 90.0(5)
F(14)-S(4)-F(15) 91.8(5) F(12)-S(4)-F(15) 87.2(4)
F(13)-S(4)-F(15) 176.0(4) F(16)-S(4)-F(15) 89.2(4)
F(14)-S(4)-C(17) 92.2(4) F(12)-S(4)-C(17) 179.4(5)
F(13)-S(4)-C(17) 91.7(4) F(16)-S(4)-C(17) 91.8(4)
F(15)-S(4)-C(17) 92.2(4) F(21)-S(5)-F(17) 87.9(3)
F(21)-S(5)-F(20) 90.2(3) F(17)-S(5)-F(20) 88.0(2)
F(21)-S(5)-F(18) 90.6(3) F(17)-S(5)-F(18) 88.0(2)
F(20)-S(5)-F(18) 175.8(3) F(21)-S(5)-F(19) 175.2(2)
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F(17)-S(5)-F(19) 87.3(3) F(20)-S(5)-F(19) 89.5(3)
F(18)-S(5)-F(19) 89.3(3) F(21)-S(5)-C(31) 92.5(3)
F(17)-S(5)-C(31) 179.5(3) F(20)-S(5)-C(31) 92.4(3)
F(18)-S(5)-C(31) 91.7(3) F(19)-S(5)-C(31) 92.3(3)
F(22)-S(6)-F(23) 88.3(3) F(22)-S(6)-F(26) 87.8(3)
F(23)-S(6)-F(26) 89.9(3) F(22)-S(6)-F(25) 87.1(3)
F(23)-S(6)-F(25) 175.4(3) F(26)-S(6)-F(25) 89.7(3)
F(22)-S(6)-F(24) 87.4(3) F(23)-S(6)-F(24) 90.5(3)
F(26)-S(6)-F(24) 175.2(3) F(25)-S(6)-F(24) 89.6(3)
F(22)-S(6)-C(33) 179.2(4) F(23)-S(6)-C(33) 92.5(3)
F(26)-S(6)-C(33) 92.1(3) F(25)-S(6)-C(33) 92.0(3)
F(24)-S(6)-C(33) 92.6(3) F(29)-S(7)-F(27) 88.5(6)
F(29)-S(7)-F(31) 177.2(5) F(27)-S(7)-F(31) 88.7(7)
F(29)-S(7)-F(30) 90.1(6) F(27)-S(7)-F(30) 87.0(7)
F(31)-S(7)-F(30) 89.6(8) F(29)-S(7)-F(28) 89.4(7)
F(27)-S(7)-F(28) 90.3(7) F(31)-S(7)-F(28) 90.8(6)
F(30)-S(7)-F(28) 177.2(5) F(29)-S(7)-C(47) 92.3(5)
F(27)-S(7)-C(47) 178.1(10) F(31)-S(7)-C(47) 90.5(5)
F(30)-S(7)-C(47) 91.3(5) F(28)-S(7)-C(47) 91.4(5)
F(32)-S(8)-F(36) 88.3(3) F(32)-S(8)-F(33) 88.3(3)
F(36)-S(8)-F(33) 90.7(3) F(32)-S(8)-F(35) 87.4(3)
F(36)-S(8)-F(35) 89.3(3) F(33)-S(8)-F(35) 175.7(3)
F(32)-S(8)-F(34) 87.6(3) F(36)-S(8)-F(34) 175.9(3)
F(33)-S(8)-F(34) 89.8(3) F(35)-S(8)-F(34) 89.9(3)
F(32)-S(8)-C(49) 179.6(4) F(36)-S(8)-C(49) 92.0(3)
F(33)-S(8)-C(49) 91.8(3) F(35)-S(8)-C(49) 92.5(3)
F(34)-S(8)-C(49) 92.1(3) F(40)-S(9)-F(41) 90.7(3)
F(40)-S(9)-F(37) 88.6(3) F(41)-S(9)-F(37) 88.7(3)
F(40)-S(9)-F(38) 176.2(3) F(41)-S(9)-F(38) 89.2(3)
F(37)-S(9)-F(38) 87.6(3) F(40)-S(9)-F(39) 90.4(3)
F(41)-S(9)-F(39) 176.1(3) F(37)-S(9)-F(39) 87.6(3)
F(38)-S(9)-F(39) 89.4(3) F(40)-S(9)-C(63) 92.2(3)
F(41)-S(9)-C(63) 92.0(3) F(37)-S(9)-C(63) 178.9(3)
F(38)-S(9)-C(63) 91.6(3) F(39)-S(9)-C(63) 91.7(3)
F(44)-S(10)-F(42) 88.4(3) F(44)-S(10)-F(45) 89.9(3)
F(42)-S(10)-F(45) 87.2(3) F(44)-S(10)-F(43) 90.7(3)
F(42)-S(10)-F(43) 88.6(3) F(45)-S(10)-F(43) 175.8(3)
F(44)-S(10)-F(46) 176.3(3) F(42)-S(10)-F(46) 87.9(3)
F(45)-S(10)-F(46) 89.8(3) F(43)-S(10)-F(46) 89.4(3)
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F(44)-S(10)-C(65) 91.8(3) F(42)-S(10)-C(65) 179.0(4)
F(45)-S(10)-C(65) 91.8(3) F(43)-S(10)-C(65) 92.4(3)
F(46)-S(10)-C(65) 91.9(3) C(77)-Cl(1)-Cl(2) 53(5)
C(98)-Cl(2)-C(95) 48(6) C(98)-Cl(2)-C(77) 147(8)
C(95)-Cl(2)-C(77) 125(5) C(98)-Cl(2)-Cl(1) 161(8)
C(95)-Cl(2)-Cl(1) 117(4) C(98)-Cl(2)-C(97) 83(7)
C(77)-Cl(2)-C(97) 100(4) Cl(1)-Cl(2)-C(97) 84(4)
Cl(6)-Cl(5)-C(74) 49(2) Cl(6)-Cl(5)-C(99) 53(3)
C(74)-Cl(5)-C(99) 46(3) C(99)-Cl(5)-C(81) 74(3)
Cl(6)-Cl(5)-C(86) 95(4) C(74)-Cl(5)-C(86) 88(3)
C(99)-Cl(5)-C(86) 134(4) C(81)-Cl(5)-C(86) 61(3)
Cl(5)-Cl(6)-C(74) 109(3) Cl(5)-Cl(6)-C(81) 120(3)
Cl(5)-Cl(6)-C(99) 108(4) C(74)-Cl(6)-C(99) 57(4)
C(81)-Cl(6)-C(99) 95(4) Cl(5)-Cl(6)-Cl(7) 159(3)
C(74)-Cl(6)-Cl(7) 53.2(16) C(99)-Cl(6)-Cl(7) 72(4)
Cl(8)-Cl(7)-C(81) 120(3) Cl(8)-Cl(7)-C(74) 92(3)
Cl(8)-Cl(7)-Cl(6) 124(3) C(81)-Cl(7)-Cl(6) 47.3(14)
Cl(7)-Cl(8)-C(74) 67(2) Cl(11)-Cl(10)-C(68) 115(2)
Cl(11)-Cl(10)-Cl(12) 49.7(16) C(68)-Cl(10)-Cl(12) 69.6(15)
Cl(10)-Cl(11)-Cl(12) 110(2) Cl(9)-Cl(12)-Cl(11) 100.4(19)
Cl(9)-Cl(12)-Cl(10) 118.6(19)  
_________________________________________________________________ 
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Anisotropic displacement parameters (Å2).  
The anisotropic displacement factor exponent takes the form:  
 -2π2[ h2a*2U11 + ... + 2 h k a* b* U12 ]. 
___________________________________________________________________ 
 U11 U22 U33 U23 U13 U12 
___________________________________________________________________ 
C(1) 0.064(8)  0.109(12) 0.031(7)  0.001(7) 0.005(6)  -0.009(8) 
C(2) 0.204(17)  0.197(17) 0.209(17)  -0.002(7) -0.011(7)  0.015(7) 
C(3) 0.031(4)  0.026(4) 0.024(4)  0.004(3) -0.002(3)  0.000(3) 
C(4) 0.025(3)  0.032(4) 0.019(4)  0.003(3) -0.002(3)  0.000(3) 
C(5) 0.025(3)  0.034(4) 0.020(4)  0.006(3) 0.001(3)  -0.001(3) 
C(6) 0.034(4)  0.039(4) 0.019(4)  0.002(3) 0.003(3)  -0.001(3) 
C(7) 0.038(4)  0.035(4) 0.027(4)  0.000(3) 0.006(3)  -0.011(3) 
C(8) 0.034(4)  0.051(5) 0.026(4)  -0.007(3) 0.007(3)  -0.015(4) 
C(9) 0.026(4)  0.047(5) 0.019(4)  -0.004(3) 0.006(3)  -0.006(3) 
C(10) 0.022(3)  0.038(4) 0.020(4)  0.000(3) -0.002(3)  -0.001(3) 
C(11) 0.019(3)  0.039(4) 0.025(4)  0.004(3) -0.003(3)  -0.002(3) 
C(12) 0.030(4)  0.036(4) 0.024(4)  0.000(3) 0.000(3)  0.002(3) 
C(13) 0.035(4)  0.030(4) 0.029(4)  0.002(3) 0.001(3)  0.005(3) 
C(14) 0.034(4)  0.041(5) 0.042(5)  -0.003(3) 0.001(3)  0.000(3) 
C(15) 0.039(4)  0.038(5) 0.052(6)  -0.006(4) 0.003(4)  0.002(4) 
C(16) 0.060(6)  0.032(4) 0.062(6)  0.003(4) 0.017(5)  0.003(4) 
C(17) 0.052(5)  0.035(5) 0.059(6)  0.006(4) 0.009(4)  0.005(4) 
C(18) 0.047(5)  0.036(4) 0.040(5)  0.003(3) 0.006(4)  0.009(4) 
C(19) 0.025(3)  0.028(4) 0.018(3)  -0.001(3) -0.002(3)  0.001(3) 
C(20) 0.024(3)  0.030(4) 0.024(4)  0.003(3) -0.005(3)  -0.001(3) 
C(21) 0.026(3)  0.027(4) 0.028(4)  0.004(3) -0.004(3)  -0.003(3) 
C(22) 0.033(4)  0.039(4) 0.018(4)  0.004(3) 0.002(3)  -0.002(3) 
C(23) 0.045(4)  0.047(5) 0.018(4)  -0.002(3) -0.001(3)  -0.005(4) 
C(24) 0.034(4)  0.046(5) 0.030(4)  -0.008(3) 0.010(3)  0.000(4) 
C(25) 0.029(4)  0.037(4) 0.031(4)  -0.008(3) 0.005(3)  0.001(3) 
C(26) 0.027(3)  0.033(4) 0.023(4)  -0.002(3) 0.004(3)  0.003(3) 
C(27) 0.032(4)  0.028(4) 0.025(4)  0.003(3) -0.007(3)  0.002(3) 
C(28) 0.021(3)  0.038(4) 0.016(4)  0.002(3) 0.000(2)  0.003(3) 
C(29) 0.023(3)  0.037(4) 0.027(4)  0.002(3) -0.004(3)  0.005(3) 
C(30) 0.026(4)  0.036(4) 0.024(4)  0.003(3) -0.002(3)  0.003(3) 
C(31) 0.022(3)  0.035(4) 0.029(4)  0.001(3) 0.005(3)  0.000(3) 
C(32) 0.028(4)  0.047(4) 0.024(4)  0.004(3) 0.000(3)  0.001(3) 
C(33) 0.024(4)  0.041(4) 0.028(4)  0.000(3) 0.003(3)  0.003(3) 
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C(34) 0.023(3)  0.036(4) 0.026(4)  -0.001(3) -0.002(3)  0.000(3) 
C(35) 0.023(3)  0.039(4) 0.027(4)  -0.001(3) 0.003(3)  -0.009(3) 
C(36) 0.026(4)  0.034(4) 0.030(4)  0.001(3) 0.000(3)  -0.009(3) 
C(37) 0.028(4)  0.046(5) 0.035(4)  -0.001(3) 0.000(3)  -0.002(3) 
C(38) 0.034(4)  0.039(4) 0.035(4)  -0.002(3) 0.008(3)  -0.005(3) 
C(39) 0.026(4)  0.059(5) 0.045(5)  0.005(4) 0.008(3)  0.000(4) 
C(40) 0.037(4)  0.053(5) 0.060(6)  -0.001(4) 0.000(4)  -0.007(4) 
C(41) 0.033(4)  0.053(5) 0.042(5)  -0.004(4) -0.002(4)  -0.008(4) 
C(42) 0.028(4)  0.044(5) 0.036(5)  0.000(3) -0.001(3)  -0.009(3) 
C(43) 0.036(4)  0.043(4) 0.038(5)  -0.002(3) -0.007(3)  -0.008(4) 
C(44) 0.035(4)  0.043(4) 0.026(4)  0.002(3) -0.004(3)  -0.004(3) 
C(45) 0.043(4)  0.041(4) 0.025(4)  -0.008(3) 0.001(3)  -0.011(4) 
C(46) 0.082(7)  0.065(6) 0.042(6)  -0.015(5) 0.017(5)  -0.025(6) 
C(47) 0.095(8)  0.060(6) 0.049(6)  -0.028(5) 0.037(6)  -0.027(6) 
C(48) 0.078(7)  0.059(6) 0.046(6)  -0.022(5) 0.020(5)  -0.019(5) 
C(49) 0.042(4)  0.041(5) 0.030(4)  -0.001(3) 0.004(3)  -0.003(4) 
C(50) 0.031(4)  0.045(4) 0.024(4)  -0.002(3) 0.001(3)  -0.003(3) 
C(51) 0.032(4)  0.031(4) 0.023(4)  0.000(3) 0.003(3)  0.000(3) 
C(52) 0.030(4)  0.039(4) 0.019(4)  0.002(3) 0.000(3)  -0.003(3) 
C(53) 0.023(3)  0.046(4) 0.017(4)  0.002(3) 0.001(3)  -0.004(3) 
C(54) 0.027(4)  0.044(4) 0.027(4)  0.003(3) 0.000(3)  0.000(3) 
C(55) 0.030(4)  0.056(5) 0.031(4)  0.005(4) -0.001(3)  0.004(4) 
C(56) 0.037(4)  0.039(4) 0.032(4)  -0.001(3) 0.009(3)  0.004(3) 
C(57) 0.034(4)  0.035(4) 0.024(4)  0.000(3) -0.005(3)  0.000(3) 
C(58) 0.027(3)  0.035(4) 0.024(4)  -0.002(3) 0.007(3)  -0.004(3) 
C(59) 0.031(4)  0.039(4) 0.025(4)  -0.006(3) -0.004(3)  -0.005(3) 
C(60) 0.031(4)  0.028(4) 0.021(4)  0.001(3) -0.003(3)  0.000(3) 
C(61) 0.035(4)  0.026(4) 0.022(4)  -0.002(3) -0.001(3)  0.002(3) 
C(62) 0.032(4)  0.035(4) 0.026(4)  -0.007(3) -0.003(3)  -0.008(3) 
C(63) 0.034(4)  0.024(4) 0.024(4)  -0.004(3) 0.000(3)  -0.001(3) 
C(64) 0.045(4)  0.034(4) 0.025(4)  0.000(3) 0.000(3)  0.005(3) 
C(65) 0.042(4)  0.024(4) 0.026(4)  0.003(3) -0.005(3)  -0.004(3) 
C(66) 0.034(4)  0.036(4) 0.026(4)  0.002(3) -0.004(3)  -0.001(3) 
N(1) 0.019(3)  0.050(4) 0.040(4)  -0.010(3) -0.005(3)  -0.007(3) 
N(2A) 0.058(4)  0.039(4) 0.047(5)  -0.016(3) 0.018(3)  0.008(3) 
N(2B) 0.058(4)  0.039(4) 0.047(5)  -0.016(3) 0.018(3)  0.008(3) 
N(3A) 0.083(6)  0.054(5) 0.062(6)  -0.033(4) 0.011(5)  -0.010(4) 
N(3B) 0.083(6)  0.054(5) 0.062(6)  -0.033(4) 0.011(5)  -0.010(4) 
O(1) 0.026(2)  0.030(3) 0.041(3)  0.007(2) -0.007(2)  -0.005(2) 
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O(2) 0.031(3)  0.028(3) 0.025(3)  -0.001(2) -0.002(2)  0.006(2) 
O(3) 0.023(2)  0.056(3) 0.025(3)  0.005(2) 0.000(2)  -0.005(2) 
O(4) 0.031(3)  0.035(3) 0.027(3)  -0.003(2) -0.002(2)  -0.002(2) 
O(5) 0.073(5)  0.062(5) 0.054(5)  -0.023(4) -0.010(4)  0.044(4) 
O(6) 0.031(4)  0.069(5) 0.045(4)  -0.012(4) 0.004(3)  -0.008(3) 
O(7) 0.138(9)  0.119(8) 0.100(8)  0.020(7) 0.035(7)  0.046(8) 
O(8) 0.197(12)  0.218(13) 0.143(11)  -0.064(10) -0.025(10)  0.089(10) 
F(1) 0.095(6)  0.198(11) 0.028(4)  0.025(5) 0.008(4)  -0.002(7) 
F(2) 0.126(7)  0.077(5) 0.065(5)  0.025(4) -0.020(5)  0.036(5) 
F(3) 0.068(5)  0.139(8) 0.040(4)  -0.031(4) -0.017(3)  0.024(5) 
F(4) 0.371(13)  0.350(13) 0.372(13)  -0.008(8) 0.023(8)  0.006(8) 
F(5) 0.371(13)  0.350(13) 0.372(13)  -0.008(8) 0.023(8)  0.006(8) 
F(6) 0.371(13)  0.350(13) 0.372(13)  -0.008(8) 0.023(8)  0.006(8) 
F(7) 0.082(4)  0.070(4) 0.099(5)  -0.030(4) 0.041(4)  0.009(3) 
F(8) 0.063(3)  0.058(4) 0.103(5)  0.001(3) 0.024(3)  0.027(3) 
F(9) 0.086(4)  0.059(4) 0.095(5)  -0.038(3) 0.029(4)  -0.011(3) 
F(10) 0.101(5)  0.080(4) 0.055(4)  -0.012(3) 0.036(3)  0.014(4) 
F(11) 0.043(3)  0.062(3) 0.101(5)  -0.021(3) 0.019(3)  -0.002(3) 
F(12) 0.172(8)  0.047(4) 0.203(9)  0.051(5) 0.139(8)  0.040(4) 
F(13) 0.090(5)  0.053(4) 0.193(9)  0.040(5) 0.083(5)  0.018(3) 
F(14) 0.231(10)  0.051(4) 0.085(5)  0.031(4) 0.079(6)  0.031(5) 
F(15) 0.128(6)  0.043(3) 0.107(5)  0.024(3) 0.054(5)  0.031(4) 
F(16) 0.106(5)  0.048(4) 0.158(7)  -0.015(4) 0.062(5)  -0.020(4) 
F(17) 0.015(2)  0.084(3) 0.034(3)  0.000(2) -0.001(2)  0.001(2) 
F(18) 0.027(2)  0.070(3) 0.036(3)  -0.011(2) 0.002(2)  0.009(2) 
F(19) 0.029(2)  0.055(3) 0.037(3)  0.013(2) 0.000(2)  -0.007(2) 
F(20) 0.029(2)  0.072(3) 0.028(2)  -0.013(2) 0.000(2)  -0.002(2) 
F(21) 0.030(2)  0.069(3) 0.040(3)  0.020(2) -0.002(2)  0.008(2) 
F(22) 0.030(2)  0.111(5) 0.032(3)  0.022(3) 0.000(2)  -0.015(3) 
F(23) 0.023(2)  0.082(3) 0.034(3)  0.005(2) 0.003(2)  0.006(2) 
F(24) 0.036(2)  0.070(3) 0.035(3)  0.010(2) -0.007(2)  -0.018(2) 
F(25) 0.030(2)  0.061(3) 0.034(2)  0.020(2) -0.007(2)  -0.004(2) 
F(26) 0.032(2)  0.080(3) 0.024(2)  -0.004(2) 0.004(2)  -0.006(2) 
F(27) 0.372(19)  0.140(8) 0.192(10)  -0.132(8) 0.193(12)  -0.181(11) 
F(28) 0.205(10)  0.064(4) 0.130(7)  -0.041(5) 0.103(8)  -0.043(5) 
F(29) 0.244(12)  0.059(4) 0.130(7)  -0.031(4) 0.117(8)  -0.058(6) 
F(30) 0.208(11)  0.188(10) 0.113(7)  -0.096(7) 0.084(7)  -0.162(9) 
F(31) 0.295(15)  0.192(10) 0.093(7)  -0.100(7) 0.092(8)  -0.179(11) 
F(32) 0.068(3)  0.047(3) 0.061(3)  -0.002(2) 0.029(3)  -0.005(3) 
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F(33) 0.053(3)  0.041(3) 0.057(3)  -0.011(2) 0.018(2)  0.005(2) 
F(34) 0.072(4)  0.094(4) 0.026(3)  -0.004(3) 0.002(2)  -0.005(3) 
F(35) 0.067(3)  0.058(3) 0.050(3)  0.017(2) 0.018(3)  0.024(3) 
F(36) 0.047(3)  0.048(3) 0.047(3)  -0.014(2) 0.007(2)  -0.009(2) 
F(37) 0.069(3)  0.038(3) 0.061(3)  0.005(2) 0.005(3)  -0.014(2) 
F(38) 0.066(3)  0.043(3) 0.032(3)  0.006(2) 0.002(2)  -0.008(2) 
F(39) 0.044(3)  0.042(3) 0.059(3)  0.005(2) 0.010(2)  -0.005(2) 
F(40) 0.068(3)  0.031(2) 0.043(3)  -0.010(2) -0.003(2)  -0.012(2) 
F(41) 0.061(3)  0.026(2) 0.055(3)  0.000(2) 0.007(2)  0.005(2) 
F(42) 0.046(3)  0.050(3) 0.051(3)  0.012(2) -0.018(2)  -0.016(2) 
F(43) 0.050(3)  0.034(2) 0.045(3)  -0.001(2) -0.011(2)  -0.008(2) 
F(44) 0.063(3)  0.056(3) 0.029(3)  0.017(2) -0.015(2)  -0.019(2) 
F(45) 0.042(3)  0.040(3) 0.059(3)  0.006(2) -0.011(2)  0.003(2) 
F(46) 0.038(2)  0.049(3) 0.038(3)  0.013(2) -0.004(2)  -0.006(2) 
P(1) 0.026(1)  0.033(1) 0.029(1)  -0.005(1) 0.002(1)  0.001(1) 
P(2) 0.031(1)  0.037(1) 0.029(1)  -0.008(1) 0.000(1)  -0.003(1) 
S(1A) 0.034(1)  0.050(1) 0.025(1)  -0.005(1) -0.002(1)  0.008(1) 
S(1B) 0.056(8)  0.088(10) 0.063(9)  -0.022(7) -0.019(6)  0.020(7) 
S(3) 0.057(1)  0.048(1) 0.069(2)  -0.012(1) 0.021(1)  0.004(1) 
S(2A) 0.054(2)  0.055(2) 0.093(3)  -0.038(2) 0.008(2)  -0.003(2) 
S(2B) 0.114(14)  0.055(8) 0.077(10)  -0.010(7) 0.023(9)  -0.014(8) 
S(4) 0.109(2)  0.034(1) 0.117(3)  0.021(2) 0.068(2)  0.016(1) 
S(5) 0.022(1)  0.051(1) 0.025(1)  0.001(1) -0.001(1)  0.002(1) 
S(6) 0.023(1)  0.069(1) 0.025(1)  0.007(1) -0.002(1)  -0.006(1) 
S(7) 0.228(5)  0.097(3) 0.110(3)  -0.071(2) 0.107(3)  -0.104(3) 
S(8) 0.046(1)  0.038(1) 0.035(1)  0.000(1) 0.007(1)  0.002(1) 
S(9) 0.052(1)  0.028(1) 0.039(1)  -0.002(1) 0.003(1)  -0.005(1) 
S(10) 0.042(1)  0.036(1) 0.034(1)  0.009(1) -0.010(1)  -0.005(1)  
_________________________________________________________________ 
 
Hydrogen coordinates and isotropic displacement parameters (Å2).  
_________________________________________________________________ 
 x  y  z  Ueq 
_________________________________________________________________ 
 
H(6) -0.1313 0.2314 0.1820 0.037 
H(7) -0.2371 0.2028 0.1630 0.040 
7 EXPERIMENTAL PART 
 
217 
   
H(8) -0.3483 0.2297 0.1631 0.044 
H(9) -0.3523 0.2848 0.1762 0.036 
H(11) -0.2908 0.3361 0.1986 0.033 
H(14) -0.2707 0.3777 0.3261 0.047 
H(16) -0.2173 0.4680 0.2504 0.062 
H(18) -0.1140 0.3921 0.1363 0.049 
H(22) -0.0905 0.2697 0.0329 0.036 
H(23) -0.0460 0.2369 -0.0826 0.044 
H(24) 0.0552 0.2051 -0.0534 0.044 
H(25) 0.1126 0.2072 0.0860 0.039 
H(27) 0.1246 0.2306 0.2435 0.034 
H(30) 0.1950 0.2676 0.3595 0.035 
H(32) 0.1667 0.2474 0.6322 0.039 
H(34) -0.0026 0.2526 0.4609 0.034 
H(38) 0.3730 0.3305 0.1275 0.043 
H(39) 0.4907 0.3456 0.1043 0.052 
H(40) 0.5588 0.3658 0.2254 0.060 
H(41) 0.5075 0.3778 0.3643 0.051 
H(43) 0.4005 0.3805 0.4642 0.047 
H(46) 0.3164 0.4236 0.5097 0.076 
H(48) 0.1865 0.4123 0.7343 0.073 
H(50) 0.2059 0.3405 0.5463 0.040 
H(54) 0.3372 0.2820 0.2662 0.039 
H(55) 0.3520 0.2290 0.2129 0.047 
H(56) 0.2904 0.2116 0.0811 0.043 
H(57) 0.2073 0.2437 0.0099 0.038 
H(59) 0.1393 0.2958 0.0050 0.038 
H(62) 0.1665 0.3935 0.0465 0.037 
H(64) -0.0115 0.4094 -0.1069 0.042 
H(66) 0.0184 0.3229 0.0233 0.038 
H(2A) -0.0204 0.3771 0.4271 0.057 
H(2B) -0.0865 0.3665 0.3770 0.057 
H(3A) 0.1802 0.4111 0.3476 0.080 
H(3B)  0.0897  0.4079  0.3521    0.080     
_________________________________________________________________ 
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7.4.4 Mechanistic Studies 
Excess Diene Reaction: 
In a flame-dried Schlenk tube under argon, catalyst 22c (27 mg, 12 µmol, 0.05 equiv), 5 
Å molecular sieves (210 mg), MeCy (3.0 mL) were added. Subsequently, benzaldehyde 
(250 mg, 2.36 mmol, 1.0 equiv), followed by 2,3-dimethyl-1,3-butadiene (20a)  (800 mg, 
9.74 mmol，4.1 equiv) were added in at −78 °C. The reaction mixture was then stirred at 
−20 °C for 30 min and quenched by the addition of trimethylamine (1 drop). The solution 
was warmed to room temperature and 1,2,4,5-tetramethylbenzene (134 mg, 1.0 mmol) 
was added as an internal standard. Analysis of the crude reaction mixture by 1H NMR 
showed that the reaction was quenched at 15 ± 0.6% completion of 20a (relative to 
starting diene 20a). Purification of 21a was performed by column chromatography on 
silica gel using diethyl 2−6% ether/pentane as the eluent (198 mg, 1.05 mmol). Under 
argon, the obtained 21a was transferred to a NMR tube (50 mg of 21a in 0.5 mL CD2Cl2), 
and the NMR tube was then sealed by melting. Two samples were identically prepared 
for the following NMR analysis.  
The reaction was carefully repeated and 21a (210 mg, 1.12 mmol) was obtained at 16 ± 
0.8% completion of 20a (relative to starting diene 20a). Another two identical NMR 
samples were prepared. 
13C Spectra Measurement: 
The 13C spectra were measured at 150.93 MHz on an Avance 600MHz NMR 
spectrometer equipped with a cryogenically-cooled TXI (1H/13C/15N) probehead, using a 
single pulse calibrated at 40° followed by inverse-gated decoupling. A 40-s delay was 
used between pulses, the longest T1 for the 
13C of interest being about 6s (C3). To obtain 
digital resolution of at least 5 points at the peak linewidth at half-height, an instrumental 
maximum of 128K points were collected over a sweep-width of 155 ppm centered at 46 
ppm, followed by zero-filling to 256K points before Fourier transformation. Integrations 
were determined numerically using a ±7.5 Hz region for each peak. In general, an 
automatic polynomial baseline correction of order of at least 3 was applied. Integrals 
were simply calculated by summing the signal intensities over the peak regions. 
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The relative 13C compositions at C3 and C4 were assigned to be 1.000 in this 
intramolecular KIE measurement. The relative 13C composition at C1 was calculated 
from the integration at C1 versus C4. The intramolecular KIE of C1 was the reciprocal of 
the average of relative 13C compositions at C1. Similarly, the relative 13C composition at 
C2 was calculated from the integration at C2 versus C3. The intramolecular KIE of C2 
was the reciprocal of the average of relative 13C compositions at C2. The standard 
deviations in the parentheses were calculated in a standard way. 
Values shown are raw 13C integrals of 21a at 15 ± 0.6% completion of 20a 
C2 C3 C4
91898 91307 88351
92516 91861 87659
92491 92002 88020
Sample
1
1
1
C1
85901
85960
86779
92518 93114 87888
102349 101247 97308
101747 101450 97669
1
1
1
86069
95521
95284
101314 101403 97199
92809 93180 88907
373893 373560 360129
1
1
2
95647
86724
350900
377562 376117 362694
377015 377226 362330
378537 378589 363559
2
2
2
355073
354592
355307
379971 379377 365966
382854 381606 366213
379629 380955 364419
2
2
2
356656
358969
357178
381297 380861 3656022 357657
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Values shown are raw 13C integrals of 21a at 16 ± 0.8% completion of 20a 
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